[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"_public_publisher_byId_e077f62b-0b41-45e0-9dbe-556a13fe2a9e":3,"_public_publication_all{\"sortAscending\":false,\"sortField\":\"updateTime\",\"page\":0,\"size\":10,\"facet\":true,\"searchKey\":\"publisherId:e077f62b-0b41-45e0-9dbe-556a13fe2a9e,\"}":126},{"code":4,"data":5,"meta":23},"SUCCESS",{"id":6,"createTime":7,"updateTime":8,"relativeEntities":9,"slug":10,"properties":11,"entityType":21,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24,"subjectFields":25,"manageAffiliations":58,"indexDatabases":82,"url":125,"thumbnailPath":23,"statistic":23,"gsStatistic":23,"type":23,"analyzePriority":23},"e077f62b-0b41-45e0-9dbe-556a13fe2a9e","2023-05-29T10:26:39.146+00:00","2025-11-21T09:51:26.195+00:00",[],"Leukemia",{"country":12,"issn":14,"introduce":16,"eissn":18,"title":20},{"VOID":13},"GB",{"VOID":15},"08876924",{"EN":17},"Leukemia publishes high quality, peer reviewed research that covers all aspects of the research and treatment of leukemia and allied diseases. Studies of normal hemopoiesis are covered because of their comparative relevance. Topics of interest include oncogenes, growth factors, stem cells, leukemia genomics, cell cycle, signal transduction, molecular targets for therapy and more. We publish a range of content types including original research articles, reviews, letters, correspondence and comments that elaborate on significant advances in the field and cover topical issues.",{"VOID":19},"14765551",{"EN":10},"PUBLISHER","PENDING",null,0,[26,34,42,50],{"id":27,"createTime":28,"updateTime":29,"relativeEntities":30,"label":31,"description":33,"parentId":23,"standard":23,"scholarHubFieldId":23},"d9687dc3-fd83-46ff-aef4-1925044c24eb","2023-05-29T10:24:05.052+00:00","2023-11-21T05:08:37.643+00:00",[],{"EN":32},"Oncology",{},{"id":35,"createTime":36,"updateTime":37,"relativeEntities":38,"label":39,"description":41,"parentId":23,"standard":23,"scholarHubFieldId":23},"213c5703-df41-467a-ab05-e3ba2a11c009","2023-05-29T10:24:53.705+00:00","2023-11-21T07:54:04.602+00:00",[],{"EN":40},"Anesthesiology and Pain Medicine",{},{"id":43,"createTime":44,"updateTime":45,"relativeEntities":46,"label":47,"description":49,"parentId":23,"standard":23,"scholarHubFieldId":23},"29ae3c22-bde7-4d3e-a891-c7786d7b00cb","2023-05-29T10:25:20.407+00:00","2023-11-21T07:03:27.757+00:00",[],{"EN":48},"Hematology",{},{"id":51,"createTime":52,"updateTime":53,"relativeEntities":54,"label":55,"description":57,"parentId":23,"standard":23,"scholarHubFieldId":23},"740fbbd4-0204-4499-bc5d-be3ba61fc9be","2023-05-29T10:24:05.032+00:00","2023-11-21T05:08:37.653+00:00",[],{"EN":56},"Cancer Research",{},[59,71],{"id":60,"createTime":61,"updateTime":62,"relativeEntities":63,"slug":64,"properties":65,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":69,"url":23,"parentIds":70,"statistic":23},"ae54b068-a7dd-4746-b752-b7b24439de47","2023-05-29T10:24:12.391+00:00","2025-11-21T09:53:50.486+00:00",[],"Nature-Publishing-Group",{"title":66},{"EN":67},"Nature Publishing Group","AFFILIATION",6,[],{"id":72,"createTime":73,"updateTime":74,"relativeEntities":75,"slug":76,"properties":77,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24,"url":23,"parentIds":80,"statistic":23},"8e7fce10-23c9-4f81-8998-abcf28ea16a0","2024-04-11T20:35:34.338+00:00","2025-11-21T10:07:28.515+00:00",[],"Springer-Nature",{"title":78},{"EN":79},"Springer Nature",[81],"9a7c7208-b28a-42c2-a634-5a7f90eee3ab",[83,103],{"id":84,"indexDatabase":85,"url":99,"indexYears":23,"academicFieldIds":100,"indexDatabaseRanking":23},"25149046-68dd-44d3-9134-eda3a52611cf",{"id":86,"createTime":87,"updateTime":88,"relativeEntities":89,"label":90,"description":92,"key":95,"publicationTags":96,"standard":23},"a4921856-b128-4d9f-8f1f-e80813d3bbd4","2023-05-22T09:59:31.026+00:00","2025-11-21T10:07:52.153+00:00",[],{"EN":91,"VI":91},"ISI\u002FSCIE - Science Citation Index Expanded",{"VI":93,"EN":94},"Cơ sở dữ liệu SCIE","SCIE database","scie",[97,98],"SCIE","ISI","https:\u002F\u002Fmjl.clarivate.com\u002Fsearch-results?issn=0887-6924",[101,102],"4f363738-bd8a-4ecf-bff7-e3fa60978c08","248e54de-c562-4c06-8a10-d7f8a37c06fe",{"id":104,"indexDatabase":105,"url":117,"indexYears":118,"academicFieldIds":119,"indexDatabaseRanking":124},"b5b46408-9693-4953-8893-2b7518f3507b",{"id":106,"createTime":107,"updateTime":108,"relativeEntities":109,"label":110,"description":112,"key":114,"publicationTags":115,"standard":23},"3c7051d4-eb7d-4c57-a56b-36fc74c5d1e9","2023-05-22T09:57:18.509+00:00","2025-11-21T10:07:52.274+00:00",[],{"EN":111,"VI":111},"Scopus - Elsevier",{"EN":111,"VI":113},"Cơ sở dữ liệu Scopus thuộc Elsevier","scopus",[116],"SCOPUS","https:\u002F\u002Fwww.scopus.com\u002Fsourceid\u002F26015","1987-2025",[120,121,122,123],"88a9f23e-67cb-4b76-b4cb-cf09ce4cd8e7","562f3a16-6ded-439a-822f-7e9037fac1eb","ee505398-b96f-423d-82ed-9f73f07d49d4","462e3fe4-4fc0-4c02-80d6-8d2af4fc74ea","SCOPUS__Q1","https:\u002F\u002Fwww.nature.com\u002Fleu\u002F",{"meta":127,"data":129},{"total":128},"209",[130,1781,3081,4267,4591,4923,5071,5540,5894,6219],{"id":131,"createTime":132,"updateTime":132,"relativeEntities":133,"slug":134,"properties":135,"entityType":150,"verifyStatus":151,"verifyTime":132,"verifyNote":152,"syncStatus":22,"languages":153,"translateLanguages":23,"viewCount":24,"primaryUrl":155,"fullTextUrl":23,"authors":156,"publicationType":1646,"publisherRelationship":1647,"citationCount":1680,"citationInfo":1681,"publishDate":1683,"publishYear":1684,"citationAnalyzeStatus":22,"lastCitationAnalyze":23,"indexDatabases":23,"openAccess":23,"references":1685,"isForceReanalyzing":1780},"ae10589a-6468-4459-b926-e4898ed1056c","2024-08-31T23:42:45.701+00:00",[],"A-certified-plasmid-reference-material-for-the-standardisation-of-BCR-ABL1-mRNA-quantification-by-real-time-quantitative-PCR",{"mag":136,"keywords":138,"pmc":139,"openalex":141,"abstract":143,"title":144,"pm":146,"doi":148},{"VOID":137},"2133908319",{},{"VOID":140},"4320294",{"VOID":142},"W2133908319",{},{"EN":145},"A certified plasmid reference material for the standardisation of BCR–ABL1 mRNA quantification by real-time quantitative PCR",{"VOID":147},"25036192",{"VOID":149},"10.1038\u002Fleu.2014.217","PUBLICATION","VERIFIED","Auto Verify",[154],"EN","https:\u002F\u002Fwww.nature.com\u002Farticles\u002Fleu2014217",[157,180,203,226,247,268,290,312,334,351,373,395,416,438,458,478,498,516,538,561,581,603,623,645,667,687,707,727,750,773,791,814,837,858,880,902,922,945,968,989,1010,1030,1051,1071,1092,1115,1135,1155,1175,1198,1214,1237,1258,1280,1300,1321,1343,1366,1387,1410,1430,1451,1469,1487,1510,1526,1548,1570,1591,1609,1625],{"id":158,"sortIndex":159,"researcher":23,"roles":160,"affiliations":161,"properties":173},"006ebfd0-75f2-4eff-9948-51238465c26d",51,[],[162],{"id":163,"sortIndex":24,"affiliation":164,"properties":23},"7894e42f-e476-46e8-b699-cb4ccfc3e675",{"id":165,"createTime":166,"updateTime":167,"relativeEntities":168,"slug":169,"properties":170,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},"46ff2d08-940c-405c-87e5-0a9987abdc77","2024-02-10T03:46:47.389+00:00","2024-08-31T23:42:46.918+00:00",[],"Laboratoire-d-H%C3%A9matologie-CHU-Lille-Lille-France",{"title":171},{"VI":172},"Laboratoire d’Hématologie, CHU Lille, Lille, France",{"openalex":174,"orcid":176,"title":178},{"VOID":175},"A5018416096",{"VOID":177},"https:\u002F\u002Forcid.org\u002F0000-0002-1267-9546",{"EN":179},"Claude Preudhomme",{"id":181,"sortIndex":182,"researcher":23,"roles":183,"affiliations":184,"properties":196},"dcff6073-0723-4ebe-a4f3-3cbea90a3ff3",70,[],[185],{"id":186,"sortIndex":24,"affiliation":187,"properties":23},"8f591346-ac67-4b8a-8a83-77224fdcdfa4",{"id":188,"createTime":189,"updateTime":190,"relativeEntities":191,"slug":192,"properties":193,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},"bbc67753-7978-4196-830a-87d001b339c2","2023-12-02T04:52:12.498+00:00","2024-11-25T15:20:52.038+00:00",[],"European-Commission-Joint-Research-Centre-Institute-for-Reference-Materials-and-Measurements-Geel-Belgium",{"title":194},{"VI":195},"European Commission, Joint Research Centre, Institute for Reference Materials and Measurements, Geel, Belgium",{"openalex":197,"orcid":199,"title":201},{"VOID":198},"A5086424628",{"VOID":200},"https:\u002F\u002Forcid.org\u002F0000-0002-6690-9810",{"EN":202},"Hendrik Emons",{"id":204,"sortIndex":205,"researcher":23,"roles":206,"affiliations":207,"properties":219},"bda350b6-2c6a-47f1-94a5-20b27cb4255e",7,[],[208],{"id":209,"sortIndex":24,"affiliation":210,"properties":23},"88443bdd-1bf6-4b06-9146-851515b711c8",{"id":211,"createTime":212,"updateTime":213,"relativeEntities":214,"slug":215,"properties":216,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},"5be52554-2eb3-48a6-803e-1e5ed307faf8","2024-01-25T01:40:04.185+00:00","2024-08-31T23:42:46.772+00:00",[],"Department-of-Haematology-Aarhus-University-Hospital-Aarhus-Denmark-",{"title":217},{"VI":218},"Department of Haematology, Aarhus University Hospital, Aarhus, Denmark;",{"openalex":220,"orcid":222,"title":224},{"VOID":221},"A5033723505",{"VOID":223},"https:\u002F\u002Forcid.org\u002F0000-0002-8915-0122",{"EN":225},"Anni Aggerholm",{"id":227,"sortIndex":228,"researcher":23,"roles":229,"affiliations":230,"properties":242},"b99e7471-17c6-479c-92bb-77374002bf77",42,[],[231],{"id":232,"sortIndex":24,"affiliation":233,"properties":23},"1b9f83ca-256d-4685-9a0e-5ca30778dd94",{"id":234,"createTime":235,"updateTime":236,"relativeEntities":237,"slug":238,"properties":239,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},"1e9be64b-658a-4bdf-840c-0c964426e2ba","2024-02-08T19:57:48.081+00:00","2025-01-06T21:11:16.235+00:00",[],"Department-of-Laboratory-Medicine-Medical-University-of-Vienna-Vienna-Austria",{"title":240},{"VI":241},"Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria",{"openalex":243,"title":245},{"VOID":244},"A5074878867",{"EN":246},"Gerlinde Mitterbauer‐Hohendanner",{"id":248,"sortIndex":249,"researcher":23,"roles":250,"affiliations":251,"properties":263},"70c7a081-d7c6-4d4a-8552-30e24952691c",35,[],[252],{"id":253,"sortIndex":24,"affiliation":254,"properties":23},"03be6908-b1b1-403a-b7ec-3f9c718092bf",{"id":255,"createTime":256,"updateTime":257,"relativeEntities":258,"slug":259,"properties":260,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},"c85a451b-f76e-421d-9a65-1531c861e2e0","2024-04-07T02:48:58.447+00:00","2024-08-31T23:42:46.289+00:00",[],"Abteilung-f%C3%BCr-H%C3%A4matologie-und-internistische-Onkologie-Universit%C3%A4t-Leipzig-Leipzig-Germany",{"title":261},{"VI":262},"Abteilung für Hämatologie und internistische Onkologie, Universität Leipzig, Leipzig, Germany",{"openalex":264,"title":266},{"VOID":265},"A5055821837",{"EN":267},"Thoralf Lange",{"id":269,"sortIndex":270,"researcher":23,"roles":271,"affiliations":272,"properties":283},"94b65cff-d9a3-44ec-82f4-6a94a2a45974",47,[],[273],{"id":274,"sortIndex":24,"affiliation":275,"properties":23},"05f9c7bb-07df-435e-9e6b-7d9154c0b91e",{"id":276,"createTime":277,"updateTime":277,"relativeEntities":278,"slug":279,"properties":280,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},"3f39ce82-97aa-4567-98ec-41bf18b818d3","2024-08-31T23:42:46.130+00:00",[],"Department-of-Hematology-Molecular-Diagnostics-Laboratory-University-Hospital-Bern-Bern-Switzerland-",{"title":281},{"EN":282},"Department of Hematology, Molecular Diagnostics Laboratory, University Hospital Bern, Bern, Switzerland,",{"openalex":284,"orcid":286,"title":288},{"VOID":285},"A5051240594",{"VOID":287},"https:\u002F\u002Forcid.org\u002F0000-0002-6652-4160",{"EN":289},"Elisabeth Oppliger Leibundgut",{"id":291,"sortIndex":292,"researcher":23,"roles":293,"affiliations":294,"properties":305},"c81b7551-a0d7-4d60-a669-6cc9fb921153",27,[],[295],{"id":296,"sortIndex":24,"affiliation":297,"properties":23},"9d173f71-840c-4c99-930d-1c1fd569337f",{"id":298,"createTime":299,"updateTime":299,"relativeEntities":300,"slug":301,"properties":302,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},"3dbd88da-9e32-4a90-925f-4d6e24efbe3e","2024-08-31T23:42:46.879+00:00",[],"Medical-Genetics-Department-Erasme-Hospital-Brussels-Belgium-",{"title":303},{"EN":304},"Medical Genetics Department, Erasme Hospital, Brussels, Belgium,",{"openalex":306,"orcid":308,"title":310},{"VOID":307},"A5062547899",{"VOID":309},"https:\u002F\u002Forcid.org\u002F0000-0002-6782-9345",{"EN":311},"Hakim El Housni",{"id":313,"sortIndex":314,"researcher":23,"roles":315,"affiliations":316,"properties":327},"78bfa498-a508-432f-94a2-c2a98eaac427",63,[],[317],{"id":318,"sortIndex":24,"affiliation":319,"properties":23},"075734b6-16c3-4d90-85be-af9b384af40f",{"id":320,"createTime":321,"updateTime":321,"relativeEntities":322,"slug":323,"properties":324,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},"785b38ef-0143-4249-acac-e6b134026850","2024-08-31T23:42:46.792+00:00",[],"Department-of-Laboratory-Diagnostics-Clinical-Hospital-Center-Zagreb-University-School-of-Medicine-Zagreb-Croatia-",{"title":325},{"EN":326},"Department of Laboratory Diagnostics, Clinical Hospital Center, Zagreb University School of Medicine, Zagreb, Croatia,",{"openalex":328,"orcid":330,"title":332},{"VOID":329},"A5035243916",{"VOID":331},"https:\u002F\u002Forcid.org\u002F0000-0003-1590-0514",{"EN":333},"Renata Zadro",{"id":335,"sortIndex":69,"researcher":23,"roles":336,"affiliations":337,"properties":344},"ced8a486-d1df-4f24-b0f9-d0555bf1395c",[],[338],{"id":339,"sortIndex":24,"affiliation":340,"properties":23},"45f90a2f-ea50-497c-9746-f5d30e279918",{"id":188,"createTime":189,"updateTime":190,"relativeEntities":341,"slug":192,"properties":342,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},[],{"title":343},{"VI":195},{"openalex":345,"orcid":347,"title":349},{"VOID":346},"A5005864167",{"VOID":348},"https:\u002F\u002Forcid.org\u002F0000-0002-8465-7231",{"EN":350},"Stefanie Trapmann",{"id":352,"sortIndex":24,"researcher":23,"roles":353,"affiliations":354,"properties":366},"ff61acc8-ad5c-4bf7-9601-6522eb40167f",[],[355],{"id":356,"sortIndex":24,"affiliation":357,"properties":23},"3c0084c4-78c8-4657-ab5a-5b0b823ebc43",{"id":358,"createTime":359,"updateTime":360,"relativeEntities":361,"slug":362,"properties":363,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},"81a77394-c501-4d4f-9959-a8c0b6f9b8ae","2024-01-20T15:09:48.841+00:00","2024-09-26T15:50:57.238+00:00",[],"National-Genetics-Reference-Laboratory-Wessex-Salisbury-District-Hospital-Salisbury-UK",{"title":364},{"VI":365},"National Genetics Reference Laboratory (Wessex), Salisbury District Hospital, Salisbury, UK",{"openalex":367,"orcid":369,"title":371},{"VOID":368},"A5101551399",{"VOID":370},"https:\u002F\u002Forcid.org\u002F0000-0001-7823-7831",{"EN":372},"Helen White",{"id":374,"sortIndex":375,"researcher":23,"roles":376,"affiliations":377,"properties":388},"a7ada14e-3aad-4f1a-8373-5b94800e3fb6",10,[],[378],{"id":379,"sortIndex":24,"affiliation":380,"properties":23},"cdab8abd-fc5b-4e4a-b08e-36d0e3621531",{"id":381,"createTime":382,"updateTime":382,"relativeEntities":383,"slug":384,"properties":385,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},"9c57660b-ca91-46c2-8e40-b22b88236eca","2024-08-31T23:42:46.972+00:00",[],"Department-of-Molecular-Medicine-and-Surgery-Clinical-Genetics-Karolinska-Institutet-Stockholm-Sweden",{"title":386},{"EN":387},"Department of Molecular Medicine and Surgery, Clinical Genetics Karolinska Institutet, Stockholm, Sweden",{"openalex":389,"orcid":391,"title":393},{"VOID":390},"A5080947541",{"VOID":392},"https:\u002F\u002Forcid.org\u002F0000-0003-3185-2962",{"EN":394},"Gisela Barbany",{"id":396,"sortIndex":397,"researcher":23,"roles":398,"affiliations":399,"properties":411},"cc76d2b0-8137-4bbd-9040-2ac0c30a0994",18,[],[400],{"id":401,"sortIndex":24,"affiliation":402,"properties":23},"10d7dc5a-684b-4733-8e08-0beff78a5636",{"id":403,"createTime":404,"updateTime":405,"relativeEntities":406,"slug":407,"properties":408,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},"57786d8f-31ad-4b55-ad97-a4cbaf134d0b","2024-01-26T10:27:30.101+00:00","2024-08-31T23:42:46.620+00:00",[],"Department-of-Clinical-and-Biological-Science-University-of-Turin-Turin-Italy",{"title":409},{"VI":410},"Department of Clinical and Biological Science, University of Turin, Turin, Italy",{"openalex":412,"title":414},{"VOID":413},"A5036407704",{"EN":415},"Filomena Daraio",{"id":417,"sortIndex":418,"researcher":23,"roles":419,"affiliations":420,"properties":431},"0606cb8a-9d52-439a-8025-da5c452938f8",55,[],[421],{"id":422,"sortIndex":24,"affiliation":423,"properties":23},"3ad906d0-e479-4841-a6f7-7174547a5279",{"id":424,"createTime":425,"updateTime":425,"relativeEntities":426,"slug":427,"properties":428,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},"12acdf96-85a7-4998-8c83-d077d6a7b73a","2024-08-31T23:42:46.988+00:00",[],"Hematology-Department-Fundeni-Clinical-Institute-University-of-Medicine-and-Pharmacy-Carol-Davila-Bucharest-Romania-",{"title":429},{"EN":430},"Hematology Department, Fundeni Clinical Institute, University of Medicine and Pharmacy ‘Carol Davila’, Bucharest, Romania,",{"openalex":432,"orcid":434,"title":436},{"VOID":433},"A5090860509",{"VOID":435},"https:\u002F\u002Forcid.org\u002F0000-0003-0223-0400",{"EN":437},"Rodica Tălmaci",{"id":439,"sortIndex":440,"researcher":23,"roles":441,"affiliations":442,"properties":453},"a1668c61-ebdf-4206-9fb1-40e35daff9de",52,[],[443],{"id":444,"sortIndex":24,"affiliation":445,"properties":23},"13d33ce7-4c53-45ad-b93e-c1fc72a16c71",{"id":446,"createTime":447,"updateTime":447,"relativeEntities":448,"slug":449,"properties":450,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},"302dc8ff-8e8c-48ef-8929-83210642b348","2024-08-31T23:42:46.897+00:00",[],"United-Laboratories-of-Tartu-University-Hospitals-Tartu-Estonia-",{"title":451},{"EN":452},"United Laboratories of Tartu University Hospitals, Tartu, Estonia,",{"openalex":454,"title":456},{"VOID":455},"A5029943413",{"EN":457},"Kadri Raudsepp",{"id":459,"sortIndex":460,"researcher":23,"roles":461,"affiliations":462,"properties":473},"acecaf57-7495-4b4e-b91d-26fb3e0223f6",12,[],[463],{"id":464,"sortIndex":24,"affiliation":465,"properties":23},"59654c28-7185-449c-9147-65fe623a5281",{"id":466,"createTime":467,"updateTime":467,"relativeEntities":468,"slug":469,"properties":470,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},"8b3032be-e41e-4630-92c1-b3905afc679c","2024-08-31T23:42:46.101+00:00",[],"Molecular-Malignancy-Laboratory-and-Haemato-Oncology-Diagnostic-Service-Cambridge-University-Hospitals-NHS-Foundation-Trust-Cambridge-UK",{"title":471},{"EN":472},"Molecular Malignancy Laboratory and Haemato-Oncology Diagnostic Service, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK",{"openalex":474,"title":476},{"VOID":475},"A5086616451",{"EN":477},"Anthony J. Bench",{"id":479,"sortIndex":480,"researcher":23,"roles":481,"affiliations":482,"properties":493},"5e83d054-6656-44ba-9653-296d1bc3804f",62,[],[483],{"id":484,"sortIndex":24,"affiliation":485,"properties":23},"ee9e4cb3-85d1-41f1-a451-3606661ef1ad",{"id":486,"createTime":487,"updateTime":487,"relativeEntities":488,"slug":489,"properties":490,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},"39b14138-3ea2-4455-8b52-cd8cea24d66d","2024-08-31T23:42:46.403+00:00",[],"Molecular-Diagnostics-The-Royal-Marsden-NHS-Foundation-Trust-Sutton-UK-",{"title":491},{"EN":492},"Molecular Diagnostics, The Royal Marsden NHS Foundation Trust, Sutton, UK,",{"openalex":494,"title":496},{"VOID":495},"A5083951157",{"EN":497},"Dörte Wren",{"id":499,"sortIndex":500,"researcher":23,"roles":501,"affiliations":502,"properties":509},"4467fe29-a1d5-430d-9c1f-86133c0f2d69",1,[],[503],{"id":504,"sortIndex":24,"affiliation":505,"properties":23},"dcef2ff4-385f-44ee-9d1a-3fbeeaa3400a",{"id":188,"createTime":189,"updateTime":190,"relativeEntities":506,"slug":192,"properties":507,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},[],{"title":508},{"VI":195},{"openalex":510,"orcid":512,"title":514},{"VOID":511},"A5010408809",{"VOID":513},"https:\u002F\u002Forcid.org\u002F0000-0002-6895-0382",{"EN":515},"Liesbet Deprez",{"id":517,"sortIndex":518,"researcher":23,"roles":519,"affiliations":520,"properties":531},"ff6e4da1-6840-41c7-8f5e-cb71f89229ba",11,[],[521],{"id":522,"sortIndex":24,"affiliation":523,"properties":23},"638a0fae-d10a-40cd-b8ff-0762fb35ea65",{"id":524,"createTime":525,"updateTime":525,"relativeEntities":526,"slug":527,"properties":528,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},"1e864c3b-fb09-4c25-b97a-350b9971bc0f","2024-08-31T23:42:47.022+00:00",[],"Department-of-Laboratory-Medicine-UZ-Leuven-Belgium",{"title":529},{"EN":530},"Department of Laboratory Medicine, UZ Leuven, Belgium",{"openalex":532,"orcid":534,"title":536},{"VOID":533},"A5026103367",{"VOID":535},"https:\u002F\u002Forcid.org\u002F0000-0002-7746-0414",{"EN":537},"Nancy Boeckx",{"id":539,"sortIndex":540,"researcher":23,"roles":541,"affiliations":542,"properties":554},"e3ebf4eb-a496-446b-b454-2b7bfa586eec",64,[],[543],{"id":544,"sortIndex":24,"affiliation":545,"properties":23},"cff98ab4-71e9-41d2-9068-83f60164b13a",{"id":546,"createTime":547,"updateTime":548,"relativeEntities":549,"slug":550,"properties":551,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},"920a74b9-eaf8-48a5-b0c7-558e0f161732","2024-01-09T19:01:22.302+00:00","2024-08-31T23:42:46.455+00:00",[],"Department-of-Hematology-Oncology-Jena-University-Hospital-Jena-Germany",{"title":552},{"VI":553},"Department of Hematology\u002FOncology, Jena University Hospital, Jena, Germany",{"openalex":555,"orcid":557,"title":559},{"VOID":556},"A5028654511",{"VOID":558},"https:\u002F\u002Forcid.org\u002F0000-0002-1264-9240",{"EN":560},"Janine M. Ziermann",{"id":562,"sortIndex":563,"researcher":23,"roles":564,"affiliations":565,"properties":576},"2676d3a9-b40c-453f-9d2e-4a7d143be55b",44,[],[566],{"id":567,"sortIndex":24,"affiliation":568,"properties":23},"5a189dde-1f20-47d1-ada6-08166c2389f8",{"id":569,"createTime":570,"updateTime":570,"relativeEntities":571,"slug":572,"properties":573,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},"7d22c294-5e5b-4ec3-bbdb-209d1424cdec","2024-08-31T23:42:46.719+00:00",[],"Molecular-Oncology-Diagnostics-Unit-Guy-s-Hospital-London-UK-",{"title":574},{"EN":575},"Molecular Oncology Diagnostics Unit, Guy’s Hospital, London, UK,",{"openalex":577,"title":579},{"VOID":578},"A5048268774",{"EN":580},"Guillermina Nickless",{"id":582,"sortIndex":583,"researcher":23,"roles":584,"affiliations":585,"properties":596},"c9c3a8e4-e2a2-4cfd-ae44-385c844f9270",24,[],[586],{"id":587,"sortIndex":24,"affiliation":588,"properties":23},"4c6a21ab-c068-4fa9-b90f-22def570f24d",{"id":589,"createTime":590,"updateTime":590,"relativeEntities":591,"slug":592,"properties":593,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},"b087d952-bd6e-4199-a477-8a4fe78a8810","2024-08-31T23:42:46.071+00:00",[],"Imperial-Molecular-Pathology-Centre-for-Haematology-Imperial-College-London-London-UK-",{"title":594},{"EN":595},"Imperial Molecular Pathology, Centre for Haematology, Imperial College London, London, UK,",{"openalex":597,"orcid":599,"title":601},{"VOID":598},"A5063569331",{"VOID":600},"https:\u002F\u002Forcid.org\u002F0000-0002-4614-227X",{"EN":602},"Gareth Gerrard",{"id":604,"sortIndex":605,"researcher":23,"roles":606,"affiliations":607,"properties":618},"228f36c7-94dd-49bd-a4e0-3b823b752d12",25,[],[608],{"id":609,"sortIndex":24,"affiliation":610,"properties":23},"6d5c4fc1-8701-4c97-9bc0-c36c8fc861bc",{"id":611,"createTime":612,"updateTime":612,"relativeEntities":613,"slug":614,"properties":615,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},"6c49e850-0317-4895-ab89-78ee0ed2b212","2024-08-31T23:42:46.146+00:00",[],"Hematology-Oncology-and-Transfusion-Medicine-Center-Vilnius-University-Hospital-Santariskiu-Clinics-Vilnius-Lithuania-",{"title":616},{"EN":617},"Hematology, Oncology and Transfusion Medicine Center, Vilnius University Hospital Santariskiu Clinics, Vilnius, Lithuania,",{"openalex":619,"title":621},{"VOID":620},"A5068127249",{"EN":622},"Eglė Gineikienė",{"id":624,"sortIndex":625,"researcher":23,"roles":626,"affiliations":627,"properties":638},"06cecf84-f407-4de4-8a13-adec43abe2a9",48,[],[628],{"id":629,"sortIndex":24,"affiliation":630,"properties":23},"2763ced4-9da7-4041-9ad3-e8ec11cf4314",{"id":631,"createTime":632,"updateTime":632,"relativeEntities":633,"slug":634,"properties":635,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},"5450af77-c2cc-459b-b93e-36e0daa2aa37","2024-08-31T23:42:46.801+00:00",[],"Genetics-Department-Institute-of-Experimental-Medicine-DETAE-Istanbul-University-Istanbul-Turkey-",{"title":636},{"EN":637},"Genetics Department, Institute of Experimental Medicine (DETAE), Istanbul University, Istanbul, Turkey,",{"openalex":639,"orcid":641,"title":643},{"VOID":640},"A5023263554",{"VOID":642},"https:\u002F\u002Forcid.org\u002F0000-0001-5319-0547",{"EN":644},"Uğur Özbek",{"id":646,"sortIndex":647,"researcher":23,"roles":648,"affiliations":649,"properties":660},"9467215f-6e88-43a9-8fc5-4721adc9a833",26,[],[650],{"id":651,"sortIndex":24,"affiliation":652,"properties":23},"b42b2d5c-a8a6-4d1c-99b7-ab907067f2e1",{"id":653,"createTime":654,"updateTime":654,"relativeEntities":655,"slug":656,"properties":657,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},"48f81dc3-e9d4-441c-971a-6e2d98a1685d","2024-08-31T23:42:46.752+00:00",[],"Laboratory-of-Molecular-Biology-and-UMR5239-Centre-Hospitalier-Lyon-Sud-Hospices-Civils-de-Lyon-Pierre-B%C3%A9nite-France-",{"title":658},{"EN":659},"Laboratory of Molecular Biology and UMR5239, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, Pierre Bénite, France,",{"openalex":661,"orcid":663,"title":665},{"VOID":662},"A5023619034",{"VOID":664},"https:\u002F\u002Forcid.org\u002F0000-0001-7098-092X",{"EN":666},"Emmanuelle Clappier",{"id":668,"sortIndex":669,"researcher":23,"roles":670,"affiliations":671,"properties":682},"062e36fb-805a-47bb-98f5-4cec82638490",41,[],[672],{"id":673,"sortIndex":24,"affiliation":674,"properties":23},"86e694ea-8f4b-4126-bfac-354073fcb841",{"id":675,"createTime":676,"updateTime":676,"relativeEntities":677,"slug":678,"properties":679,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},"61226a54-8bfd-43f2-9674-0b6433442020","2024-08-31T23:42:46.691+00:00",[],"Department-of-Medical-Genetics-NHS-Grampian-Aberdeen-UK-",{"title":680},{"EN":681},"Department of Medical Genetics, NHS-Grampian, Aberdeen, UK,",{"openalex":683,"title":685},{"VOID":684},"A5068379605",{"EN":686},"Beth Milner",{"id":688,"sortIndex":689,"researcher":23,"roles":690,"affiliations":691,"properties":702},"18a1fd21-a32c-4795-a6ba-0df229580d89",14,[],[692],{"id":693,"sortIndex":24,"affiliation":694,"properties":23},"a69ad005-676e-4808-b574-b1f6714a7fc8",{"id":695,"createTime":696,"updateTime":696,"relativeEntities":697,"slug":698,"properties":699,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},"84295f73-84b5-453c-b1dc-d3cfdd01e36c","2024-08-31T23:42:46.733+00:00",[],"Haematology-Laboratory-and-EA3518-University-Hospital-Saint-Louis-AP-HP-University-Paris-Diderot-Paris-France",{"title":700},{"EN":701},"Haematology Laboratory and EA3518, University Hospital Saint-Louis, AP-HP, University Paris Diderot, Paris, France",{"openalex":703,"title":705},{"VOID":704},"A5021229301",{"EN":706},"J-M Cayuela",{"id":708,"sortIndex":709,"researcher":23,"roles":710,"affiliations":711,"properties":722},"af7aab2e-99c7-498b-a156-143f20bc02ee",33,[],[712],{"id":713,"sortIndex":24,"affiliation":714,"properties":23},"422fb759-bed8-40fe-9640-8f29cce1a427",{"id":715,"createTime":716,"updateTime":716,"relativeEntities":717,"slug":718,"properties":719,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},"946ca3b7-f9ee-461f-bf16-91c79b77f69d","2024-08-31T23:42:47.012+00:00",[],"Laboratory-for-Molecular-Haemato-Oncology-Kings-College-Hospital-London-UK-",{"title":720},{"EN":721},"Laboratory for Molecular Haemato-Oncology, Kings College Hospital, London, UK,",{"openalex":723,"title":725},{"VOID":724},"A5030927335",{"EN":726},"Aytug Kizilors",{"id":728,"sortIndex":729,"researcher":23,"roles":730,"affiliations":731,"properties":743},"3365dd28-b9e7-4153-885b-08052f734d16",8,[],[732],{"id":733,"sortIndex":24,"affiliation":734,"properties":23},"5c38b93e-de41-42e6-9e81-70dee166419f",{"id":735,"createTime":736,"updateTime":737,"relativeEntities":738,"slug":739,"properties":740,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},"2aa346b1-5e8d-4c2b-9156-6e45f3b575df","2024-01-16T15:31:21.237+00:00","2024-08-31T23:42:46.858+00:00",[],"Hungarian-National-Blood-Transfusion-Service-Budapest-Hungary",{"title":741},{"VI":742},"Hungarian National Blood Transfusion Service, Budapest, Hungary",{"openalex":744,"orcid":746,"title":748},{"VOID":745},"A5082857027",{"VOID":747},"https:\u002F\u002Forcid.org\u002F0000-0002-8368-9784",{"EN":749},"Hajnalka Andrikovics",{"id":751,"sortIndex":752,"researcher":23,"roles":753,"affiliations":754,"properties":766},"fc41635b-7c4d-4b19-b792-6794828d15ed",66,[],[755],{"id":756,"sortIndex":24,"affiliation":757,"properties":23},"72cf9ddf-2e30-47c9-89a4-aa3be3024e7b",{"id":758,"createTime":759,"updateTime":760,"relativeEntities":761,"slug":762,"properties":763,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},"d531291f-ae8c-4c39-82be-68548b425fb8","2024-01-12T11:54:11.163+00:00","2024-12-01T14:32:35.280+00:00",[],"III-Medizinische-Klinik-Medizinische-Fakult%C3%A4t-Mannheim-der-Universit%C3%A4t-Heidelberg-Mannheim-Germany",{"title":764},{"VI":765},"III. Medizinische Klinik, Medizinische Fakultät Mannheim der Universität Heidelberg, Mannheim, Germany",{"openalex":767,"orcid":769,"title":771},{"VOID":768},"A5011234127",{"VOID":770},"https:\u002F\u002Forcid.org\u002F0000-0001-7740-7798",{"EN":772},"Martin Müller",{"id":774,"sortIndex":775,"researcher":23,"roles":776,"affiliations":777,"properties":784},"06bc49e3-eafc-41a9-ade1-f7fc9fb68650",67,[],[778],{"id":779,"sortIndex":24,"affiliation":780,"properties":23},"7bdd1998-3610-4cba-aea6-e56c1d287def",{"id":546,"createTime":547,"updateTime":548,"relativeEntities":781,"slug":550,"properties":782,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},[],{"title":783},{"VI":553},{"openalex":785,"orcid":787,"title":789},{"VOID":786},"A5035964802",{"VOID":788},"https:\u002F\u002Forcid.org\u002F0000-0003-0626-0834",{"EN":790},"Andreas Hochhaus",{"id":792,"sortIndex":793,"researcher":23,"roles":794,"affiliations":795,"properties":807},"248653c5-e809-480a-b3b7-1c3060f0d3d5",50,[],[796],{"id":797,"sortIndex":24,"affiliation":798,"properties":23},"820b6c60-e898-4c4f-9329-757434b7ab8a",{"id":799,"createTime":800,"updateTime":801,"relativeEntities":802,"slug":803,"properties":804,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},"b4225b2a-923c-4502-9c14-1c65b2fb1639","2024-01-20T16:09:06.600+00:00","2024-08-31T23:42:46.758+00:00",[],"Department-of-Internal-Medicine-Hematology-Oncology-Goethe-University-Frankfurt-Germany",{"title":805},{"VI":806},"Department of Internal Medicine, Hematology\u002FOncology, Goethe University, Frankfurt, Germany",{"openalex":808,"orcid":810,"title":812},{"VOID":809},"A5101553405",{"VOID":811},"https:\u002F\u002Forcid.org\u002F0000-0003-1543-3995",{"EN":813},"Roman Pfeifer",{"id":815,"sortIndex":816,"researcher":23,"roles":817,"affiliations":818,"properties":830},"4805a1eb-5d72-4102-a2ca-8ef8f097e057",38,[],[819],{"id":820,"sortIndex":24,"affiliation":821,"properties":23},"8dd8a2b3-b8c0-4ce9-9b33-1ac4da719161",{"id":822,"createTime":823,"updateTime":824,"relativeEntities":825,"slug":826,"properties":827,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},"6b2cb3bf-c9f2-4ea0-8056-b8d8f1d439ce","2023-12-23T09:51:49.584+00:00","2024-10-10T01:09:04.300+00:00",[],"Department-of-Experimental-Diagnostic-and-Specialty-Medicine-University-of-Bologna-Bologna-Italy",{"title":828},{"VI":829},"Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy",{"openalex":831,"orcid":833,"title":835},{"VOID":832},"A5073761054",{"VOID":834},"https:\u002F\u002Forcid.org\u002F0000-0002-1025-4210",{"EN":836},"Giovanni Martinelli",{"id":838,"sortIndex":839,"researcher":23,"roles":840,"affiliations":841,"properties":853},"def2acde-c790-47dc-8b04-b1a319a603bc",43,[],[842],{"id":843,"sortIndex":24,"affiliation":844,"properties":23},"46f6f07d-b824-4d83-ad73-971c863fd40d",{"id":845,"createTime":846,"updateTime":847,"relativeEntities":848,"slug":849,"properties":850,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},"87f44975-d97b-48c0-a2b0-15fda62710c3","2024-01-04T06:50:16.669+00:00","2024-08-31T23:42:46.054+00:00",[],"Laboratory-of-Hematology-Sheba-Medical-Center-Tel-Hashomer-Israel",{"title":851},{"VI":852},"Laboratory of Hematology, Sheba Medical Center, Tel Hashomer, Israel",{"openalex":854,"title":856},{"VOID":855},"A5068012384",{"EN":857},"Meital Nagar",{"id":859,"sortIndex":860,"researcher":23,"roles":861,"affiliations":862,"properties":873},"5ff5a9f9-9a65-4e3b-a27b-e5b587356861",19,[],[863],{"id":864,"sortIndex":24,"affiliation":865,"properties":23},"14486932-3e25-4cfd-95b3-ca1b82fa5e9d",{"id":866,"createTime":867,"updateTime":867,"relativeEntities":868,"slug":869,"properties":870,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},"525b6fcb-f3c8-4613-a93e-a01595393f32","2024-08-31T23:42:46.259+00:00",[],"Laboratoire-Hematologie-CHU-Bordeaux-Hematopoiese-Leucemique-et-Cibles-Therapeutiques-INSERM-U1035-Universite-Bordeaux-Bordeaux-France-",{"title":871},{"EN":872},"Laboratoire Hematologie, CHU Bordeaux, Hematopoiese Leucemique et Cibles Therapeutiques, INSERM U1035, Universite Bordeaux, Bordeaux, France,",{"openalex":874,"orcid":876,"title":878},{"VOID":875},"A5046360304",{"VOID":877},"https:\u002F\u002Forcid.org\u002F0000-0003-2728-7243",{"EN":879},"Stéphanie Dulucq",{"id":881,"sortIndex":882,"researcher":23,"roles":883,"affiliations":884,"properties":895},"1a5840e7-3a46-4c3e-8cf8-5696a08ccc28",49,[],[885],{"id":886,"sortIndex":24,"affiliation":887,"properties":23},"b8c3abb6-6fdc-40a5-9d46-cfb3ff56e0c9",{"id":888,"createTime":889,"updateTime":889,"relativeEntities":890,"slug":891,"properties":892,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},"cf134800-25d5-4dc8-8e1e-32d65672cf95","2024-08-31T23:42:46.872+00:00",[],"Division-of-Internal-Medicine-Department-of-Haematology-Specialized-Haematology-Laboratory-University-Medical-Centre-Ljubljana-Slovenia-",{"title":893},{"EN":894},"Division of Internal Medicine, Department of Haematology, Specialized Haematology Laboratory, University Medical Centre, Ljubljana, Slovenia,",{"openalex":896,"orcid":898,"title":900},{"VOID":897},"A5011692704",{"VOID":899},"https:\u002F\u002Forcid.org\u002F0000-0002-6535-0357",{"EN":901},"Tadej Pajič",{"id":903,"sortIndex":904,"researcher":23,"roles":905,"affiliations":906,"properties":917},"77d4e402-e9a0-4ab0-a61c-f6b467e39713",31,[],[907],{"id":908,"sortIndex":24,"affiliation":909,"properties":23},"f0496dcf-28fe-41e7-a319-31026b5d7890",{"id":910,"createTime":911,"updateTime":911,"relativeEntities":912,"slug":913,"properties":914,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},"45e6517c-ea80-4371-9548-0d2c1e7a6e20","2024-08-31T23:42:46.953+00:00",[],"Department-of-Internal-Medicine-Hematology-and-Oncology-Masaryk-University-and-University-Hospital-Brno-Brno-Czech-Republic-",{"title":915},{"EN":916},"Department of Internal Medicine-Hematology and Oncology, Masaryk University and University Hospital Brno, Brno, Czech Republic,",{"openalex":918,"title":920},{"VOID":919},"A5001656335",{"EN":921},"Tomáš Jurček",{"id":923,"sortIndex":924,"researcher":23,"roles":925,"affiliations":926,"properties":938},"0f650fa9-827a-44b7-b988-7da9711ac5ae",4,[],[927],{"id":928,"sortIndex":24,"affiliation":929,"properties":23},"73592b7f-cd26-4c7f-b97e-07067be162a8",{"id":930,"createTime":931,"updateTime":932,"relativeEntities":933,"slug":934,"properties":935,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},"74302418-c331-46e8-8ec3-9f4589f28070","2023-12-07T16:22:23.313+00:00","2024-12-10T09:21:13.637+00:00",[],"Faculty-of-Medicine-University-of-Southampton-Southampton-UK",{"title":936},{"VI":937},"Faculty of Medicine, University of Southampton, Southampton, UK",{"openalex":939,"orcid":941,"title":943},{"VOID":940},"A5103241560",{"VOID":942},"https:\u002F\u002Forcid.org\u002F0000-0001-9115-239X",{"EN":944},"Feng Lin",{"id":946,"sortIndex":947,"researcher":23,"roles":948,"affiliations":949,"properties":961},"131f8696-cc4a-4a37-9366-45c18f5b6901",13,[],[950],{"id":951,"sortIndex":24,"affiliation":952,"properties":23},"50fe3e7c-ba6f-4e2d-b931-4150c73d7e71",{"id":953,"createTime":954,"updateTime":955,"relativeEntities":956,"slug":957,"properties":958,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},"6d604f15-bdd2-4ee7-a754-80a343aece7c","2024-01-18T13:17:19.468+00:00","2024-08-31T23:42:46.967+00:00",[],"Haematology-Department-Belfast-City-Hospital-Belfast-UK",{"title":959},{"VI":960},"Haematology Department, Belfast City Hospital, Belfast, UK",{"openalex":962,"orcid":964,"title":966},{"VOID":963},"A5051652459",{"VOID":965},"https:\u002F\u002Forcid.org\u002F0000-0001-8219-4651",{"EN":967},"Mark Catherwood",{"id":969,"sortIndex":970,"researcher":23,"roles":971,"affiliations":972,"properties":984},"b40203bc-4569-48aa-9edf-00cca13a2788",59,[],[973],{"id":974,"sortIndex":24,"affiliation":975,"properties":23},"23b52c93-8c45-4610-ad99-a7b758e60161",{"id":976,"createTime":977,"updateTime":978,"relativeEntities":979,"slug":980,"properties":981,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},"4bc86d54-2240-4292-854b-94d842d7c55a","2024-01-11T22:29:06.033+00:00","2024-12-01T14:32:14.565+00:00",[],"Department-of-Haematology-Royal-Liverpool-University-Hospital-Liverpool-UK",{"title":982},{"VI":983},"Department of Haematology, Royal Liverpool University Hospital, Liverpool, UK",{"openalex":985,"title":987},{"VOID":986},"A5087133383",{"EN":988},"L Wang",{"id":990,"sortIndex":991,"researcher":23,"roles":992,"affiliations":993,"properties":1005},"a4a7cf91-af92-4581-b364-97fa6a14e9e7",29,[],[994],{"id":995,"sortIndex":24,"affiliation":996,"properties":23},"5aec2377-3fe0-4ee8-8c03-881f3264cc6f",{"id":997,"createTime":998,"updateTime":999,"relativeEntities":1000,"slug":1001,"properties":1002,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},"858e9ad5-5bef-49bd-9c27-83d37f4d60f6","2023-12-07T17:55:25.908+00:00","2024-12-25T09:53:49.011+00:00",[],"Department-of-Immunology-Genetics-and-Pathology-Uppsala-University-Uppsala-Sweden",{"title":1003},{"VI":1004},"Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden",{"openalex":1006,"title":1008},{"VOID":1007},"A5057413183",{"EN":1009},"Mattias Jansson",{"id":1011,"sortIndex":1012,"researcher":23,"roles":1013,"affiliations":1014,"properties":1025},"48bb21b4-0b8f-431b-98fe-71954e906739",15,[],[1015],{"id":1016,"sortIndex":24,"affiliation":1017,"properties":23},"8c08ecb6-8887-4188-81a3-08fa8e982eb2",{"id":1018,"createTime":1019,"updateTime":1019,"relativeEntities":1020,"slug":1021,"properties":1022,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},"ea99d5cc-67c4-4edf-91f0-05644eb8fdeb","2024-08-31T23:42:46.168+00:00",[],"Department-of-Molecular-Haematology-Yorkhill-NHS-Trust-Glasgow-UK",{"title":1023},{"EN":1024},"Department of Molecular Haematology, Yorkhill NHS Trust, Glasgow, UK",{"openalex":1026,"title":1028},{"VOID":1027},"A5036283350",{"EN":1029},"Sandra Chudleigh",{"id":1031,"sortIndex":1032,"researcher":23,"roles":1033,"affiliations":1034,"properties":1046},"8b7fb00f-a772-4e4c-a7d6-020886e7edab",21,[],[1035],{"id":1036,"sortIndex":24,"affiliation":1037,"properties":23},"3bbb0d51-8978-4e1e-95f0-ed33a3c87938",{"id":1038,"createTime":1039,"updateTime":1040,"relativeEntities":1041,"slug":1042,"properties":1043,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},"63974b19-71dd-46fb-b21f-29ce03d6edb8","2024-01-25T15:04:37.745+00:00","2024-08-31T23:42:46.643+00:00",[],"Department-of-Genetics-and-Molecular-Pathology-SA-Pathology-Adelaide-SA-Australia",{"title":1044},{"VI":1045},"Department of Genetics and Molecular Pathology, SA Pathology, Adelaide, SA, Australia",{"openalex":1047,"title":1049},{"VOID":1048},"A5008922637",{"EN":1050},"Linda Fletcher",{"id":1052,"sortIndex":1053,"researcher":23,"roles":1054,"affiliations":1055,"properties":1066},"ed08e337-c660-440f-a87c-96a032075bde",53,[],[1056],{"id":1057,"sortIndex":24,"affiliation":1058,"properties":23},"402a8735-0210-4e84-94a3-619389ac32e6",{"id":1059,"createTime":1060,"updateTime":1060,"relativeEntities":1061,"slug":1062,"properties":1063,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},"d7c4252c-9937-4c93-8f15-599bb14f1ca3","2024-08-31T23:42:46.826+00:00",[],"Molecular-Haematology-Laboratory-PathWest-Laboratory-Medicine-Royal-Perth-Hospital-Perth-WA-Australia-",{"title":1064},{"EN":1065},"Molecular Haematology Laboratory, PathWest Laboratory Medicine, Royal Perth Hospital, Perth, WA, Australia,",{"openalex":1067,"title":1069},{"VOID":1068},"A5075798306",{"EN":1070},"Giuliana Romeo",{"id":1072,"sortIndex":1073,"researcher":23,"roles":1074,"affiliations":1075,"properties":1087},"8d6d64bf-101f-4127-a72d-28ce3f4f8692",58,[],[1076],{"id":1077,"sortIndex":24,"affiliation":1078,"properties":23},"0a2e633a-b3ee-4e05-aaed-112d90af1101",{"id":1079,"createTime":1080,"updateTime":1081,"relativeEntities":1082,"slug":1083,"properties":1084,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},"f88b7445-0782-42aa-b25a-0042278a4a65","2023-11-27T21:05:27.656+00:00","2024-08-31T23:42:46.809+00:00",[],"Bristol-Genetics-Laboratory-Southmead-Hospital-Bristol-UK",{"title":1085},{"VI":1086},"Bristol Genetics Laboratory, Southmead Hospital, Bristol, UK",{"openalex":1088,"title":1090},{"VOID":1089},"A5086738822",{"EN":1091},"Paula Waits",{"id":1093,"sortIndex":1094,"researcher":23,"roles":1095,"affiliations":1096,"properties":1108},"7b7161ef-c663-4895-8152-4fd60a984165",17,[],[1097],{"id":1098,"sortIndex":24,"affiliation":1099,"properties":23},"1d4cfd04-5301-4186-be5c-df45406520bd",{"id":1100,"createTime":1101,"updateTime":1102,"relativeEntities":1103,"slug":1104,"properties":1105,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},"39494339-e12c-435a-a8e2-02aed5bb2113","2024-01-01T18:47:30.737+00:00","2024-08-31T23:42:46.111+00:00",[],"Hematopathology-Unit-Hospital-Clinic-IDIBAPS-Barcelona-Spain",{"title":1106},{"VI":1107},"Hematopathology Unit, Hospital Clinic, IDIBAPS, Barcelona, Spain",{"openalex":1109,"orcid":1111,"title":1113},{"VOID":1110},"A5081889907",{"VOID":1112},"https:\u002F\u002Forcid.org\u002F0000-0001-7486-8484",{"EN":1114},"Dolors Colomer",{"id":1116,"sortIndex":1117,"researcher":23,"roles":1118,"affiliations":1119,"properties":1130},"cfe7c945-868e-44bd-8d86-4219453f9cd3",23,[],[1120],{"id":1121,"sortIndex":24,"affiliation":1122,"properties":23},"839e2fa4-152f-4c81-af9f-3f8561cc5373",{"id":1123,"createTime":1124,"updateTime":1124,"relativeEntities":1125,"slug":1126,"properties":1127,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},"f81a41e3-c24f-49d4-9226-812b1d08e544","2024-08-31T23:42:46.004+00:00",[],"Molecular-Pathology-University-Hospitals-Southampton-NHS-Foundation-Trust-Southampton-UK-",{"title":1128},{"EN":1129},"Molecular Pathology, University Hospitals Southampton NHS Foundation Trust, Southampton, UK,",{"openalex":1131,"title":1133},{"VOID":1132},"A5059042760",{"EN":1134},"Rosalind H. Ganderton",{"id":1136,"sortIndex":1137,"researcher":23,"roles":1138,"affiliations":1139,"properties":1150},"efcde923-aa1d-485c-9697-818bee220785",16,[],[1140],{"id":1141,"sortIndex":24,"affiliation":1142,"properties":23},"ec72b4ed-6276-4c51-9ed7-16c39596fc1a",{"id":1143,"createTime":1144,"updateTime":1144,"relativeEntities":1145,"slug":1146,"properties":1147,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},"6023cfa5-afd7-4193-ae24-80ab34f90e14","2024-08-31T23:42:46.931+00:00",[],"Molecular-Haematology-Bristol-Royal-Infirmary-Bristol-UK-",{"title":1148},{"EN":1149},"Molecular Haematology, Bristol Royal Infirmary, Bristol, UK,",{"openalex":1151,"title":1153},{"VOID":1152},"A5015074289",{"EN":1154},"Tim Clench",{"id":1156,"sortIndex":1157,"researcher":23,"roles":1158,"affiliations":1159,"properties":1170},"01237ab4-6f18-4721-8a77-59b9cdd2a261",30,[],[1160],{"id":1161,"sortIndex":24,"affiliation":1162,"properties":23},"04a3cf86-bd20-4b7c-8c45-718af4208145",{"id":1163,"createTime":1164,"updateTime":1164,"relativeEntities":1165,"slug":1166,"properties":1167,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},"ee3b2fca-8532-4d75-95a4-8d821a90e1f0","2024-08-31T23:42:46.303+00:00",[],"Department-of-Clinical-Genetics-University-and-Regional-Laboratories-Lund-Sweden-",{"title":1168},{"EN":1169},"Department of Clinical Genetics, University and Regional Laboratories, Lund, Sweden,",{"openalex":1171,"title":1173},{"VOID":1172},"A5077282129",{"EN":1174},"Petra Johnels",{"id":1176,"sortIndex":1177,"researcher":23,"roles":1178,"affiliations":1179,"properties":1191},"ef1833d2-e8cf-46e7-a2be-ead5fa13987a",57,[],[1180],{"id":1181,"sortIndex":24,"affiliation":1182,"properties":23},"9c1e1910-70b4-490d-acd1-ec6c90f96a70",{"id":1183,"createTime":1184,"updateTime":1185,"relativeEntities":1186,"slug":1187,"properties":1188,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},"2f204bfb-b66e-49bb-a14b-281d618684b1","2023-12-23T20:02:01.840+00:00","2025-02-07T02:08:02.899+00:00",[],"Department-of-Immunology-Erasmus-MC-Rotterdam-The-Netherlands",{"title":1189},{"VI":1190},"Department of Immunology, Erasmus MC, Rotterdam, The Netherlands",{"openalex":1192,"orcid":1194,"title":1196},{"VOID":1193},"A5027341200",{"VOID":1195},"https:\u002F\u002Forcid.org\u002F0000-0001-9457-3763",{"EN":1197},"Vincent H. J. van der Velden",{"id":1199,"sortIndex":1200,"researcher":23,"roles":1201,"affiliations":1202,"properties":1209},"1c7a6dd4-655b-49c7-857f-23ab2e6c90cb",22,[],[1203],{"id":1204,"sortIndex":24,"affiliation":1205,"properties":23},"4b3b2744-e3db-49d8-82e1-ac0f6330a934",{"id":589,"createTime":590,"updateTime":590,"relativeEntities":1206,"slug":592,"properties":1207,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},[],{"title":1208},{"EN":595},{"openalex":1210,"title":1212},{"VOID":1211},"A5013998402",{"EN":1213},"Letizia Foroni",{"id":1215,"sortIndex":1216,"researcher":23,"roles":1217,"affiliations":1218,"properties":1230},"d2ec66af-492c-44b6-ba0a-0ef8671f654c",9,[],[1219],{"id":1220,"sortIndex":24,"affiliation":1221,"properties":23},"f07ee266-c8b0-453a-95a6-3002e1ec2bd8",{"id":1222,"createTime":1223,"updateTime":1224,"relativeEntities":1225,"slug":1226,"properties":1227,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},"03051cba-168e-4e18-bbaf-ace9271a415b","2024-08-31T23:42:46.910+00:00","2025-06-11T16:23:21.838+00:00",[],"Regional-Genetics-Laboratory-Birmingham-Women-s-NHS-Foundation-Trust-Birmingham-UK",{"title":1228},{"EN":1229},"Regional Genetics Laboratory, Birmingham Women’s NHS Foundation Trust, Birmingham, UK",{"openalex":1231,"orcid":1233,"title":1235},{"VOID":1232},"A5037260848",{"VOID":1234},"https:\u002F\u002Forcid.org\u002F0000-0003-2817-7601",{"EN":1236},"Susanna Akiki",{"id":1238,"sortIndex":1239,"researcher":23,"roles":1240,"affiliations":1241,"properties":1253},"7833b31c-0d03-4907-85e2-98127025fc84",40,[],[1242],{"id":1243,"sortIndex":24,"affiliation":1244,"properties":23},"fe342d84-cb50-478e-b073-8c1028d16db4",{"id":1245,"createTime":1246,"updateTime":1247,"relativeEntities":1248,"slug":1249,"properties":1250,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},"64d0d3d5-193c-4c77-8f5d-710780c52ab5","2024-01-19T00:17:04.245+00:00","2024-08-31T23:42:46.767+00:00",[],"Department-of-Haematology-VU-Medical-Centre-Amsterdam-the-Netherlands",{"title":1251},{"VI":1252},"Department of Haematology, VU Medical Centre, Amsterdam, the Netherlands",{"openalex":1254,"title":1256},{"VOID":1255},"A5081157564",{"EN":1257},"Pauline A. Merle",{"id":1259,"sortIndex":1260,"researcher":23,"roles":1261,"affiliations":1262,"properties":1273},"0ea15251-ca98-455c-8256-6c3cfc32122b",36,[],[1263],{"id":1264,"sortIndex":24,"affiliation":1265,"properties":23},"01943e8d-daa3-473e-8e7a-f1f60b4fe1e9",{"id":1266,"createTime":1267,"updateTime":1267,"relativeEntities":1268,"slug":1269,"properties":1270,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},"920ce71a-a4a3-446b-825a-04a4cb7936a3","2024-08-31T23:42:46.784+00:00",[],"Children-s-Cancer-Research-Institute-LabDia-Labordiagnostik-and-Medical-University-Vienna-Austria-",{"title":1271},{"EN":1272},"Children's Cancer Research Institute\u002FLabDia Labordiagnostik and Medical University, Vienna, Austria,",{"openalex":1274,"orcid":1276,"title":1278},{"VOID":1275},"A5042206697",{"VOID":1277},"https:\u002F\u002Forcid.org\u002F0000-0001-9346-0994",{"EN":1279},"Thomas Lion",{"id":1281,"sortIndex":1282,"researcher":23,"roles":1283,"affiliations":1284,"properties":1295},"e1bb97e5-6acb-4c7e-b0da-a3174b1fe7c0",20,[],[1285],{"id":1286,"sortIndex":24,"affiliation":1287,"properties":23},"baec1673-3599-4c83-a5eb-c7f24005d735",{"id":1288,"createTime":1289,"updateTime":1289,"relativeEntities":1290,"slug":1291,"properties":1292,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},"989fe991-7bd5-45c3-8181-9b67e380d662","2024-08-31T23:42:46.996+00:00",[],"Combined-Laboratories-Derriford-Hospital-Plymouth-UK-",{"title":1293},{"EN":1294},"Combined Laboratories, Derriford Hospital, Plymouth, UK,",{"openalex":1296,"title":1298},{"VOID":1297},"A5035361173",{"EN":1299},"Joanna Farrugia",{"id":1301,"sortIndex":1302,"researcher":23,"roles":1303,"affiliations":1304,"properties":1316},"ff50c95a-0fe9-4a1b-a2be-78d227a76000",39,[],[1305],{"id":1306,"sortIndex":24,"affiliation":1307,"properties":23},"ae7ef1c7-c7b8-4184-82c6-8b3431d77e1a",{"id":1308,"createTime":1309,"updateTime":1310,"relativeEntities":1311,"slug":1312,"properties":1313,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},"b02185e5-b47d-4682-acf0-9e116856e81b","2023-12-07T20:02:39.999+00:00","2024-08-31T23:42:46.886+00:00",[],"Cancer-Molecular-Diagnostics-St-James-s-Hospital-Dublin-Ireland",{"title":1314},{"VI":1315},"Cancer Molecular Diagnostics, St. James’s Hospital, Dublin, Ireland",{"openalex":1317,"title":1319},{"VOID":1318},"A5021068435",{"EN":1320},"Sarah L. McCarron",{"id":1322,"sortIndex":1323,"researcher":23,"roles":1324,"affiliations":1325,"properties":1336},"8a25b453-07f7-4f92-9394-58d1b0eba89f",32,[],[1326],{"id":1327,"sortIndex":24,"affiliation":1328,"properties":23},"1ca5621b-8f86-4975-801c-24b0e50ddb0f",{"id":1329,"createTime":1330,"updateTime":1330,"relativeEntities":1331,"slug":1332,"properties":1333,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},"66e3373d-5769-4327-bf6e-70d7e7d8aedd","2024-08-31T23:42:45.958+00:00",[],"Turku-University-Hospital-TYKSLAB-Laboratory-of-Molecular-Genetics-Turku-Finland-",{"title":1334},{"EN":1335},"Turku University Hospital, TYKSLAB, Laboratory of Molecular Genetics, Turku, Finland,",{"openalex":1337,"orcid":1339,"title":1341},{"VOID":1338},"A5090910971",{"VOID":1340},"https:\u002F\u002Forcid.org\u002F0000-0002-0562-8054",{"EN":1342},"Veli Kairisto",{"id":1344,"sortIndex":1345,"researcher":23,"roles":1346,"affiliations":1347,"properties":1359},"4c87f4fc-cf74-44fe-8728-f5166613bcd3",37,[],[1348],{"id":1349,"sortIndex":24,"affiliation":1350,"properties":23},"d6a98f01-3194-4cda-8308-4d9a2766c352",{"id":1351,"createTime":1352,"updateTime":1353,"relativeEntities":1354,"slug":1355,"properties":1356,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},"9a385419-e17e-4eba-a818-c67f6e123da9","2023-12-06T01:34:47.412+00:00","2024-12-05T19:19:39.827+00:00",[],"Institute-of-Hematology-and-Blood-Transfusion-Prague-Czech-Republic",{"title":1357},{"VI":1358},"Institute of Hematology and Blood Transfusion, Prague, Czech Republic",{"openalex":1360,"orcid":1362,"title":1364},{"VOID":1361},"A5066839326",{"VOID":1363},"https:\u002F\u002Forcid.org\u002F0000-0002-7398-5555",{"EN":1365},"Kateřina Machová Poláková",{"id":1367,"sortIndex":1368,"researcher":23,"roles":1369,"affiliations":1370,"properties":1382},"11c533bb-cb8e-412e-8c1b-616813a6883c",61,[],[1371],{"id":1372,"sortIndex":24,"affiliation":1373,"properties":23},"ab6b654e-9cff-4a17-a832-f0fc57e527d9",{"id":1374,"createTime":1375,"updateTime":1376,"relativeEntities":1377,"slug":1378,"properties":1379,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},"043eb979-0d80-456f-b8b8-ba9bc0dd533b","2024-02-07T12:16:04.692+00:00","2025-06-11T17:31:29.154+00:00",[],"Sheffield-Diagnostic-Genetics-Service-Sheffield-Children-s-NHS-Foundation-Trust-Sheffield-UK",{"title":1380},{"VI":1381},"Sheffield Diagnostic Genetics Service, Sheffield Children's NHS Foundation Trust, Sheffield, UK",{"openalex":1383,"title":1385},{"VOID":1384},"A5083734125",{"EN":1386},"Gill Wilson",{"id":1388,"sortIndex":1389,"researcher":23,"roles":1390,"affiliations":1391,"properties":1403},"557e302e-0648-4394-924f-14bd10bc4275",34,[],[1392],{"id":1393,"sortIndex":24,"affiliation":1394,"properties":23},"ae97f0b2-b61b-4240-9550-05b95cb26b6d",{"id":1395,"createTime":1396,"updateTime":1397,"relativeEntities":1398,"slug":1399,"properties":1400,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},"65d0a7d4-1d24-46ea-9fd8-69f5674ed0ce","2023-12-11T17:19:43.404+00:00","2024-08-31T23:42:46.121+00:00",[],"Cancer-Research-Institute-The-Catholic-University-of-Korea-Seoul-South-Korea",{"title":1401},{"VI":1402},"Cancer Research Institute, The Catholic University of Korea, Seoul, South Korea",{"openalex":1404,"orcid":1406,"title":1408},{"VOID":1405},"A5100389863",{"VOID":1407},"https:\u002F\u002Forcid.org\u002F0000-0002-5687-7739",{"EN":1409},"Dongwook Kim",{"id":1411,"sortIndex":1412,"researcher":23,"roles":1413,"affiliations":1414,"properties":1425},"64a001f1-376c-426c-8cee-c5d540f58072",46,[],[1415],{"id":1416,"sortIndex":24,"affiliation":1417,"properties":23},"f775d5c3-cfae-40ef-ae7d-5c62fa34ba49",{"id":1418,"createTime":1419,"updateTime":1419,"relativeEntities":1420,"slug":1421,"properties":1422,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},"660d88a8-4e8b-4394-948c-e59712a98307","2024-08-31T23:42:47.005+00:00",[],"Division-of-Pathology-Rikshospital-Oslo-University-Hospital-Oslo-Norway-",{"title":1423},{"EN":1424},"Division of Pathology, Rikshospital, Oslo University Hospital, Oslo, Norway,",{"openalex":1426,"title":1428},{"VOID":1427},"A5021716497",{"EN":1429},"Dag André Nymoen",{"id":1431,"sortIndex":1432,"researcher":23,"roles":1433,"affiliations":1434,"properties":1446},"593c19c2-f52d-4838-acec-f263e066e66c",65,[],[1435],{"id":1436,"sortIndex":24,"affiliation":1437,"properties":23},"0e48a5ca-1fd8-4899-8c6c-81ac52d3efc2",{"id":1438,"createTime":1439,"updateTime":1440,"relativeEntities":1441,"slug":1442,"properties":1443,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},"c751f5b8-104e-4695-8ffe-f0f7de1ce05b","2024-01-12T08:31:42.103+00:00","2024-09-23T06:03:40.984+00:00",[],"Haematology-Research-Laboratory-Biomedical-Research-Foundation-Academy-of-Athens-Athens-Greece",{"title":1444},{"VI":1445},"Haematology Research Laboratory, Biomedical Research Foundation, Academy of Athens, Athens, Greece",{"openalex":1447,"title":1449},{"VOID":1448},"A5069571779",{"EN":1450},"Katerina Zoi",{"id":1452,"sortIndex":1453,"researcher":23,"roles":1454,"affiliations":1455,"properties":1462},"bc68280a-85f6-4f02-9b55-d785f640b231",3,[],[1456],{"id":1457,"sortIndex":24,"affiliation":1458,"properties":23},"04b7c2c4-0ad6-4fc1-97dd-00c51d3af13a",{"id":358,"createTime":359,"updateTime":360,"relativeEntities":1459,"slug":362,"properties":1460,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},[],{"title":1461},{"VI":365},{"openalex":1463,"orcid":1465,"title":1467},{"VOID":1464},"A5014115346",{"VOID":1466},"https:\u002F\u002Forcid.org\u002F0000-0002-3598-2214",{"EN":1468},"Vanessa Jane Hall",{"id":1470,"sortIndex":1471,"researcher":23,"roles":1472,"affiliations":1473,"properties":1480},"8b898c51-3972-4640-bffa-8d0a12435e1f",69,[],[1474],{"id":1475,"sortIndex":24,"affiliation":1476,"properties":23},"6894406f-a078-4bc7-b4bf-7370fe6fa673",{"id":930,"createTime":931,"updateTime":932,"relativeEntities":1477,"slug":934,"properties":1478,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},[],{"title":1479},{"VI":937},{"openalex":1481,"orcid":1483,"title":1485},{"VOID":1482},"A5036839901",{"VOID":1484},"https:\u002F\u002Forcid.org\u002F0000-0001-5481-2555",{"EN":1486},"Nicholas C.P. Cross",{"id":1488,"sortIndex":1489,"researcher":23,"roles":1490,"affiliations":1491,"properties":1503},"6a8014eb-d629-49a4-b9f4-bf10b359629a",28,[],[1492],{"id":1493,"sortIndex":24,"affiliation":1494,"properties":23},"a1736d1f-441f-4521-bf8f-ea7995474771",{"id":1495,"createTime":1496,"updateTime":1497,"relativeEntities":1498,"slug":1499,"properties":1500,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},"0f2612e7-d81b-4af7-9019-7b15499a0e84","2024-01-12T21:12:59.131+00:00","2024-11-26T10:44:40.877+00:00",[],"Department-of-Clinical-Medicine-and-Surgery-University-Federico-II-of-Naples-Naples-Italy",{"title":1501},{"VI":1502},"Department of Clinical Medicine and Surgery, University \"Federico II\" of Naples, Naples, Italy",{"openalex":1504,"orcid":1506,"title":1508},{"VOID":1505},"A5037698212",{"VOID":1507},"https:\u002F\u002Forcid.org\u002F0000-0002-7021-0367",{"EN":1509},"Barbara Izzo",{"id":1511,"sortIndex":1512,"researcher":23,"roles":1513,"affiliations":1514,"properties":1521},"fd5386b1-88dc-40df-9793-1fef4a361625",5,[],[1515],{"id":1516,"sortIndex":24,"affiliation":1517,"properties":23},"45c257b1-bb20-49bc-a30d-fbc113ec3dd7",{"id":188,"createTime":189,"updateTime":190,"relativeEntities":1518,"slug":192,"properties":1519,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},[],{"title":1520},{"VI":195},{"openalex":1522,"title":1524},{"VOID":1523},"A5084587799",{"EN":1525},"Mazoua Stephane",{"id":1527,"sortIndex":1528,"researcher":23,"roles":1529,"affiliations":1530,"properties":1541},"23f1fbdd-91ea-47fe-8852-3303e76ac5f0",54,[],[1531],{"id":1532,"sortIndex":24,"affiliation":1533,"properties":23},"25262879-8e37-4010-9fb3-9d36294d0b34",{"id":1534,"createTime":1535,"updateTime":1535,"relativeEntities":1536,"slug":1537,"properties":1538,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},"bf63d9f9-8590-4c40-a3f9-27a20a2db1b1","2024-08-31T23:42:45.896+00:00",[],"Hematology-Department-Jagiellonian-University-Krakow-Poland-",{"title":1539},{"EN":1540},"Hematology Department, Jagiellonian University, Krakow, Poland,",{"openalex":1542,"orcid":1544,"title":1546},{"VOID":1543},"A5029712912",{"VOID":1545},"https:\u002F\u002Forcid.org\u002F0000-0002-7207-6595",{"EN":1547},"Tomasz Sacha",{"id":1549,"sortIndex":1550,"researcher":23,"roles":1551,"affiliations":1552,"properties":1563},"f6c779ff-f5b5-493d-85db-19bc01f018b5",45,[],[1553],{"id":1554,"sortIndex":24,"affiliation":1555,"properties":23},"e994d21c-fd85-4bf6-bf45-4d91ff17f094",{"id":1556,"createTime":1557,"updateTime":1557,"relativeEntities":1558,"slug":1559,"properties":1560,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},"6efb83ab-8578-4b47-83f4-1c45f86e3de5","2024-08-31T23:42:46.633+00:00",[],"Lab-Hematologia-Hospital-de-la-Santa-Creu-i-Sant-Pau-Barcelona-Spain-",{"title":1561},{"EN":1562},"Lab Hematologia, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain,",{"openalex":1564,"orcid":1566,"title":1568},{"VOID":1565},"A5027357638",{"VOID":1567},"https:\u002F\u002Forcid.org\u002F0000-0003-3399-346X",{"EN":1569},"Josep Nomdedéu",{"id":1571,"sortIndex":1572,"researcher":23,"roles":1573,"affiliations":1574,"properties":1586},"4108ca05-59e2-447b-a108-b0643710d219",56,[],[1575],{"id":1576,"sortIndex":24,"affiliation":1577,"properties":23},"0774f4e1-1543-432a-a99a-78aeaa37c70a",{"id":1578,"createTime":1579,"updateTime":1580,"relativeEntities":1581,"slug":1582,"properties":1583,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},"6bb6b3bc-e7e5-4d31-8170-be80fb07be67","2024-01-17T06:43:28.455+00:00","2024-08-31T23:42:46.864+00:00",[],"Hematology-Department-and-HCT-Unit-G-Papanicolaou-Hospital-Thessaloniki-Greece",{"title":1584},{"VI":1585},"Hematology Department and HCT Unit, G. Papanicolaou Hospital, Thessaloniki, Greece",{"openalex":1587,"title":1589},{"VOID":1588},"A5001778425",{"EN":1590},"Tasoula Touloumenidou",{"id":1592,"sortIndex":1593,"researcher":23,"roles":1594,"affiliations":1595,"properties":1602},"02603bda-976c-4912-8309-a3f2f966079a",2,[],[1596],{"id":1597,"sortIndex":24,"affiliation":1598,"properties":23},"3501eefa-cd49-42c2-989c-586694246d25",{"id":188,"createTime":189,"updateTime":190,"relativeEntities":1599,"slug":192,"properties":1600,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},[],{"title":1601},{"VI":195},{"openalex":1603,"orcid":1605,"title":1607},{"VOID":1604},"A5078783691",{"VOID":1606},"https:\u002F\u002Forcid.org\u002F0000-0002-4191-1391",{"EN":1608},"Philippe Corbisier",{"id":1610,"sortIndex":1611,"researcher":23,"roles":1612,"affiliations":1613,"properties":1620},"29417b97-6a68-4259-a50b-07e552ff41a8",68,[],[1614],{"id":1615,"sortIndex":24,"affiliation":1616,"properties":23},"5151cf3e-83e6-4f94-9e50-b70cc3cfd5bb",{"id":188,"createTime":189,"updateTime":190,"relativeEntities":1617,"slug":192,"properties":1618,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},[],{"title":1619},{"VI":195},{"openalex":1621,"title":1623},{"VOID":1622},"A5037644876",{"EN":1624},"Heinz Schimmel",{"id":1626,"sortIndex":1627,"researcher":23,"roles":1628,"affiliations":1629,"properties":1641},"82d3f49d-5348-4949-8717-353406e38b40",60,[],[1630],{"id":1631,"sortIndex":24,"affiliation":1632,"properties":23},"ebca8fac-fb00-48a6-b376-69c1999a5b91",{"id":1633,"createTime":1634,"updateTime":1635,"relativeEntities":1636,"slug":1637,"properties":1638,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},"014bd96b-63e0-4cea-889b-5e72c1b12c6f","2024-08-31T23:42:46.924+00:00","2025-06-11T14:45:36.201+00:00",[],"HMDS-Leeds-Institute-of-Oncology-St-James-s-University-Hospital-Leeds-UK-",{"title":1639},{"EN":1640},"HMDS, Leeds Institute of Oncology, St James's University Hospital, Leeds, UK,",{"openalex":1642,"title":1644},{"VOID":1643},"A5038115299",{"EN":1645},"Elizabeth J. Wilkinson","ARTICLE",{"url":23,"publisher":1648,"properties":1673},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":1649,"slug":10,"properties":1650,"entityType":21,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24,"subjectFields":1656,"manageAffiliations":1657,"indexDatabases":1658,"url":125,"thumbnailPath":23,"statistic":23,"gsStatistic":23,"type":23,"analyzePriority":23},[],{"country":1651,"issn":1652,"introduce":1653,"eissn":1654,"title":1655},{"VOID":13},{"VOID":15},{"EN":17},{"VOID":19},{"EN":10},[],[],[1659,1666],{"id":84,"indexDatabase":1660,"url":99,"indexYears":23,"academicFieldIds":1665,"indexDatabaseRanking":23},{"id":86,"createTime":87,"updateTime":88,"relativeEntities":1661,"label":1662,"description":1663,"key":95,"publicationTags":1664,"standard":23},[],{"EN":91,"VI":91},{"VI":93,"EN":94},[97,98],[101,102],{"id":104,"indexDatabase":1667,"url":117,"indexYears":118,"academicFieldIds":1672,"indexDatabaseRanking":124},{"id":106,"createTime":107,"updateTime":108,"relativeEntities":1668,"label":1669,"description":1670,"key":114,"publicationTags":1671,"standard":23},[],{"EN":111,"VI":111},{"EN":111,"VI":113},[116],[120,121,122,123],{"volume":1674,"pages":1676,"issue":1678},{"VOID":1675},"29",{"VOID":1677},"369-376",{"VOID":1679},"2",76,{"total":1680,"publishYear":23,"statisticByYear":1682},{"2015":1512,"2016":1282,"2017":69,"2018":1512,"2019":375,"2020":1216,"2021":1512,"2022":1512,"2023":924,"2024":924},"2015-02-01",2015,[1686,1690,1694,1698,1702,1706,1710,1714,1718,1722,1726,1730,1734,1738,1742,1746,1750,1754,1758,1761,1764,1768,1772,1776],{"id":23,"text":1687,"url":23,"identifiers":1688},"Cross NC . Standardisation of molecular monitoring for chronic myeloid leukaemia. Best Pract Res Clin Haematol 2009; 22: 355–365.",{"doi":1689},"10.1016\u002Fj.beha.2009.04.001",{"id":23,"text":1691,"url":23,"identifiers":1692},"Press RD, Kamel-Reid S, Ang D . BCR–ABL1 RT-qPCR for monitoring the molecular response to tyrosine kinase inhibitors in chronic myeloid leukemia. J Mol Diagn 2013; 15: 565–576.",{"doi":1693},"10.1016\u002Fj.jmoldx.2013.04.007",{"id":23,"text":1695,"url":23,"identifiers":1696},"Branford S, Prime J . Chronic myelogenous leukemia: monitoring response to therapy. Curr Hematol Malig Rep 2011; 6: 75–81.",{"doi":1697},"10.1007\u002Fs11899-011-0082-1",{"id":23,"text":1699,"url":23,"identifiers":1700},"Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia. Blood 2013; 122: 872–884.",{"doi":1701},"10.1182\u002Fblood-2013-05-501569",{"id":23,"text":1703,"url":23,"identifiers":1704},"Gabert J, Beillard E, van der Velden VH, Bi W, Grimwade D, Pallisgaard N et al. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia—a Europe Against Cancer program. Leukemia 2003; 17: 2318–2357.",{"doi":1705},"10.1038\u002Fsj.leu.2403135",{"id":23,"text":1707,"url":23,"identifiers":1708},"Foroni L, Wilson G, Gerrard G, Mason J, Grimwade D, White HE et al. Guidelines for the measurement of BCR–ABL1 transcripts in chronic myeloid leukaemia. Br J Haematol 2011; 153: 179–190.",{"doi":1709},"10.1111\u002Fj.1365-2141.2011.08603.x",{"id":23,"text":1711,"url":23,"identifiers":1712},"Zhang T, Grenier S, Nwachukwu B, Wei C, Lipton JH, Kamel-Reid S et al. Inter-laboratory comparison of chronic myeloid leukemia minimal residual disease monitoring: summary and recommendations. J Mol Diagn 2007; 9: 421–430.",{"doi":1713},"10.2353\u002Fjmoldx.2007.060134",{"id":23,"text":1715,"url":23,"identifiers":1716},"Hughes T, Deininger M, Hochhaus A, Branford S, Radich J, Kaeda J et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR–ABL transcripts and kinase domain mutations and for expressing results. Blood 2006; 108: 28–37.",{"doi":1717},"10.1182\u002Fblood-2006-01-0092",{"id":23,"text":1719,"url":23,"identifiers":1720},"Branford S, Fletcher L, Cross NC, Muller MC, Hochhaus A, Kim DW et al. Desirable performance characteristics for BCR–ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. Blood 2008; 112: 3330–3338.",{"doi":1721},"10.1182\u002Fblood-2008-04-150680",{"id":23,"text":1723,"url":23,"identifiers":1724},"White HE, Matejtschuk P, Rigsby P, Gabert J, Lin F, Lynn Wang Y et al. Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR–ABL mRNA. Blood 2010; 116: e111–e117.",{"doi":1725},"10.1182\u002Fblood-2010-06-291641",{"id":23,"text":1727,"url":23,"identifiers":1728},"White HE, Hedges J, Bendit I, Branford S, Colomer D, Hochhaus A et al. Establishment and validation of analytical reference panels for the standardization of quantitative BCR–ABL1 measurements on the international scale. Clin Chem 2013; 59: 938–948.",{"doi":1729},"10.1373\u002Fclinchem.2012.196477",{"id":23,"text":1731,"url":23,"identifiers":1732},"Hughes TP, Kaeda J, Branford S, Rudzki Z, Hochhaus A, Hensley ML et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003; 349: 1423–1432.",{"doi":1733},"10.1056\u002FNEJMoa030513",{"id":23,"text":1735,"url":23,"identifiers":1736},"Muller MC, Cross NC, Erben P, Schenk T, Hanfstein B, Ernst T et al. Harmonization of molecular monitoring of CML therapy in Europe. Leukemia 2009; 23: 1957–1963.",{"doi":1737},"10.1038\u002Fleu.2009.168",{"id":23,"text":1739,"url":23,"identifiers":1740},"Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010; 362: 2251–2259.",{"doi":1741},"10.1056\u002FNEJMoa0912614",{"id":23,"text":1743,"url":23,"identifiers":1744},"Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010; 362: 2260–2270.",{"doi":1745},"10.1056\u002FNEJMoa1002315",{"id":23,"text":1747,"url":23,"identifiers":1748},"Cross NC, White HE, Muller MC, Saglio G, Hochhaus A . Standardized definitions of molecular response in chronic myeloid leukemia. Leukemia 2012; 26: 2172–2175.",{"doi":1749},"10.1038\u002Fleu.2012.104",{"id":23,"text":1751,"url":23,"identifiers":1752},"Hehlmann R, Muller MC, Lauseker M, Hanfstein B, Fabarius A, Schreiber A et al. Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV. J Clin Oncol 2014; 32: 415–423.",{"doi":1753},"10.1200\u002FJCO.2013.49.9020",{"id":23,"text":1755,"url":23,"identifiers":1756},"Beillard E, Pallisgaard N, van der Velden VH, Bi W, Dee R, van der Schoot E et al. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR)—a Europe against cancer program. Leukemia 2003; 17: 2474–2486.",{"doi":1757},"10.1038\u002Fsj.leu.2403136",{"id":23,"text":1759,"url":23,"identifiers":1760},"Deprez L, Mazoua S, Corbisier P, Trapmann S, Schimmel H, White H et al. The certification of the copy number concentration of solutions of plasmid DNA containing a BCR–ABL b3a2 transcript fragment. Certified reference material: ERM-AD623a, ERM-AD623b, ERM-AD623c, ERM-AD623d, ERM-AD623e ERM-AD623f. Luxembourg: Publications Office of the European Union, 2012; Report number EUR 25248; ISBN 978-92-79-23343-2. 2012.",{},{"id":23,"text":1762,"url":23,"identifiers":1763},"Joint Committee for Guides in Metrology. Evaluation of measurement data: Guide to expression of uncertainty in measurement (GUM) \n                    http:\u002F\u002Fwww.bipm.org\u002Futils\u002Fcommon\u002Fdocuments\u002Fjcgm\u002FJCGM_100_2008_E.pdf\n                    \n                  . 2008.",{},{"id":23,"text":1765,"url":23,"identifiers":1766},"Linsinger TP, Pauwels J, Lamberty A, Schimmel HG, van der Veen AM, Siekmann L et al. Estimating the uncertainty of stability for matrix CRMs. Fresenius J Anal Chem 2001; 370: 183–188.",{"doi":1767},"10.1007\u002Fs002160100719",{"id":23,"text":1769,"url":23,"identifiers":1770},"Muller MC, Erben P, Saglio G, Gottardi E, Nyvold CG, Schenk T et al. Harmonization of BCR–ABL mRNA quantification using a uniform multifunctional control plasmid in 37 international laboratories. Leukemia 2008; 22: 96–102.",{"doi":1771},"10.1038\u002Fsj.leu.2404983",{"id":23,"text":1773,"url":23,"identifiers":1774},"van der Velden VH, Hochhaus A, Cazzaniga G, Szczepanski T, Gabert J, van Dongen JJ et al. Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects. Leukemia 2003; 17: 1013–1034.",{"doi":1775},"10.1038\u002Fsj.leu.2402922",{"id":23,"text":1777,"url":23,"identifiers":1778},"Jennings LJ, Smith FA, Halling KC, Persons DL, Kamel-Reid S . Molecular Oncology Resource Committee of the College of American P. Design and analytic validation of BCR–ABL1 quantitative reverse transcription polymerase chain reaction assay for monitoring minimal residual disease. Arch Pathol Lab Med 2012; 136: 33–40.",{"doi":1779},"10.5858\u002Farpa.2011-0136-OA",false,{"id":1782,"createTime":1783,"updateTime":1783,"relativeEntities":1784,"slug":1785,"properties":1786,"entityType":150,"verifyStatus":151,"verifyTime":1783,"verifyNote":152,"syncStatus":22,"languages":1802,"translateLanguages":23,"viewCount":24,"primaryUrl":1803,"fullTextUrl":23,"authors":1804,"publicationType":1646,"publisherRelationship":2510,"citationCount":2543,"citationInfo":2544,"publishDate":2551,"publishYear":2552,"citationAnalyzeStatus":22,"lastCitationAnalyze":23,"indexDatabases":23,"openAccess":23,"references":2553,"isForceReanalyzing":1780},"46339cd8-75f7-46be-8fa2-9445061b19bd","2024-08-31T23:42:41.260+00:00",[],"European-LeukemiaNet-2020-recommendations-for-treating-chronic-myeloid-leukemia",{"mag":1787,"keywords":1789,"pmc":1790,"openalex":1792,"abstract":1794,"title":1796,"pm":1798,"doi":1800},{"VOID":1788},"3009751715",{},{"VOID":1791},"7214240",{"VOID":1793},"W3009751715",{"EN":1795},"\u003Cjats:title>Abstract\u003C\u002Fjats:title>\u003Cjats:p>The therapeutic landscape of chronic myeloid leukemia (CML) has profoundly changed over the past 7 years. Most patients with chronic phase (CP) now have a normal life expectancy. Another goal is achieving a stable deep molecular response (DMR) and discontinuing medication for treatment-free remission (TFR). The European LeukemiaNet convened an expert panel to critically evaluate and update the evidence to achieve these goals since its previous recommendations. First-line treatment is a tyrosine kinase inhibitor (TKI; imatinib brand or generic, dasatinib, nilotinib, and bosutinib are available first-line). Generic imatinib is the cost-effective initial treatment in CP. Various contraindications and side-effects of all TKIs should be considered. Patient risk status at diagnosis should be assessed with the new EUTOS long-term survival (ELTS)-score. Monitoring of response should be done by quantitative polymerase chain reaction whenever possible. A change of treatment is recommended when intolerance cannot be ameliorated or when molecular milestones are not reached. Greater than 10% BCR-ABL1 at 3 months indicates treatment failure when confirmed. Allogeneic transplantation continues to be a therapeutic option particularly for advanced phase CML. TKI treatment should be withheld during pregnancy. Treatment discontinuation may be considered in patients with durable DMR with the goal of achieving TFR.\u003C\u002Fjats:p>",{"EN":1797},"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia",{"VOID":1799},"32127639",{"VOID":1801},"10.1038\u002Fs41375-020-0776-2",[154],"https:\u002F\u002Fwww.nature.com\u002Farticles\u002Fs41375-020-0776-2",[1805,1824,1846,1867,1886,1907,1927,1949,1971,1991,2013,2033,2055,2075,2097,2119,2141,2163,2185,2205,2225,2246,2268,2290,2312,2334,2353,2368,2385,2407,2429,2449,2469,2488],{"id":1806,"sortIndex":689,"researcher":23,"roles":1807,"affiliations":1808,"properties":1819},"d1f90189-5fc3-4ad1-a2ae-d18f94bf41f7",[],[1809],{"id":1810,"sortIndex":24,"affiliation":1811,"properties":23},"44d667b2-aa5d-4861-8e15-e549f257d153",{"id":1812,"createTime":1813,"updateTime":1813,"relativeEntities":1814,"slug":1815,"properties":1816,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},"2e76c372-ae7d-493c-a947-88b54278914a","2024-08-31T23:42:41.852+00:00",[],"St-Mary-s-Hematology-Hospital-The-Catholic-University-Seoul-Korea",{"title":1817},{"EN":1818},"St. Mary´s Hematology Hospital, The Catholic University, Seoul, Korea",{"openalex":1820,"title":1822},{"VOID":1821},"A5040840581",{"EN":1823},"D. W. Kim",{"id":1825,"sortIndex":518,"researcher":23,"roles":1826,"affiliations":1827,"properties":1839},"3456596e-c0f3-4596-a4a9-2114583fc208",[],[1828],{"id":1829,"sortIndex":24,"affiliation":1830,"properties":23},"a7e14541-6616-4e63-be03-dd355bc0fb10",{"id":1831,"createTime":1832,"updateTime":1833,"relativeEntities":1834,"slug":1835,"properties":1836,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},"21ed0508-5227-4422-bb1f-5b1104feeb72","2023-11-29T17:03:04.809+00:00","2024-10-15T17:20:21.861+00:00",[],"South-Australian-Health-and-Medical-Research-Institute-Adelaide-SA-Australia",{"title":1837},{"VI":1838},"South Australian Health and Medical Research Institute, Adelaide, SA, Australia",{"openalex":1840,"orcid":1842,"title":1844},{"VOID":1841},"A5049971021",{"VOID":1843},"https:\u002F\u002Forcid.org\u002F0000-0002-0910-3730",{"EN":1845},"Timothy P. Hughes",{"id":1847,"sortIndex":1323,"researcher":23,"roles":1848,"affiliations":1849,"properties":1860},"1d55f091-fad4-451c-aec9-fc4a43fe11a7",[],[1850],{"id":1851,"sortIndex":24,"affiliation":1852,"properties":23},"819e423b-927f-4119-ac8f-63d40ea5eb46",{"id":1853,"createTime":1854,"updateTime":1854,"relativeEntities":1855,"slug":1856,"properties":1857,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},"8d7d202e-f035-4124-b8e1-d6d8fe8295a7","2024-08-31T23:42:41.643+00:00",[],"Almazov-National-Research-Centre-St-Petersburg-Russian-Federation",{"title":1858},{"EN":1859},"Almazov National Research Centre, St. Petersburg, Russian Federation",{"openalex":1861,"orcid":1863,"title":1865},{"VOID":1862},"A5059723473",{"VOID":1864},"https:\u002F\u002Forcid.org\u002F0000-0001-7682-440X",{"EN":1866},"Andrey Zaritskey",{"id":1868,"sortIndex":647,"researcher":23,"roles":1869,"affiliations":1870,"properties":1881},"f501989a-312d-4118-8c2c-b861d252b533",[],[1871],{"id":1872,"sortIndex":24,"affiliation":1873,"properties":23},"9f58cffb-cf82-4384-9856-f103b17929ec",{"id":1874,"createTime":1875,"updateTime":1875,"relativeEntities":1876,"slug":1877,"properties":1878,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},"d3ed1509-a912-4b1a-92d0-625f6e5fcfb8","2024-08-31T23:42:41.618+00:00",[],"Centre-Hospitalier-de-Versailles-University-of-Versailles-Saint-Quentin-en-Yvelines-Versailles-France",{"title":1879},{"EN":1880},"Centre Hospitalier de Versailles, University of Versailles Saint-Quentin-en-Yvelines, Versailles, France",{"openalex":1882,"title":1884},{"VOID":1883},"A5001998092",{"EN":1885},"Philipe Rousselot",{"id":1887,"sortIndex":460,"researcher":23,"roles":1888,"affiliations":1889,"properties":1900},"4b80f87a-32af-444a-8c03-937123217bf1",[],[1890],{"id":1891,"sortIndex":24,"affiliation":1892,"properties":23},"7e857ef4-787a-424c-a320-90adb0dcef43",{"id":1893,"createTime":1894,"updateTime":1894,"relativeEntities":1895,"slug":1896,"properties":1897,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},"2ab2e03e-2bda-4906-b201-38627b7919dd","2024-08-31T23:42:41.432+00:00",[],"Amsterdam-University-Medical-Center-VUMC-Amsterdam-The-Netherlands",{"title":1898},{"EN":1899},"Amsterdam University Medical Center, VUMC, Amsterdam, The Netherlands",{"openalex":1901,"orcid":1903,"title":1905},{"VOID":1902},"A5022468485",{"VOID":1904},"https:\u002F\u002Forcid.org\u002F0000-0001-5855-4119",{"EN":1906},"Jeroen Janssen",{"id":1908,"sortIndex":69,"researcher":23,"roles":1909,"affiliations":1910,"properties":1922},"2b35acd2-8157-48a0-a054-93c80e8beb55",[],[1911],{"id":1912,"sortIndex":24,"affiliation":1913,"properties":23},"5c296f5d-68cd-4695-96ec-4e5c3be7f244",{"id":1914,"createTime":1915,"updateTime":1916,"relativeEntities":1917,"slug":1918,"properties":1919,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},"925cf552-13a1-4580-95a4-291950457626","2024-01-20T13:37:21.917+00:00","2024-08-31T23:42:41.932+00:00",[],"Department-of-Molecular-Clinical-Cancer-Medicine-University-of-Liverpool-Liverpool-UK",{"title":1920},{"VI":1921},"Department of Molecular & Clinical Cancer Medicine, University of Liverpool, Liverpool, UK",{"openalex":1923,"title":1925},{"VOID":1924},"A5091359239",{"EN":1926},"R E Clark",{"id":1928,"sortIndex":947,"researcher":23,"roles":1929,"affiliations":1930,"properties":1942},"bf76726d-3ee7-460d-ac12-200bc40e34e6",[],[1931],{"id":1932,"sortIndex":24,"affiliation":1933,"properties":23},"2c470b3a-440d-44c2-aa15-db47629d14fb",{"id":1934,"createTime":1935,"updateTime":1936,"relativeEntities":1937,"slug":1938,"properties":1939,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},"218ec971-b67b-46a0-8634-6335acdb0a5f","2023-12-08T21:30:18.736+00:00","2025-02-24T05:07:22.897+00:00",[],"MD-Anderson-Cancer-Center-Houston-TX-USA",{"title":1940},{"VI":1941},"MD Anderson Cancer Center, Houston, TX, USA",{"openalex":1943,"orcid":1945,"title":1947},{"VOID":1944},"A5090435894",{"VOID":1946},"https:\u002F\u002Forcid.org\u002F0000-0002-1908-3307",{"EN":1948},"Hagop M. Kantarjian",{"id":1950,"sortIndex":1012,"researcher":23,"roles":1951,"affiliations":1952,"properties":1964},"6d6c1146-0d02-45d7-b170-76fa4c5a43cf",[],[1953],{"id":1954,"sortIndex":24,"affiliation":1955,"properties":23},"b4e3467e-c9c6-428b-943d-86c8523f6ff5",{"id":1956,"createTime":1957,"updateTime":1958,"relativeEntities":1959,"slug":1960,"properties":1961,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},"9639a5a0-0a62-43d4-8019-56563ceb34ac","2023-12-02T18:45:46.278+00:00","2024-12-30T10:21:42.878+00:00",[],"University-of-Chicago-Chicago-IL-USA",{"title":1962},{"VI":1963},"University of Chicago, Chicago, IL USA",{"openalex":1965,"orcid":1967,"title":1969},{"VOID":1966},"A5072420982",{"VOID":1968},"https:\u002F\u002Forcid.org\u002F0000-0001-9168-3203",{"EN":1970},"Richard A. Larson",{"id":1972,"sortIndex":24,"researcher":23,"roles":1973,"affiliations":1974,"properties":1986},"69a9c292-37af-4830-8cc3-a26d44e8b7bd",[],[1975],{"id":1976,"sortIndex":24,"affiliation":1977,"properties":23},"4464377b-8ba0-4d0b-9a59-96ab9988b06d",{"id":1978,"createTime":1979,"updateTime":1980,"relativeEntities":1981,"slug":1982,"properties":1983,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},"126b3b04-2d71-4d2b-a1a2-0e10dcd7ec21","2023-12-18T18:46:38.592+00:00","2024-12-01T14:32:35.917+00:00",[],"Klinik-f%C3%BCr-Innere-Medizin-II-Universit%C3%A4tsklinikum-Jena-Germany",{"title":1984},{"VI":1985},"Klinik für Innere Medizin II, Universitätsklinikum, Jena, Germany",{"openalex":1987,"title":1989},{"VOID":1988},"A5001164320",{"EN":1990},"A. Hochhaus",{"id":1992,"sortIndex":924,"researcher":23,"roles":1993,"affiliations":1994,"properties":2006},"d84d9f28-9dfc-44a8-8f05-74c855e5ed8b",[],[1995],{"id":1996,"sortIndex":24,"affiliation":1997,"properties":23},"cdee9748-a328-424c-b69f-cb7e44939bcb",{"id":1998,"createTime":1999,"updateTime":2000,"relativeEntities":2001,"slug":2002,"properties":2003,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},"597b7f0c-8f9e-4b15-abaa-6be1ca6f235b","2023-12-21T11:39:45.399+00:00","2024-08-31T23:42:41.556+00:00",[],"Hammersmith-Hospital-Imperial-College-London-UK",{"title":2004},{"VI":2005},"Hammersmith Hospital, Imperial College London, UK",{"openalex":2007,"orcid":2009,"title":2011},{"VOID":2008},"A5074115908",{"VOID":2010},"https:\u002F\u002Forcid.org\u002F0000-0002-1710-1794",{"EN":2012},"Jane F. Apperley",{"id":2014,"sortIndex":1453,"researcher":23,"roles":2015,"affiliations":2016,"properties":2028},"b63844e3-701d-45f2-8580-7497c196b22d",[],[2017],{"id":2018,"sortIndex":24,"affiliation":2019,"properties":23},"4352f9ae-2a7c-42a8-94f4-49919f744c29",{"id":2020,"createTime":2021,"updateTime":2022,"relativeEntities":2023,"slug":2024,"properties":2025,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},"99c2b264-7b86-4a4d-b3fa-3f0f558866d7","2024-01-28T09:59:47.337+00:00","2024-08-31T23:42:41.420+00:00",[],"Karmanos-Cancer-Center-Detroit-MI-USA",{"title":2026},{"VI":2027},"Karmanos Cancer Center, Detroit, MI, USA",{"openalex":2029,"title":2031},{"VOID":2030},"A5052762910",{"EN":2032},"CA Schiffer",{"id":2034,"sortIndex":1032,"researcher":23,"roles":2035,"affiliations":2036,"properties":2048},"15853358-a32c-4f99-bf7e-53f8ba21cfd0",[],[2037],{"id":2038,"sortIndex":24,"affiliation":2039,"properties":23},"9033e066-89e3-47a8-8c45-ebd9c7f36966",{"id":2040,"createTime":2041,"updateTime":2042,"relativeEntities":2043,"slug":2044,"properties":2045,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},"028f7924-4efb-4aa8-bcaa-36d535364f82","2024-08-31T23:42:41.456+00:00","2025-06-11T15:57:42.260+00:00",[],"Department-Clinical-Medicine-and-Surgery-University-Federico-Secondo-Naples-Italy",{"title":2046},{"EN":2047},"Department Clinical Medicine and Surgery, University Federico Secondo, Naples, Italy",{"openalex":2049,"orcid":2051,"title":2053},{"VOID":2050},"A5057084037",{"VOID":2052},"https:\u002F\u002Forcid.org\u002F0000-0003-2563-4125",{"EN":2054},"Fabrizio Pane",{"id":2056,"sortIndex":1157,"researcher":23,"roles":2057,"affiliations":2058,"properties":2070},"c2200685-4060-48e0-8344-d99698ca0ddb",[],[2059],{"id":2060,"sortIndex":24,"affiliation":2061,"properties":23},"32c948f5-5ca7-4601-a310-e8cc79452c90",{"id":2062,"createTime":2063,"updateTime":2064,"relativeEntities":2065,"slug":2066,"properties":2067,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},"0348fe67-a6d9-4741-8e29-d8d22b9cea0d","2024-01-10T09:31:38.886+00:00","2025-06-11T16:38:10.243+00:00",[],"Hospital-de-La-Princesa-Madrid-Spain",{"title":2068},{"VI":2069},"Hospital de La Princesa, Madrid, Spain",{"openalex":2071,"title":2073},{"VOID":2072},"A5068067485",{"EN":2074},"Steegmann Jl",{"id":2076,"sortIndex":375,"researcher":23,"roles":2077,"affiliations":2078,"properties":2090},"276e23c7-04c9-4498-9cf7-e524d97493c8",[],[2079],{"id":2080,"sortIndex":24,"affiliation":2081,"properties":23},"f9a12c4d-c82f-4635-9e7d-5614600a4e80",{"id":2082,"createTime":2083,"updateTime":2084,"relativeEntities":2085,"slug":2086,"properties":2087,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},"299dc3a8-89a3-4e86-8091-409c4f21ad20","2023-12-31T09:12:31.663+00:00","2025-02-11T06:15:22.505+00:00",[],"Norwegian-University-of-Science-and-Technology-Trondheim-Norway",{"title":2088},{"VI":2089},"Norwegian University of Science and Technology, Trondheim, Norway",{"openalex":2091,"orcid":2093,"title":2095},{"VOID":2092},"A5062230211",{"VOID":2094},"https:\u002F\u002Forcid.org\u002F0000-0002-2670-5696",{"EN":2096},"Henrik Hjorth‐Hansen",{"id":2098,"sortIndex":1200,"researcher":23,"roles":2099,"affiliations":2100,"properties":2112},"be23cbc1-706c-43f2-92c8-f79db3e5f3f0",[],[2101],{"id":2102,"sortIndex":24,"affiliation":2103,"properties":23},"50b69901-3020-4f12-85e9-4620c8e905fa",{"id":2104,"createTime":2105,"updateTime":2106,"relativeEntities":2107,"slug":2108,"properties":2109,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},"c1a659f1-14a0-4416-b09c-5a0653bba920","2023-12-06T07:42:42.119+00:00","2024-12-10T15:47:02.175+00:00",[],"Fred-Hutchinson-Cancer-Center-Seattle-WA-USA",{"title":2110},{"VI":2111},"Fred Hutchinson Cancer Center, Seattle, WA, USA",{"openalex":2113,"orcid":2115,"title":2117},{"VOID":2114},"A5089541690",{"VOID":2116},"https:\u002F\u002Forcid.org\u002F0000-0002-1618-230X",{"EN":2118},"Jerald P. Radich",{"id":2120,"sortIndex":1512,"researcher":23,"roles":2121,"affiliations":2122,"properties":2134},"dc3aec27-4ddb-481b-896e-ca11e06629a1",[],[2123],{"id":2124,"sortIndex":24,"affiliation":2125,"properties":23},"56242146-35dd-41fa-8749-06027ed8f659",{"id":2126,"createTime":2127,"updateTime":2128,"relativeEntities":2129,"slug":2130,"properties":2131,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},"d79813f1-d2e0-489f-91d4-af7247178873","2023-12-13T08:18:10.488+00:00","2024-10-16T16:39:11.130+00:00",[],"Hospital-Clinic-IDIBAPS-Barcelona-Spain",{"title":2132},{"VI":2133},"Hospital Clinic–IDIBAPS, Barcelona, Spain",{"openalex":2135,"orcid":2137,"title":2139},{"VOID":2136},"A5018111458",{"VOID":2138},"https:\u002F\u002Forcid.org\u002F0000-0003-2664-8131",{"EN":2140},"Francisco Cervantes",{"id":2142,"sortIndex":397,"researcher":23,"roles":2143,"affiliations":2144,"properties":2156},"66a44b31-f867-486c-bead-3dc57ec0c684",[],[2145],{"id":2146,"sortIndex":24,"affiliation":2147,"properties":23},"66b04df2-bf45-41bf-bd05-51915f2a9375",{"id":2148,"createTime":2149,"updateTime":2150,"relativeEntities":2151,"slug":2152,"properties":2153,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},"90607e1e-00af-4fb8-a8d5-95a485108288","2023-12-26T00:35:51.098+00:00","2024-08-31T23:42:41.496+00:00",[],"Department-of-Internal-Medicine-Masaryk-University-Hospital-Brno-Czech-Republic",{"title":2154},{"VI":2155},"Department of Internal Medicine, Masaryk University Hospital, Brno, Czech Republic",{"openalex":2157,"orcid":2159,"title":2161},{"VOID":2158},"A5033393628",{"VOID":2160},"https:\u002F\u002Forcid.org\u002F0000-0001-6610-2008",{"EN":2162},"Grzegorz Mazur",{"id":2164,"sortIndex":583,"researcher":23,"roles":2165,"affiliations":2166,"properties":2178},"8f24f2d4-9b51-4566-b26e-b3019e1d38d3",[],[2167],{"id":2168,"sortIndex":24,"affiliation":2169,"properties":23},"0929a3b8-748c-4bed-976e-911c373edfcc",{"id":2170,"createTime":2171,"updateTime":2172,"relativeEntities":2173,"slug":2174,"properties":2175,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},"15614e58-a2e5-4fb3-959e-a624db42d489","2023-12-20T15:03:54.409+00:00","2024-11-28T01:21:33.460+00:00",[],"University-of-Lund-Lund-Sweden",{"title":2176},{"VI":2177},"University of Lund, Lund, Sweden",{"openalex":2179,"orcid":2181,"title":2183},{"VOID":2180},"A5062726602",{"VOID":2182},"https:\u002F\u002Forcid.org\u002F0000-0002-0374-6823",{"EN":2184},"Johan Richter",{"id":2186,"sortIndex":709,"researcher":23,"roles":2187,"affiliations":2188,"properties":2200},"493c633e-17b9-4128-990b-517890b4175e",[],[2189],{"id":2190,"sortIndex":24,"affiliation":2191,"properties":23},"959a20ac-ec4f-447f-b66b-6b27c3a11d17",{"id":2192,"createTime":2193,"updateTime":2194,"relativeEntities":2195,"slug":2196,"properties":2197,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},"dadd79a8-22a3-40cf-8680-d382191cb4a6","2024-01-17T15:10:07.999+00:00","2024-08-31T23:42:41.744+00:00",[],"ELN-Foundation-Weinheim-Germany",{"title":2198},{"VI":2199},"ELN Foundation, Weinheim, Germany",{"openalex":2201,"title":2203},{"VOID":2202},"A5076276301",{"EN":2204},"Rüediger Hehlmann",{"id":2206,"sortIndex":205,"researcher":23,"roles":2207,"affiliations":2208,"properties":2220},"4e0267e4-9f75-4427-b8f3-05010aa55b5b",[],[2209],{"id":2210,"sortIndex":24,"affiliation":2211,"properties":23},"a9917ffe-744b-4f97-bacd-49a6cdef48d6",{"id":2212,"createTime":2213,"updateTime":2214,"relativeEntities":2215,"slug":2216,"properties":2217,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},"69aca2f9-fdb0-4be8-938c-03713d96fe82","2024-01-08T06:36:05.616+00:00","2024-09-20T02:37:50.670+00:00",[],"Georgia-Cancer-Center-Augusta-University-Augusta-GA-USA",{"title":2218},{"VI":2219},"Georgia Cancer Center, Augusta University, Augusta, GA, USA",{"openalex":2221,"title":2223},{"VOID":2222},"A5070369983",{"EN":2224},"J. E. Cortes",{"id":2226,"sortIndex":729,"researcher":23,"roles":2227,"affiliations":2228,"properties":2239},"e0e98bbb-5006-4e49-a48c-141e50987cbc",[],[2229],{"id":2230,"sortIndex":24,"affiliation":2231,"properties":23},"fccf2d8a-8b39-4be2-838d-65e43e4629b2",{"id":2232,"createTime":2233,"updateTime":2233,"relativeEntities":2234,"slug":2235,"properties":2236,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},"7ec6ed55-2250-465a-a65e-b9e691c49c4f","2024-08-31T23:42:42.034+00:00",[],"Huntsman-Cancer-Center-Salt-Lake-City-Salt-Lake-City-UT-USA",{"title":2237},{"EN":2238},"Huntsman Cancer Center Salt Lake City, Salt Lake City, UT, USA",{"openalex":2240,"orcid":2242,"title":2244},{"VOID":2241},"A5007755609",{"VOID":2243},"https:\u002F\u002Forcid.org\u002F0000-0002-2987-1331",{"EN":2245},"Michael W. Deininger",{"id":2247,"sortIndex":904,"researcher":23,"roles":2248,"affiliations":2249,"properties":2261},"69448374-25bd-4625-ae33-eb5ed3e61e29",[],[2250],{"id":2251,"sortIndex":24,"affiliation":2252,"properties":23},"3b97836a-f479-4991-ac91-cd96ef015d7f",{"id":2253,"createTime":2254,"updateTime":2255,"relativeEntities":2256,"slug":2257,"properties":2258,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},"67a3147a-fcfc-4b71-b312-5d79cf8a89de","2024-01-14T05:42:56.797+00:00","2024-08-31T23:42:41.522+00:00",[],"National-Research-Center-for-Hematology-Moscow-Russian-Federation",{"title":2259},{"VI":2260},"National Research Center for Hematology, Moscow, Russian Federation",{"openalex":2262,"orcid":2264,"title":2266},{"VOID":2263},"A5003294629",{"VOID":2265},"https:\u002F\u002Forcid.org\u002F0000-0001-9947-2371",{"EN":2267},"Anna Turkina",{"id":2269,"sortIndex":1216,"researcher":23,"roles":2270,"affiliations":2271,"properties":2283},"65cc6924-882e-4413-b6a8-c0fdf5468864",[],[2272],{"id":2273,"sortIndex":24,"affiliation":2274,"properties":23},"2429627d-3251-4699-95ba-f816a3366b15",{"id":2275,"createTime":2276,"updateTime":2277,"relativeEntities":2278,"slug":2279,"properties":2280,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},"97e5b35f-be6d-4c97-886f-99934bcc8a11","2023-12-29T13:10:10.229+00:00","2024-08-31T23:42:42.069+00:00",[],"Centre-Hospitalier-Universitaire-de-Poitiers-Poitiers-France",{"title":2281},{"VI":2282},"Centre Hospitalier Universitaire de Poitiers, Poitiers, France",{"openalex":2284,"orcid":2286,"title":2288},{"VOID":2285},"A5079181777",{"VOID":2287},"https:\u002F\u002Forcid.org\u002F0000-0001-7222-487X",{"EN":2289},"François Guilhot",{"id":2291,"sortIndex":1593,"researcher":23,"roles":2292,"affiliations":2293,"properties":2305},"7f20a58f-131a-400f-9d1d-95448f5b5f53",[],[2294],{"id":2295,"sortIndex":24,"affiliation":2296,"properties":23},"66244dc4-01a3-4a19-8e64-9e89fa6501f8",{"id":2297,"createTime":2298,"updateTime":2299,"relativeEntities":2300,"slug":2301,"properties":2302,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},"0b296885-9895-49fb-958c-42265afcc9dd","2024-02-05T15:01:02.868+00:00","2025-06-12T00:03:01.363+00:00",[],"Weill-Cornell-Medical-College-New-York-NY-USA",{"title":2303},{"VI":2304},"Weill Cornell Medical College, New York, NY, USA",{"openalex":2306,"orcid":2308,"title":2310},{"VOID":2307},"A5040941721",{"VOID":2309},"https:\u002F\u002Forcid.org\u002F0000-0002-8524-0964",{"EN":2311},"Richard T. Silver",{"id":2313,"sortIndex":292,"researcher":23,"roles":2314,"affiliations":2315,"properties":2327},"1bdb6f79-5616-41d2-bc80-8b1c9253032b",[],[2316],{"id":2317,"sortIndex":24,"affiliation":2318,"properties":23},"52efec6a-7d17-4117-9185-cb9d02f80036",{"id":2319,"createTime":2320,"updateTime":2321,"relativeEntities":2322,"slug":2323,"properties":2324,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},"186174f6-3dd8-4f52-8029-3947bbecbbef","2024-01-14T22:49:43.869+00:00","2024-12-02T15:17:28.340+00:00",[],"University-of-Turin-Turin-Italy",{"title":2325},{"VI":2326},"University of Turin, Turin, Italy",{"openalex":2328,"orcid":2330,"title":2332},{"VOID":2329},"A5019949455",{"VOID":2331},"https:\u002F\u002Forcid.org\u002F0000-0002-1046-3514",{"EN":2333},"Giuseppe Saglio",{"id":2335,"sortIndex":500,"researcher":23,"roles":2336,"affiliations":2337,"properties":2348},"28d18983-4586-4577-a7e7-017b338b6cb8",[],[2338],{"id":2339,"sortIndex":24,"affiliation":2340,"properties":23},"41146e90-efd8-49e6-890a-a94ddcb53afa",{"id":2341,"createTime":2342,"updateTime":2342,"relativeEntities":2343,"slug":2344,"properties":2345,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},"ff7592ab-a302-441d-9635-e79a143f4ffd","2024-08-31T23:42:41.300+00:00",[],"Department-of-Hematology-Oncology-Policlinico-S-Orsola-Malpighi-University-of-Bologna-Bologna-Italy",{"title":2346},{"EN":2347},"Department of Hematology\u002FOncology, Policlinico S. Orsola-Malpighi, University of Bologna, Bologna, Italy",{"openalex":2349,"title":2351},{"VOID":2350},"A5052453031",{"EN":2352},"Michele Baccarani",{"id":2354,"sortIndex":605,"researcher":23,"roles":2355,"affiliations":2356,"properties":2363},"64c95ce9-3054-45c1-90e6-54d04881db4a",[],[2357],{"id":2358,"sortIndex":24,"affiliation":2359,"properties":23},"6b55918e-265b-49ad-9e8a-dbc9be2e77fc",{"id":2341,"createTime":2342,"updateTime":2342,"relativeEntities":2360,"slug":2344,"properties":2361,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},[],{"title":2362},{"EN":2347},{"openalex":2364,"title":2366},{"VOID":2365},"A5022396648",{"EN":2367},"G Rosti",{"id":2369,"sortIndex":991,"researcher":23,"roles":2370,"affiliations":2371,"properties":2378},"9a59f55e-c683-4f4c-99c2-d60ea9f97785",[],[2372],{"id":2373,"sortIndex":24,"affiliation":2374,"properties":23},"c3042332-59b2-46ba-8e87-717ec634a0d0",{"id":2341,"createTime":2342,"updateTime":2342,"relativeEntities":2375,"slug":2344,"properties":2376,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},[],{"title":2377},{"EN":2347},{"openalex":2379,"orcid":2381,"title":2383},{"VOID":2380},"A5016041461",{"VOID":2382},"https:\u002F\u002Forcid.org\u002F0000-0002-4508-0353",{"EN":2384},"Simona Soverini",{"id":2386,"sortIndex":1117,"researcher":23,"roles":2387,"affiliations":2388,"properties":2400},"da4819b9-fa07-413e-9b05-cc4ea7e4dab6",[],[2389],{"id":2390,"sortIndex":24,"affiliation":2391,"properties":23},"4fb9f166-a9bc-47a2-b0c9-d0f2e7cd2f9a",{"id":2392,"createTime":2393,"updateTime":2394,"relativeEntities":2395,"slug":2396,"properties":2397,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},"9220a0a6-7910-40b9-8fac-0bf9c0b550ba","2024-02-14T01:40:47.187+00:00","2024-10-14T10:47:02.459+00:00",[],"H%C3%B4pital-St-Louis-Paris-France",{"title":2398},{"VI":2399},"Hôpital St. Louis, Paris, France",{"openalex":2401,"orcid":2403,"title":2405},{"VOID":2402},"A5055797334",{"VOID":2404},"https:\u002F\u002Forcid.org\u002F0000-0001-5379-7461",{"EN":2406},"Delphine Réa",{"id":2408,"sortIndex":1489,"researcher":23,"roles":2409,"affiliations":2410,"properties":2422},"e4cfd61b-aadc-4b7d-930f-d4de040fe913",[],[2411],{"id":2412,"sortIndex":24,"affiliation":2413,"properties":23},"52b8c80f-f6f1-4673-ae0c-aac612c3bec8",{"id":2414,"createTime":2415,"updateTime":2416,"relativeEntities":2417,"slug":2418,"properties":2419,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},"a493766c-f5a9-4a36-8963-aa4203328fee","2024-01-08T06:17:54.071+00:00","2024-08-31T23:42:41.469+00:00",[],"III-Medizinische-Klinik-Medizinische-Fakult%C3%A4t-Mannheim-Universit%C3%A4t-Heidelberg-Mannheim-Germany",{"title":2420},{"VI":2421},"III. Medizinische Klinik, Medizinische Fakultät Mannheim, Universität Heidelberg, Mannheim, Germany",{"openalex":2423,"orcid":2425,"title":2427},{"VOID":2424},"A5013024565",{"VOID":2426},"https:\u002F\u002Forcid.org\u002F0000-0003-0357-5785",{"EN":2428},"Susanne Saußele",{"id":2430,"sortIndex":1137,"researcher":23,"roles":2431,"affiliations":2432,"properties":2444},"cf29c424-77cb-483b-b10f-29a5d131bec5",[],[2433],{"id":2434,"sortIndex":24,"affiliation":2435,"properties":23},"76be2da2-dfbb-4c51-88cb-de57c3c3525f",{"id":2436,"createTime":2437,"updateTime":2438,"relativeEntities":2439,"slug":2440,"properties":2441,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},"1a803831-80d7-445a-a68b-270a29b33f80","2024-01-03T05:54:51.558+00:00","2025-02-05T01:22:09.797+00:00",[],"University-of-Toronto-Toronto-Canada",{"title":2442},{"VI":2443},"University of Toronto, Toronto, Canada",{"openalex":2445,"title":2447},{"VOID":2446},"A5032311442",{"EN":2448},"Jeff H. Lipton",{"id":2450,"sortIndex":1282,"researcher":23,"roles":2451,"affiliations":2452,"properties":2464},"31ae44a2-15e7-43d3-8d49-583007941634",[],[2453],{"id":2454,"sortIndex":24,"affiliation":2455,"properties":23},"8c507daa-ccfd-4a28-8f5a-076376711995",{"id":2456,"createTime":2457,"updateTime":2458,"relativeEntities":2459,"slug":2460,"properties":2461,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},"da521201-17fa-4b36-9e4f-8276c0838f44","2024-02-09T18:00:22.524+00:00","2024-08-31T23:42:42.174+00:00",[],"Universit%C3%A4tsklinikum-Leipzig-Germany",{"title":2462},{"VI":2463},"Universitätsklinikum, Leipzig, Germany",{"openalex":2465,"title":2467},{"VOID":2466},"A5077890423",{"EN":2468},"D Niederwieser",{"id":2470,"sortIndex":1094,"researcher":23,"roles":2471,"affiliations":2472,"properties":2483},"24229565-814a-420a-b6ba-9b08183043ce",[],[2473],{"id":2474,"sortIndex":24,"affiliation":2475,"properties":23},"123a3dd0-e821-44a9-bffa-79d5366acd2a",{"id":2476,"createTime":2477,"updateTime":2477,"relativeEntities":2478,"slug":2479,"properties":2480,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},"10548ade-143a-4ddf-9136-774926ef4f07","2024-08-31T23:42:42.364+00:00",[],"Institut-Bergonie-Universit%C3%A9-de-Bordeaux-Bordeaux-France",{"title":2481},{"EN":2482},"Institut Bergonie, Université de Bordeaux, Bordeaux, France",{"openalex":2484,"title":2486},{"VOID":2485},"A5028900948",{"EN":2487},"F. X. Mahon",{"id":2489,"sortIndex":860,"researcher":23,"roles":2490,"affiliations":2491,"properties":2503},"ce9f2eee-308c-4f7a-850b-185f44143a58",[],[2492],{"id":2493,"sortIndex":24,"affiliation":2494,"properties":23},"cc155325-84f4-46e3-9197-842afb71f601",{"id":2495,"createTime":2496,"updateTime":2497,"relativeEntities":2498,"slug":2499,"properties":2500,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},"1f958d2c-372b-425d-a699-e631282edd59","2023-12-28T02:24:38.409+00:00","2024-12-10T16:45:41.335+00:00",[],"Centre-L%C3%A9on-B%C3%A9rard-Lyon-France",{"title":2501},{"VI":2502},"Centre Léon Bérard, Lyon, France",{"openalex":2504,"orcid":2506,"title":2508},{"VOID":2505},"A5079890028",{"VOID":2507},"https:\u002F\u002Forcid.org\u002F0000-0002-7651-9189",{"EN":2509},"Emmanuel Gyan",{"url":23,"publisher":2511,"properties":2536},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":2512,"slug":10,"properties":2513,"entityType":21,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24,"subjectFields":2519,"manageAffiliations":2520,"indexDatabases":2521,"url":125,"thumbnailPath":23,"statistic":23,"gsStatistic":23,"type":23,"analyzePriority":23},[],{"country":2514,"issn":2515,"introduce":2516,"eissn":2517,"title":2518},{"VOID":13},{"VOID":15},{"EN":17},{"VOID":19},{"EN":10},[],[],[2522,2529],{"id":84,"indexDatabase":2523,"url":99,"indexYears":23,"academicFieldIds":2528,"indexDatabaseRanking":23},{"id":86,"createTime":87,"updateTime":88,"relativeEntities":2524,"label":2525,"description":2526,"key":95,"publicationTags":2527,"standard":23},[],{"EN":91,"VI":91},{"VI":93,"EN":94},[97,98],[101,102],{"id":104,"indexDatabase":2530,"url":117,"indexYears":118,"academicFieldIds":2535,"indexDatabaseRanking":124},{"id":106,"createTime":107,"updateTime":108,"relativeEntities":2531,"label":2532,"description":2533,"key":114,"publicationTags":2534,"standard":23},[],{"EN":111,"VI":111},{"EN":111,"VI":113},[116],[120,121,122,123],{"volume":2537,"pages":2539,"issue":2541},{"VOID":2538},"34",{"VOID":2540},"966-984",{"VOID":2542},"4",1046,{"total":2543,"publishYear":23,"statisticByYear":2545},{"2020":2546,"2021":2547,"2022":2548,"2023":2549,"2024":2550},89,254,232,281,159,"2020-04-01",2020,[2554,2558,2562,2566,2570,2574,2578,2582,2585,2589,2593,2597,2601,2605,2609,2613,2617,2621,2625,2628,2632,2636,2640,2644,2648,2652,2656,2659,2662,2665,2669,2673,2676,2680,2684,2688,2691,2695,2699,2703,2707,2711,2715,2719,2723,2727,2731,2735,2739,2743,2747,2751,2755,2759,2763,2767,2771,2775,2779,2783,2787,2790,2794,2798,2802,2806,2810,2814,2818,2822,2826,2830,2834,2838,2842,2846,2850,2854,2858,2862,2866,2870,2874,2878,2882,2886,2890,2894,2898,2902,2906,2910,2914,2918,2922,2926,2930,2934,2938,2942,2946,2950,2954,2958,2962,2966,2970,2974,2978,2982,2986,2990,2994,2998,3002,3006,3010,3014,3018,3022,3026,3029,3033,3037,3041,3045,3049,3053,3057,3061,3065,3069,3073,3077],{"id":23,"text":2555,"url":23,"identifiers":2556},"Thielen N, Visser O, Ossenkoppele G, Janssen J. Chronic myeloid leukemia in the Netherlands: a population-based study on incidence, treatment, and survival in 3585 patients from 1989 to 2012. Eur J Haematol. 2016;97:145–54.",{"doi":2557},"10.1111\u002Fejh.12695",{"id":23,"text":2559,"url":23,"identifiers":2560},"Bower H, Bjorkholm M, Dickman PW, Hoglund M, Lambert PC, Andersson TM. Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. J Clin Oncol. 2016;34:2851–7.",{"doi":2561},"10.1200\u002FJCO.2015.66.2866",{"id":23,"text":2563,"url":23,"identifiers":2564},"Sasaki K, Strom SS, O’Brien S, Jabbour E, Ravandi F, Konopleva M, et al. Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials. Lancet Haematol. 2015;2:e186–193.",{"doi":2565},"10.1016\u002FS2352-3026(15)00048-4",{"id":23,"text":2567,"url":23,"identifiers":2568},"Hehlmann R, Lauseker M, Saussele S, Pfirrmann M, Krause S, Kolb HJ, et al. Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants. Leukemia. 2017;31:2398–406.",{"doi":2569},"10.1038\u002Fleu.2017.253",{"id":23,"text":2571,"url":23,"identifiers":2572},"Welch HG, Kramer BS, Black WC. Epidemiologic signatures in cancer. N Engl J Med. 2019;381:1378–86.",{"doi":2573},"10.1056\u002FNEJMsr1905447",{"id":23,"text":2575,"url":23,"identifiers":2576},"Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2006;108:1809–20.",{"doi":2577},"10.1182\u002Fblood-2006-02-005686",{"id":23,"text":2579,"url":23,"identifiers":2580},"Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol. 2009;27:6041–51.",{"doi":2581},"10.1200\u002FJCO.2009.25.0779",{"id":23,"text":2583,"url":23,"identifiers":2584},"Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122:872–84.",{"doi":1701},{"id":23,"text":2586,"url":23,"identifiers":2587},"Malhotra H, Radich J, Garcia-Gonzalez P. Meeting the needs of CML patients in resource-poor countries. Hematol Am Soc Hematol Educ Program. 2019;433–42.",{"doi":2588},"10.1182\u002Fhematology.2019000050",{"id":23,"text":2590,"url":23,"identifiers":2591},"Rosti G, Castagnetti F, Gugliotta G, Baccarani M. Tyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom? Nat Rev Clin Oncol. 2017;14:141–54.",{"doi":2592},"10.1038\u002Fnrclinonc.2016.139",{"id":23,"text":2594,"url":23,"identifiers":2595},"Radich JP, Deininger M, Abboud CN, Altman JK, Berman E, Bhatia R, et al. Chronic myeloid leukemia, version 1.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 2018;16:1108–35.",{"doi":2596},"10.6004\u002Fjnccn.2018.0071",{"id":23,"text":2598,"url":23,"identifiers":2599},"Khoury HJ, Williams LA, Atallah E, Hehlmann R. Chronic myeloid leukemia: what every practitioner needs to know in 2017. Am Soc Clin Oncol Educ Book. 2017;37:468–79.",{"doi":2600},"10.14694\u002FEDBK_175712",{"id":23,"text":2602,"url":23,"identifiers":2603},"Buesche G, Hehlmann R, Hecker H, Heimpel H, Heinze B, Schmeil A, et al. Marrow fibrosis, indicator of therapy failure in chronic myeloid leukemia - prospective long-term results from a randomized-controlled trial. Leukemia. 2003;17:2444–53.",{"doi":2604},"10.1038\u002Fsj.leu.2403172",{"id":23,"text":2606,"url":23,"identifiers":2607},"Buesche G, Ganser A, Schlegelberger B, von Neuhoff N, Gadzicki D, Hecker H, et al. Marrow fibrosis and its relevance during imatinib treatment of chronic myeloid leukemia. Leukemia. 2007;21:2420–7.",{"doi":2608},"10.1038\u002Fsj.leu.2404917",{"id":23,"text":2610,"url":23,"identifiers":2611},"Hidalgo-Lopez JE, Kanagal-Shamanna R, Quesada AE, Gong Z, Wang W, Hu S, et al. Bone marrow core biopsy in 508 consecutive patients with chronic myeloid leukemia: assessment of potential value. Cancer. 2018;124:3849–55.",{"doi":2612},"10.1002\u002Fcncr.31663",{"id":23,"text":2614,"url":23,"identifiers":2615},"Fabarius A, Kalmanti L, Dietz CT, Lauseker M, Rinaldetti S, Haferlach C, et al. Impact of unbalanced minor route versus major route karyotypes at diagnosis on prognosis of CML. Ann Hematol. 2015;94:2015–24.",{"doi":2616},"10.1007\u002Fs00277-015-2494-9",{"id":23,"text":2618,"url":23,"identifiers":2619},"Wang W, Cortes JE, Tang G, Khoury JD, Wang S, Bueso-Ramos CE, et al. Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy. Blood. 2016;127:2742–50.",{"doi":2620},"10.1182\u002Fblood-2016-01-690230",{"id":23,"text":2622,"url":23,"identifiers":2623},"Hehlmann R, Voskanyan A, Lauseker M, Pfirrmann M, Kalmanti L, Rinaldetti S, et al. High-risk additional chromosomal abnormalities in CML herald death by blast crisis already at low blast levels. Blood. 2019;134:666. (abstract).",{"doi":2624},"10.1182\u002Fblood-2019-127127",{"id":23,"text":2626,"url":23,"identifiers":2627},"Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: International Agency for Research on Cancer; 2017.",{},{"id":23,"text":2629,"url":23,"identifiers":2630},"Hoffmann VS, Baccarani M, Hasford J, Lindoerfer D, Burgstaller S, Sertic D, et al. The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries. Leukemia. 2015;29:1336–43.",{"doi":2631},"10.1038\u002Fleu.2015.73",{"id":23,"text":2633,"url":23,"identifiers":2634},"Sokal JE, Cox EB, Baccarani M, Tura S, Gomez GA, Robertson JE, et al. Prognostic discrimination in “good-risk” chronic granulocytic leukemia. Blood. 1984;63:789–99.",{"doi":2635},"10.1182\u002Fblood.V63.4.789.789",{"id":23,"text":2637,"url":23,"identifiers":2638},"Hasford J, Pfirrmann M, Hehlmann R, Allan NC, Baccarani M, Kluin-Nelemans JC, et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst. 1998;90:850–8.",{"doi":2639},"10.1093\u002Fjnci\u002F90.11.850",{"id":23,"text":2641,"url":23,"identifiers":2642},"Hasford J, Baccarani M, Hoffmann V, Guilhot J, Saussele S, Rosti G, et al. Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score. Blood. 2011;118:686–92.",{"doi":2643},"10.1182\u002Fblood-2010-12-319038",{"id":23,"text":2645,"url":23,"identifiers":2646},"Pfirrmann M, Baccarani M, Saussele S, Guilhot J, Cervantes F, Ossenkoppele G, et al. Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia. Leukemia. 2016;30:48–56.",{"doi":2647},"10.1038\u002Fleu.2015.261",{"id":23,"text":2649,"url":23,"identifiers":2650},"Geelen IGP, Sandin F, Thielen N, Janssen J, Hoogendoorn M, Visser O, et al. Validation of the EUTOS long-term survival score in a recent independent cohort of “real world” CML patients. Leukemia. 2018;32:2299–303.",{"doi":2651},"10.1038\u002Fs41375-018-0136-7",{"id":23,"text":2653,"url":23,"identifiers":2654},"Castagnetti F, Gugliotta G, Breccia M, Stagno F, Specchia G, Levato L, et al. The use of EUTOS long-term survival score instead of Sokal score is strongly advised in elderly chronic myeloid leukemia patients. Blood. 2018;132:44. (abstract).",{"doi":2655},"10.1182\u002Fblood-2018-99-117409",{"id":23,"text":2657,"url":23,"identifiers":2658},"Hughes T, Deininger M, Hochhaus A, Branford S, Radich J, Kaeda J, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood. 2006;108:28–37.",{"doi":1717},{"id":23,"text":2660,"url":23,"identifiers":2661},"Branford S, Fletcher L, Cross NC, Müller MC, Hochhaus A, Kim DW, et al. Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. Blood. 2008;112:3330–8.",{"doi":1721},{"id":23,"text":2663,"url":23,"identifiers":2664},"Cross NC, White HE, Müller MC, Saglio G, Hochhaus A. Standardized definitions of molecular response in chronic myeloid leukemia. Leukemia. 2012;26:2172–5.",{"doi":1749},{"id":23,"text":2666,"url":23,"identifiers":2667},"Lauseker M, Hanfstein B, Haferlach C, Schnittger S, Pfirrmann M, Fabarius A, et al. Equivalence of BCR-ABL transcript levels with complete cytogenetic remission in patients with chronic myeloid leukemia in chronic phase. J Cancer Res Clin Oncol. 2014;140:1965–9.",{"doi":2668},"10.1007\u002Fs00432-014-1746-8",{"id":23,"text":2670,"url":23,"identifiers":2671},"Cross NC, White HE, Colomer D, Ehrencrona H, Foroni L, Gottardi E, et al. Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia. Leukemia. 2015;29:999–1003.",{"doi":2672},"10.1038\u002Fleu.2015.29",{"id":23,"text":2674,"url":23,"identifiers":2675},"Cross NC. Standardisation of molecular monitoring for chronic myeloid leukaemia. Best Pr Res Clin Haematol. 2009;22:355–65.",{"doi":1689},{"id":23,"text":2677,"url":23,"identifiers":2678},"Guilhot J, Preudhomme C, Mahon FX, Guilhot F. Analyzing molecular response in chronic myeloid leukemia clinical trials: pitfalls and golden rules. Cancer. 2015;121:490–7.",{"doi":2679},"10.1002\u002Fcncr.29053",{"id":23,"text":2681,"url":23,"identifiers":2682},"O’Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348:994–1004.",{"doi":2683},"10.1056\u002FNEJMoa022457",{"id":23,"text":2685,"url":23,"identifiers":2686},"Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, et al. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med. 2017;376:917–27.",{"doi":2687},"10.1056\u002FNEJMoa1609324",{"id":23,"text":2689,"url":23,"identifiers":2690},"Hehlmann R, Müller MC, Lauseker M, Hanfstein B, Fabarius A, Schreiber A, et al. Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV. J Clin Oncol. 2014;32:415–23.",{"doi":1753},{"id":23,"text":2692,"url":23,"identifiers":2693},"Kalmanti L, Saussele S, Lauseker M, Müller MC, Dietz CT, Heinrich L, et al. Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV. Leukemia. 2015;29:1123–32.",{"doi":2694},"10.1038\u002Fleu.2015.36",{"id":23,"text":2696,"url":23,"identifiers":2697},"Preudhomme C, Guilhot J, Nicolini FE, Guerci-Bresler A, Rigal-Huguet F, Maloisel F, et al. Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia. N Engl J Med. 2010;363:2511–21.",{"doi":2698},"10.1056\u002FNEJMoa1004095",{"id":23,"text":2700,"url":23,"identifiers":2701},"Castagnetti F, Gugliotta G, Breccia M, Stagno F, Iurlo A, Albano F, et al. Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib. Leukemia. 2015;29:1823–31.",{"doi":2702},"10.1038\u002Fleu.2015.152",{"id":23,"text":2704,"url":23,"identifiers":2705},"Cortes JE, Saglio G, Kantarjian HM, Baccarani M, Mayer J, Boque C, et al. Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naive chronic myeloid leukemia patients trial. J Clin Oncol. 2016;34:2333–40.",{"doi":2706},"10.1200\u002FJCO.2015.64.8899",{"id":23,"text":2708,"url":23,"identifiers":2709},"Hochhaus A, Saglio G, Hughes TP, Larson RA, Kim DW, Issaragrisil S, et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia. 2016;30:1044–54.",{"doi":2710},"10.1038\u002Fleu.2016.5",{"id":23,"text":2712,"url":23,"identifiers":2713},"Wang J, Shen ZX, Saglio G, Jin J, Huang H, Hu Y, et al. Phase 3 study of nilotinib vs imatinib in Chinese patients with newly diagnosed chronic myeloid leukemia in chronic phase: ENESTchina. Blood. 2015;125:2771–8.",{"doi":2714},"10.1182\u002Fblood-2014-09-601674",{"id":23,"text":2716,"url":23,"identifiers":2717},"Cortes JE, Gambacorti-Passerini C, Deininger MW, Mauro MJ, Chuah C, Kim DW, et al. Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial. J Clin Oncol. 2018;36:231–7.",{"doi":2718},"10.1200\u002FJCO.2017.74.7162",{"id":23,"text":2720,"url":23,"identifiers":2721},"Cortes JE, Kim DW, Kantarjian HM, Brümmendorf TH, Dyagil I, Griskevicius L, et al. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial. J Clin Oncol. 2012;30:3486–92.",{"doi":2722},"10.1200\u002FJCO.2011.38.7522",{"id":23,"text":2724,"url":23,"identifiers":2725},"Kwak JY, Kim SH, Oh SJ, Zang DY, Kim H, Kim JA, et al. Phase III Clinical Trial (RERISE study) Results of Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia. Clin Cancer Res. 2017;23:7180–8.",{"doi":2726},"10.1158\u002F1078-0432.CCR-17-0957",{"id":23,"text":2728,"url":23,"identifiers":2729},"Radich JP, Kopecky KJ, Appelbaum FR, Kamel-Reid S, Stock W, Malnassy G, et al. A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia. Blood. 2012;120:3898–905.",{"doi":2730},"10.1182\u002Fblood-2012-02-410688",{"id":23,"text":2732,"url":23,"identifiers":2733},"Hjorth-Hansen H, Stenke L, Soderlund S, Dreimane A, Ehrencrona H, Gedde-Dahl T, et al. Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006). Eur J Haematol. 2015;94:243–50.",{"doi":2734},"10.1111\u002Fejh.12423",{"id":23,"text":2736,"url":23,"identifiers":2737},"O’Brien S, Cork L, Bandeira V, Bescoby R, Foroni L, Alaily L, et al. Spirit 2: final 5 year analysis of the UK national cancer research institute randomized study comparing imatinib with dasatinib in patients with newly diagnosed chronic phase CML. Blood. 2018;132:457. (abstract).",{"doi":2738},"10.1182\u002Fblood-2018-99-110128",{"id":23,"text":2740,"url":23,"identifiers":2741},"Steegmann JL, Baccarani M, Breccia M, Casado LF, Garcia-Gutierrez V, Hochhaus A, et al. European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. Leukemia. 2016;30:1648–71.",{"doi":2742},"10.1038\u002Fleu.2016.104",{"id":23,"text":2744,"url":23,"identifiers":2745},"Michel C, Burchert A, Hochhaus A, Saussele S, Neubauer A, Lauseker M, et al. Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV. Haematologica. 2019;104:955–62.",{"doi":2746},"10.3324\u002Fhaematol.2018.206797",{"id":23,"text":2748,"url":23,"identifiers":2749},"Naqvi K, Jabbour E, Skinner J, Anderson K, Dellasala S, Yilmaz M, et al. Long-term follow-up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia. Cancer. 2020;126:67–75.",{"doi":2750},"10.1002\u002Fcncr.32504",{"id":23,"text":2752,"url":23,"identifiers":2753},"Hughes T, Saglio G, Larson R, Kantarjian H, Kim D-W, Issaragrisil S, et al. Long-term outcomes in patients with chronic myeloid leukemia in chronic phase receiving frontline nilotinib versus imatinib: ENESTnd 10-year analysis. Blood. 2019;134:2924. (abstract).",{"doi":2754},"10.1182\u002Fblood-2019-128761",{"id":23,"text":2756,"url":23,"identifiers":2757},"Gugliotta G, Castagnetti F, Breccia M, Levato L, Intermesoli T, D’Adda M, et al. Ten-year follow-up of patients with chronic myeloid leukemia treated with nilotinib in first-line: final results of the gimema CML 0307 trial. Blood. 2019;134:4145. (abstract).",{"doi":2758},"10.1182\u002Fblood-2019-126163",{"id":23,"text":2760,"url":23,"identifiers":2761},"Hochhaus A, Rosti G, Cross NC, Steegmann JL, le Coutre P, Ossenkoppele G, et al. Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study. Leukemia. 2016;30:57–64.",{"doi":2762},"10.1038\u002Fleu.2015.270",{"id":23,"text":2764,"url":23,"identifiers":2765},"Gugliotta G, Castagnetti F, Breccia M, Iurlo A, D’Adda M, Stagno F, et al. Outcome of 472 chronic myeloid leukemia patients treated with frontline nilotinib: a GIMEMA CML WP analysis. Blood. 2018;132:458. (abstract).",{"doi":2766},"10.1182\u002Fblood-2018-99-119182",{"id":23,"text":2768,"url":23,"identifiers":2769},"Do YR, Kwak J-Y, Kim J-A. Long-term data from a phase 3 study of radotinib versus imatinib in patients with newly diagnosed, chronic myeloid leukemia in the chronic phase (RERISE). Brit J Haematol. 2020. https:\u002F\u002Fonlinelibrary.wiley.com\u002Fdoi\u002Ffull\u002F10.1111\u002Fbjh.16381.",{"doi":2770},"10.1111\u002Fbjh.16381",{"id":23,"text":2772,"url":23,"identifiers":2773},"Talpaz M, Hehlmann R, Quintas-Cardama A, Mercer J, Cortes J. Re-emergence of interferon-alpha in the treatment of chronic myeloid leukemia. Leukemia. 2013;27:803–12.",{"doi":2774},"10.1038\u002Fleu.2012.313",{"id":23,"text":2776,"url":23,"identifiers":2777},"Hjorth-Hansen H, Stentoft J, Richter J, Koskenvesa P, Hoglund M, Dreimane A, et al. Safety and efficacy of the combination of pegylated interferon-alpha2b and dasatinib in newly diagnosed chronic-phase chronic myeloid leukemia patients. Leukemia. 2016;30:1853–60.",{"doi":2778},"10.1038\u002Fleu.2016.121",{"id":23,"text":2780,"url":23,"identifiers":2781},"Nicolini FE, Etienne G, Dubruille V, Roy L, Huguet F, Legros L, et al. Nilotinib and peginterferon alfa-2a for newly diagnosed chronic-phase chronic myeloid leukaemia (NiloPeg): a multicentre, non-randomised, open-label phase 2 study. Lancet Haematol. 2015;2:e37–46.",{"doi":2782},"10.1016\u002FS2352-3026(14)00027-1",{"id":23,"text":2784,"url":23,"identifiers":2785},"Simonsson B, Gedde-Dahl T, Markevarn B, Remes K, Stentoft J, Almqvist A, et al. Combination of pegylated IFN-alpha2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia. Blood. 2011;118:3228–35.",{"doi":2786},"10.1182\u002Fblood-2011-02-336685",{"id":23,"text":2788,"url":23,"identifiers":2789},"Malkan UY, Aksu S, Aktimur S, Atay H, Bektas O, Buyukasik Y, et al. Generic imatinib mesylate is as effective as original Glivec in the clinical management of CML. UHOD - Uluslararasi Hematol-Onkol Derg. 2015;25:215–21. 01\u002F01",{},{"id":23,"text":2791,"url":23,"identifiers":2792},"Islamagic E, Hasic A, Kurtovic S, Suljovic Hadzimesic E, Mehinovic L, Kozaric M, et al. The efficacy of generic imatinib as first- and second-line therapy: 3-year follow-up of patients with chronic myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2017;17:238–40.",{"doi":2793},"10.1016\u002Fj.clml.2017.02.001",{"id":23,"text":2795,"url":23,"identifiers":2796},"Eskazan AE, Sadri S, Keskin D, Ayer M, Kantarcioglu B, Demirel N, et al. Outcomes of chronic myeloid leukemia patients with early molecular response at 3 and 6 months: a comparative analysis of generic imatinib and glivec. Clin Lymphoma Myeloma Leuk. 2017;17:804–11.",{"doi":2797},"10.1016\u002Fj.clml.2017.07.255",{"id":23,"text":2799,"url":23,"identifiers":2800},"Dusetzina SB, Winn AN, Abel GA, Huskamp HA, Keating NL. Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia. J Clin Oncol. 2014;32:306–11.",{"doi":2801},"10.1200\u002FJCO.2013.52.9123",{"id":23,"text":2803,"url":23,"identifiers":2804},"Winn AN, Keating NL, Dusetzina SB. Factors associated with tyrosine kinase inhibitor initiation and adherence among medicare beneficiaries with chronic myeloid leukemia. J Clin Oncol. 2016;34:4323–8.",{"doi":2805},"10.1200\u002FJCO.2016.67.4184",{"id":23,"text":2807,"url":23,"identifiers":2808},"Padula WV, Larson RA, Dusetzina SB, Apperley JF, Hehlmann R, Baccarani M, et al. Cost-effectiveness of tyrosine kinase inhibitor treatment strategies for chronic myeloid leukemia in chronic phase after generic entry of imatinib in the United States. J Natl Cancer Inst. 2016;108. https:\u002F\u002Fdoi.org\u002F10.1093\u002Fjnci\u002Fdjw003.",{"doi":2809},"10.1093\u002Fjnci\u002Fdjw003",{"id":23,"text":2811,"url":23,"identifiers":2812},"Shih YT, Cortes JE, Kantarjian HM. Treatment value of second-generation BCR-ABL1 tyrosine kinase inhibitors compared with imatinib to achieve treatment-free remission in patients with chronic myeloid leukaemia: a modelling study. Lancet Haematol. 2019;6:e398–e408.",{"doi":2813},"10.1016\u002FS2352-3026(19)30087-0",{"id":23,"text":2815,"url":23,"identifiers":2816},"Yamamoto C, Nakashima H, Ikeda T, Kawaguchi SI, Toda Y, Ito S, et al. Analysis of the cost-effectiveness of treatment strategies for CML with incorporation of treatment discontinuation. Blood Adv. 2019;3:3266–77.",{"doi":2817},"10.1182\u002Fbloodadvances.2019000745",{"id":23,"text":2819,"url":23,"identifiers":2820},"Andrews CN, Lipton J. The true value of second-generation TKIs as first-line therapy in chronic myeloid leukaemia. Lancet Haematol. 2019;6:e385–e386.",{"doi":2821},"10.1016\u002FS2352-3026(19)30112-7",{"id":23,"text":2823,"url":23,"identifiers":2824},"Shah NP, Guilhot F, Cortes JE, Schiffer CA, le Coutre P, Brummendorf TH, et al. Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study. Blood. 2014;123:2317–24.",{"doi":2825},"10.1182\u002Fblood-2013-10-532341",{"id":23,"text":2827,"url":23,"identifiers":2828},"Giles FJ, le Coutre PD, Pinilla-Ibarz J, Larson RA, Gattermann N, Ottmann OG, et al. Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study. Leukemia. 2013;27:107–12.",{"doi":2829},"10.1038\u002Fleu.2012.181",{"id":23,"text":2831,"url":23,"identifiers":2832},"Smith B, Brümmendorf T, Roboz G, Gambacorti-Passerini C, Charbonnier A, Viquiera A, et al. Efficacy of bosutinib in imatinib-resistant vs dasatinib\u002Fnilotinib-resistant chronic phase chronic myeloid leukemia: results from the Phase 4 BYOND Study. Blood. 2019;134:1650. (abstract).",{"doi":2833},"10.1182\u002Fblood-2019-122230",{"id":23,"text":2835,"url":23,"identifiers":2836},"Gambacorti-Passerini C, Aroldi A, Cordani N, Piazza R. Chronic myeloid leukemia: Second-line drugs of choice. Am J Hematol. 2016;91:67–75.",{"doi":2837},"10.1002\u002Fajh.24247",{"id":23,"text":2839,"url":23,"identifiers":2840},"Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C, et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med. 2013;369:1783–96.",{"doi":2841},"10.1056\u002FNEJMoa1306494",{"id":23,"text":2843,"url":23,"identifiers":2844},"Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre PD, Paquette R, Chuah C, et al. Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. Blood. 2018;132:393–404.",{"doi":2845},"10.1182\u002Fblood-2016-09-739086",{"id":23,"text":2847,"url":23,"identifiers":2848},"Lipton JH, Chuah C, Guerci-Bresler A, Rosti G, Simpson D, Assouline S, et al. Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial. Lancet Oncol. 2016;17:612–21.",{"doi":2849},"10.1016\u002FS1470-2045(16)00080-2",{"id":23,"text":2851,"url":23,"identifiers":2852},"Andrews C, Lipton J. The role of ponatinib in chronic myeloid leukemia in the era of treatment free remission. Leuk Lymphoma. 2019;60:3099–101.",{"doi":2853},"10.1080\u002F10428194.2019.1665667",{"id":23,"text":2855,"url":23,"identifiers":2856},"Thanarajasingam G, Minasian LM, Baron F, Cavalli F, De Claro RA, Dueck AC, et al. Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies. Lancet Haematol. 2018;5:e563–e598.",{"doi":2857},"10.1016\u002FS2352-3026(18)30051-6",{"id":23,"text":2859,"url":23,"identifiers":2860},"Valent P, Hadzijusufovic E, Schernthaner GH, Wolf D, Rea D, le Coutre P. Vascular safety issues in CML patients treated with BCR\u002FABL1 kinase inhibitors. Blood. 2015;125:901–6.",{"doi":2861},"10.1182\u002Fblood-2014-09-594432",{"id":23,"text":2863,"url":23,"identifiers":2864},"Saussele S, Krauss MP, Hehlmann R, Lauseker M, Proetel U, Kalmanti L, et al. Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML study IV. Blood. 2015;126:42–49.",{"doi":2865},"10.1182\u002Fblood-2015-01-617993",{"id":23,"text":2867,"url":23,"identifiers":2868},"Jain P, Kantarjian H, Boddu PC, Nogueras-Gonzalez GM, Verstovsek S, Garcia-Manero G, et al. Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs. Blood Adv. 2019;3:851–61.",{"doi":2869},"10.1182\u002Fbloodadvances.2018025874",{"id":23,"text":2871,"url":23,"identifiers":2872},"Dorer DJ, Knickerbocker RK, Baccarani M, Cortes JE, Hochhaus A, Talpaz M, et al. Impact of dose intensity of ponatinib on selected adverse events: Multivariate analyses from a pooled population of clinical trial patients. Leuk Res. 2016;48:84–91.",{"doi":2873},"10.1016\u002Fj.leukres.2016.07.007",{"id":23,"text":2875,"url":23,"identifiers":2876},"Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016;37:2315–81.",{"doi":2877},"10.1093\u002Feurheartj\u002Fehw106",{"id":23,"text":2879,"url":23,"identifiers":2880},"Zamorano JL, Lancellotti P, Rodriguez Munoz D, Aboyans V, Asteggiano R, Galderisi M, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J. 2016;37:2768–801.",{"doi":2881},"10.1093\u002Feurheartj\u002Fehw211",{"id":23,"text":2883,"url":23,"identifiers":2884},"Hughes TP, Laneuville P, Rousselot P, Snyder DS, Rea D, Shah NP, et al. Incidence, outcomes, and risk factors of pleural effusion in patients receiving dasatinib therapy for Philadelphia chromosome-positive leukemia. Haematologica. 2019;104:93–101.",{"doi":2885},"10.3324\u002Fhaematol.2018.188987",{"id":23,"text":2887,"url":23,"identifiers":2888},"Gong Z, Medeiros LJ, Cortes JE, Chen Z, Zheng L, Li Y, et al. Cytogenetics-based risk prediction of blastic transformation of chronic myeloid leukemia in the era of TKI therapy. Blood Adv. 2017;1:2541–52.",{"doi":2889},"10.1182\u002Fbloodadvances.2017011858",{"id":23,"text":2891,"url":23,"identifiers":2892},"Soverini S, Bavaro L, De Benedittis C, Martelli M, Iurlo A, Orofino N, et al. Prospective assessment of NGS-detectable mutations in CML patients with non-optimal response: the NEXT-in-CML study. Blood. 2019. https:\u002F\u002Fdoi.org\u002F10.1182\u002Fblood.2019002969.",{"doi":2893},"10.1182\u002Fblood.2019002969",{"id":23,"text":2895,"url":23,"identifiers":2896},"Kizilors A, Crisa E, Lea N, Passera R, Mian S, Anwar J, et al. Effect of low-level BCR-ABL1 kinase domain mutations identified by next-generation sequencing in patients with chronic myeloid leukaemia: a population-based study. Lancet Haematol. 2019;6:e276–e284.",{"doi":2897},"10.1016\u002FS2352-3026(19)30027-4",{"id":23,"text":2899,"url":23,"identifiers":2900},"Kok CH, Yeung DT, Lu L, Watkins DB, Leclercq TM, Dang P, et al. Gene expression signature that predicts early molecular response failure in chronic-phase CML patients on frontline imatinib. Blood Adv. 2019;3:1610–21.",{"doi":2901},"10.1182\u002Fbloodadvances.2019000195",{"id":23,"text":2903,"url":23,"identifiers":2904},"Grossmann V, Kohlmann A, Zenger M, Schindela S, Eder C, Weissmann S, et al. A deep-sequencing study of chronic myeloid leukemia patients in blast crisis (BC-CML) detects mutations in 76.9% of cases. Leukemia. 2011;25:557–60.",{"doi":2905},"10.1038\u002Fleu.2010.298",{"id":23,"text":2907,"url":23,"identifiers":2908},"Branford S, Wang P, Yeung DT, Thomson D, Purins A, Wadham C, et al. Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease. Blood. 2018;132:948–61.",{"doi":2909},"10.1182\u002Fblood-2018-02-832253",{"id":23,"text":2911,"url":23,"identifiers":2912},"Baccarani M, Castagnetti F, Gugliotta G, Rosti G, Soverini S, Albeer A, et al. The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia. an international overview. Leukemia. 2019;33:1173–83.",{"doi":2913},"10.1038\u002Fs41375-018-0341-4",{"id":23,"text":2915,"url":23,"identifiers":2916},"Hehlmann R, Saussele S, Voskanyan A, Silver RT. Management of CML-blast crisis. Best Pr Res Clin Haematol. 2016;29:295–307.",{"doi":2917},"10.1016\u002Fj.beha.2016.10.005",{"id":23,"text":2919,"url":23,"identifiers":2920},"Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391–405.",{"doi":2921},"10.1182\u002Fblood-2016-03-643544",{"id":23,"text":2923,"url":23,"identifiers":2924},"Spiers AS. Metamorphosis of chronic granulocytic leukaemia: diagnosis, classification, and management. Br J Haematol. 1979;41:1–7.",{"doi":2925},"10.1111\u002Fj.1365-2141.1979.tb03675.x",{"id":23,"text":2927,"url":23,"identifiers":2928},"Soderlund S, Dahlen T, Sandin F, Olsson-Stromberg U, Creignou M, Dreimane A, et al. Advanced phase chronic myeloid leukaemia (CML) in the tyrosine kinase inhibitor era—a report from the Swedish CML register. Eur J Haematol. 2017;98:57–66.",{"doi":2929},"10.1111\u002Fejh.12785",{"id":23,"text":2931,"url":23,"identifiers":2932},"Jain P, Kantarjian HM, Ghorab A, Sasaki K, Jabbour EJ, Nogueras Gonzalez G, et al. Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients. Cancer. 2017;123:4391–402.",{"doi":2933},"10.1002\u002Fcncr.30864",{"id":23,"text":2935,"url":23,"identifiers":2936},"Lubking A, Dreimane A, Sandin F, Isaksson C, Markevarn B, Brune M, et al. Allogeneic stem cell transplantation for chronic myeloid leukemia in the TKI era: population-based data from the Swedish CML registry. Bone Marrow Transpl. 2019;54:1764–74.",{"doi":2937},"10.1038\u002Fs41409-019-0513-5",{"id":23,"text":2939,"url":23,"identifiers":2940},"Milojkovic D, Ibrahim A, Reid A, Foroni L, Apperley J, Marin D. Efficacy of combining dasatinib and FLAG-IDA for patients with chronic myeloid leukemia in blastic transformation. Haematologica. 2012;97:473–4.",{"doi":2941},"10.3324\u002Fhaematol.2011.057513",{"id":23,"text":2943,"url":23,"identifiers":2944},"Copland M, Slade D, Byrne J. FLAG-IDA and ponatinib in patients with blast phase chronic myeloid leukaemia: results from the phase I\u002FII UK trials acceleration programme matchpoint trial. Blood. 2019;134:497. (abstract).",{"doi":2945},"10.1182\u002Fblood-2019-125591",{"id":23,"text":2947,"url":23,"identifiers":2948},"Strati P, Kantarjian H, Thomas D, O’Brien S, Konoplev S, Jorgensen JL, et al. HCVAD plus imatinib or dasatinib in lymphoid blastic phase chronic myeloid leukemia. Cancer. 2014;120:373–80.",{"doi":2949},"10.1002\u002Fcncr.28433",{"id":23,"text":2951,"url":23,"identifiers":2952},"Gratwohl A, Pfirrmann M, Zander A, Kroger N, Beelen D, Novotny J, et al. Long-term outcome of patients with newly diagnosed chronic myeloid leukemia: a randomized comparison of stem cell transplantation with drug treatment. Leukemia. 2016;30:562–9.",{"doi":2953},"10.1038\u002Fleu.2015.281",{"id":23,"text":2955,"url":23,"identifiers":2956},"Efficace F, Cannella L. The value of quality of life assessment in chronic myeloid leukemia patients receiving tyrosine kinase inhibitors. Hematol Am Soc Hematol Educ Program. 2016;2016:170–9.",{"doi":2957},"10.1182\u002Fasheducation-2016.1.170",{"id":23,"text":2959,"url":23,"identifiers":2960},"Phillips KM, Pinilla-Ibarz J, Sotomayor E, Lee MR, Jim HS, Small BJ, et al. Quality of life outcomes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a controlled comparison. Support Care Cancer. 2013;21:1097–103.",{"doi":2961},"10.1007\u002Fs00520-012-1630-5",{"id":23,"text":2963,"url":23,"identifiers":2964},"Zulbaran-Rojas A, Lin HK, Shi Q, Williams LA, George B, Garcia-Manero G, et al. A prospective analysis of symptom burden for patients with chronic myeloid leukemia in chronic phase treated with frontline second- and third-generation tyrosine kinase inhibitors. Cancer Med. 2018;7:5457–69.",{"doi":2965},"10.1002\u002Fcam4.1808",{"id":23,"text":2967,"url":23,"identifiers":2968},"Kim DW, Saussele S, Williams LA, Mohamed H, Rong Y, Zyczynski T, et al. Outcomes of switching to dasatinib after imatinib-related low-grade adverse events in patients with chronic myeloid leukemia in chronic phase: the DASPERSE study. Ann Hematol. 2018;97:1357–67.",{"doi":2969},"10.1007\u002Fs00277-018-3295-8",{"id":23,"text":2971,"url":23,"identifiers":2972},"Sacha T, Gora-Tybor J, Wasak-Szulkowska E, Kyrcz-Krzemien S, Medras E, Becht R, et al. Quality of life and adherence to therapy in patients with chronic myeloid leukemia treated with nilotinib as a second-line therapy: a multicenter prospective observational study. Clin Lymphoma Myeloma Leuk. 2017;17:283–95.",{"doi":2973},"10.1016\u002Fj.clml.2017.01.001",{"id":23,"text":2975,"url":23,"identifiers":2976},"Baccarani M, Efficace F, Rosti G. Moving towards patient-centered decision-making in chronic myeloid leukemia: assessment of quality of life and symptom burden. Haematologica. 2014;99:205–8.",{"doi":2977},"10.3324\u002Fhaematol.2013.094045",{"id":23,"text":2979,"url":23,"identifiers":2980},"Kantarjian HM, Mamolo CM, Gambacorti-Passerini C, Cortes JE, Brummendorf TH, Su Y, et al. Long-term patient-reported outcomes from an open-label safety and efficacy study of bosutinib in Philadelphia chromosome-positive chronic myeloid leukemia patients resistant or intolerant to prior therapy. Cancer. 2018;124:587–95.",{"doi":2981},"10.1002\u002Fcncr.31082",{"id":23,"text":2983,"url":23,"identifiers":2984},"Etienne G, Guilhot J, Rea D, Rigal-Huguet F, Nicolini F, Charbonnier A, et al. Long-term follow-up of the french stop imatinib (STIM1) study in patients with chronic myeloid leukemia. J Clin Oncol. 2017;35:298–305.",{"doi":2985},"10.1200\u002FJCO.2016.68.2914",{"id":23,"text":2987,"url":23,"identifiers":2988},"Campiotti L, Suter MB, Guasti L, Piazza R, Gambacorti-Passerini C, Grandi AM, et al. Imatinib discontinuation in chronic myeloid leukaemia patients with undetectable BCR-ABL transcript level: a systematic review and a meta-analysis. Eur J Cancer. 2017;77:48–56.",{"doi":2989},"10.1016\u002Fj.ejca.2017.02.028",{"id":23,"text":2991,"url":23,"identifiers":2992},"Saussele S, Richter J, Guilhot J, Gruber FX, Hjorth-Hansen H, Almeida A, et al. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. Lancet Oncol. 2018;19:747–57.",{"doi":2993},"10.1016\u002FS1470-2045(18)30192-X",{"id":23,"text":2995,"url":23,"identifiers":2996},"Clark RE, Polydoros F, Apperley JF, Milojkovic D, Rothwell K, Pocock C, et al. Initial reduction of therapy prior to complete treatment discontinuation in chronic myeloid leukaemia: final results of the British DESTINY Study. Lancet Haematol. 2019;6:e375–e383.",{"doi":2997},"10.1016\u002FS2352-3026(19)30094-8",{"id":23,"text":2999,"url":23,"identifiers":3000},"Rousselot P, Charbonnier A, Cony-Makhoul P, Agape P, Nicolini FE, Varet B, et al. Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease. J Clin Oncol. 2014;32:424–30.",{"doi":3001},"10.1200\u002FJCO.2012.48.5797",{"id":23,"text":3003,"url":23,"identifiers":3004},"Rea D, Nicolini FE, Tulliez M, Guilhot F, Guilhot J, Guerci-Bresler A, et al. Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study. Blood. 2017;129:846–54.",{"doi":3005},"10.1182\u002Fblood-2016-09-742205",{"id":23,"text":3007,"url":23,"identifiers":3008},"Hochhaus A, Masszi T, Giles FJ, Radich JP, Ross DM, Gomez Casares MT, et al. Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study. Leukemia. 2017;31:1525–31.",{"doi":3009},"10.1038\u002Fleu.2017.63",{"id":23,"text":3011,"url":23,"identifiers":3012},"Imagawa J, Tanaka H, Okada M, Nakamae H, Hino M, Murai K, et al. Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial. Lancet Haematol. 2015;2:e528–535.",{"doi":3013},"10.1016\u002FS2352-3026(15)00196-9",{"id":23,"text":3015,"url":23,"identifiers":3016},"Richter J, Soderlund S, Lubking A, Dreimane A, Lotfi K, Markevarn B, et al. Musculoskeletal pain in patients with chronic myeloid leukemia after discontinuation of imatinib: a tyrosine kinase inhibitor withdrawal syndrome? J Clin Oncol. 2014;32:2821–3.",{"doi":3017},"10.1200\u002FJCO.2014.55.6910",{"id":23,"text":3019,"url":23,"identifiers":3020},"Hughes TP, Ross DM. Moving treatment-free remission into mainstream clinical practice in CML. Blood. 2016;128:17–23.",{"doi":3021},"10.1182\u002Fblood-2016-01-694265",{"id":23,"text":3023,"url":23,"identifiers":3024},"Saussele S, Richter J, Hochhaus A, Mahon FX. The concept of treatment-free remission in chronic myeloid leukemia. Leukemia. 2016;30:1638–47.",{"doi":3025},"10.1038\u002Fleu.2016.115",{"id":23,"text":3027,"url":23,"identifiers":3028},"Lichtin AE, Woolf SH, Silver RT, Hehlmann R. Chronic myeloid leukemia—ASH practice guideline and beyond. Hematol Am Soc Hematol Educ Prog. 1998:435–53.",{},{"id":23,"text":3030,"url":23,"identifiers":3031},"Apperley J. Issues of imatinib and pregnancy outcome. J Natl Compr Canc Netw. 2009;7:1050–8.",{"doi":3032},"10.6004\u002Fjnccn.2009.0069",{"id":23,"text":3034,"url":23,"identifiers":3035},"Carlier P, Markarian M, Bernard N, Lagarce L, Dautriche A, Bene J, et al. Erratum to: pregnancy outcome among partners of male patients receiving imatinib, dasatinib or nilotinib in chronic myeloid leukemia: reports collected by the French network pharmacovigilance centers. Arch Gynecol Obstet. 2017;295:1059.",{"doi":3036},"10.1007\u002Fs00404-017-4321-0",{"id":23,"text":3038,"url":23,"identifiers":3039},"Cortes JE, Abruzzese E, Chelysheva E, Guha M, Wallis N, Apperley JF. The impact of dasatinib on pregnancy outcomes. Am J Hematol. 2015;90:1111–5.",{"doi":3040},"10.1002\u002Fajh.24186",{"id":23,"text":3042,"url":23,"identifiers":3043},"Abruzzese E, de Fabritiis P, Trawinska MM, Niscola P, Apperley JF, Mauro MJ. Back to the future: treatment-free remission and pregnancy in chronic myeloid leukemia. Eur J Haematol. 2019;102:197–9.",{"doi":3044},"10.1111\u002Fejh.13192",{"id":23,"text":3046,"url":23,"identifiers":3047},"Abruzzese E, Scortechini AR, Gugliotta G, Pierri I, Musolino C, Iurlo A, et al. GIMEMA registry of conception\u002Fpregnancy in adult patients diagnosed with chronic myeloid leukemia (CML) treated with tyrosine kinase inhibitors (TKIs). Blood. 2014;124:1806. (abstract).",{"doi":3048},"10.1182\u002Fblood.V124.21.1806.1806",{"id":23,"text":3050,"url":23,"identifiers":3051},"Cortes JE, Gambacorti-Passerini C, Deininger MW, Abruzzese E, DeAnnuntis L, Brümmendorf TH. Pregnancy outcomes in patients treated with bosutinib. Blood. 2018;132:1729. (abstract).",{"doi":3052},"10.1182\u002Fblood-2018-99-110547",{"id":23,"text":3054,"url":23,"identifiers":3055},"Nicolini FE, Alcazer V, Huguet F, Cony-Makhoul P, Heiblig M, Fort MP, et al. CML patients show sperm alterations at diagnosis that are not improved with imatinib treatment. Leuk Res. 2016;48:80–83.",{"doi":3056},"10.1016\u002Fj.leukres.2016.07.008",{"id":23,"text":3058,"url":23,"identifiers":3059},"Lasica M, Willcox A, Burbury K, Ross DM, Branford S, Butler J, et al. The effect of tyrosine kinase inhibitor interruption and interferon use on pregnancy outcomes and long-term disease control in chronic myeloid leukemia. Leuk Lymphoma. 2019;60:1796–802.",{"doi":3060},"10.1080\u002F10428194.2018.1551533",{"id":23,"text":3062,"url":23,"identifiers":3063},"Chelysheva E, Turkina A. Risks and challenges of CML management during pregnancy: Looking for a balanced decision. Eur J Haematol. 2019;102:378–9.",{"doi":3064},"10.1111\u002Fejh.13215",{"id":23,"text":3066,"url":23,"identifiers":3067},"Chelysheva E, Aleshin S, Polushkina E, Shmakov R, Shokhin I, Chilov G, et al. Breastfeeding in patients with chronic myeloid leukaemia: case series with measurements of drug concentrations in maternal milk and literature review. Mediterr J Hematol Infect Dis. 2018;10:e2018027.",{"doi":3068},"10.4084\u002Fmjhid.2018.027",{"id":23,"text":3070,"url":23,"identifiers":3071},"Hughes TP, Lipton JH, Spector N, Cervantes F, Pasquini R, Clementino NC, et al. Deep molecular responses achieved in patients with CML-CP who are switched to nilotinib after long-term imatinib. Blood. 2014;124:729–36.",{"doi":3072},"10.1182\u002Fblood-2013-12-544015",{"id":23,"text":3074,"url":23,"identifiers":3075},"Hughes TP, Leber B, Cervantes F, Spector N, Pasquini R, Clementino NCD, et al. Sustained deep molecular responses in patients switched to nilotinib due to persistent BCR-ABL1 on imatinib: final ENESTcmr randomized trial results. Leukemia. 2017;31:2529–31.",{"doi":3076},"10.1038\u002Fleu.2017.247",{"id":23,"text":3078,"url":23,"identifiers":3079},"Hughes TP, Mauro MJ, Cortes JE, Minami H, Rea D, DeAngelo DJ, et al. Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure. N Engl J Med. 2019;381:2315–26.",{"doi":3080},"10.1056\u002FNEJMoa1902328",{"id":3082,"createTime":3083,"updateTime":3083,"relativeEntities":3084,"slug":3085,"properties":3086,"entityType":150,"verifyStatus":151,"verifyTime":3098,"verifyNote":152,"syncStatus":22,"languages":3099,"translateLanguages":23,"viewCount":24,"primaryUrl":3100,"fullTextUrl":23,"authors":3101,"publicationType":1646,"publisherRelationship":3485,"citationCount":3518,"citationInfo":3519,"publishDate":3527,"publishYear":3528,"citationAnalyzeStatus":22,"lastCitationAnalyze":23,"indexDatabases":23,"openAccess":23,"references":3529,"isForceReanalyzing":1780},"3efc4566-8ee3-4b83-91d3-8f7f1c0ffc36","2024-08-31T23:42:35.904+00:00",[],"Standardization-and-quality-control-studies-of-real-time-quantitative-reverse-transcriptase-polymerase-chain-reaction-of-fusion-gene-transcripts-for-residual-disease-detection-in-leukemia-A-Europe-Against-Cancer-Program",{"mag":3087,"keywords":3089,"openalex":3090,"abstract":3092,"title":3093,"pm":3095,"doi":3097},{"VOID":3088},"2036862498",{},{"VOID":3091},"W2036862498",{},{"EN":3094},"Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia – A Europe Against Cancer Program",{"VOID":3096},"14562125",{"VOID":1705},"2024-08-31T23:42:35.903+00:00",[154],"https:\u002F\u002Fwww.nature.com\u002Farticles\u002F2403135",[3102,3123,3145,3166,3187,3206,3225,3246,3265,3287,3308,3330,3348,3369,3383,3398,3413,3432,3450,3470],{"id":3103,"sortIndex":500,"researcher":23,"roles":3104,"affiliations":3105,"properties":3116},"79f137a0-dee4-424c-8073-97014bdfd981",[],[3106],{"id":3107,"sortIndex":24,"affiliation":3108,"properties":23},"9adcdfc0-c712-4cf8-894b-e051bc60ee89",{"id":3109,"createTime":3110,"updateTime":3110,"relativeEntities":3111,"slug":3112,"properties":3113,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},"6ed5d6db-1608-4fc3-885c-5d9599b919ed","2024-08-31T23:42:35.997+00:00",[],"Department-of-Hematology-Biology-Institut-Paoli-Calmettes-France",{"title":3114},{"EN":3115},"Department of Hematology Biology, Institut Paoli Calmettes, France",{"openalex":3117,"orcid":3119,"title":3121},{"VOID":3118},"A5000831280",{"VOID":3120},"https:\u002F\u002Forcid.org\u002F0000-0002-2546-7614",{"EN":3122},"Emmanuel Beillard",{"id":3124,"sortIndex":860,"researcher":23,"roles":3125,"affiliations":3126,"properties":3138},"7c889b53-ccdf-41a0-ac5f-546cc1dac8b7",[],[3127],{"id":3128,"sortIndex":24,"affiliation":3129,"properties":23},"29f77b1a-2d7c-4ec9-9060-d67509fc817d",{"id":3130,"createTime":3131,"updateTime":3132,"relativeEntities":3133,"slug":3134,"properties":3135,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},"2505a4f3-5d8b-4ead-86c4-c9c479bb0daa","2024-02-10T04:54:46.396+00:00","2024-09-27T14:58:24.642+00:00",[],"Department-of-Immunology-Erasmus-MC-University-Medical-Center-Rotterdam-Rotterdam-The-Netherlands",{"title":3136},{"VI":3137},"Department of Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands",{"openalex":3139,"orcid":3141,"title":3143},{"VOID":3140},"A5006790084",{"VOID":3142},"https:\u002F\u002Forcid.org\u002F0000-0002-3650-7087",{"EN":3144},"Jacques J. M. van Dongen",{"id":3146,"sortIndex":1137,"researcher":23,"roles":3147,"affiliations":3148,"properties":3159},"e8be5252-af08-46f1-a6bd-725790610ded",[],[3149],{"id":3150,"sortIndex":24,"affiliation":3151,"properties":23},"3a464659-d131-494f-afee-a9b9c6fba9ac",{"id":3152,"createTime":3153,"updateTime":3153,"relativeEntities":3154,"slug":3155,"properties":3156,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},"795632af-8713-4cf2-aedc-4b26afc2b587","2024-08-31T23:42:36.164+00:00",[],"Biogenetics-Laboratory-Children-s-University-Hospital-Giessen-Germany",{"title":3157},{"EN":3158},"Biogenetics Laboratory, Children's University Hospital, Giessen, Germany",{"openalex":3160,"orcid":3162,"title":3164},{"VOID":3161},"A5085018653",{"VOID":3163},"https:\u002F\u002Forcid.org\u002F0000-0003-3368-5248",{"EN":3165},"Susanne Viehmann",{"id":3167,"sortIndex":1216,"researcher":23,"roles":3168,"affiliations":3169,"properties":3180},"d6969d7a-4a7e-42e4-a385-faff1fc315a9",[],[3170],{"id":3171,"sortIndex":24,"affiliation":3172,"properties":23},"210b9df6-562d-47d5-b97c-8bd08ca22893",{"id":3173,"createTime":3174,"updateTime":3174,"relativeEntities":3175,"slug":3176,"properties":3177,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},"796e20be-a4af-440f-afe8-f48358cea958","2024-08-31T23:42:36.914+00:00",[],"Department-of-Genetic-Biochemistry-H%C3%B4pital-Robert-Debr%C3%A9-Paris-France",{"title":3178},{"EN":3179},"Department of Genetic Biochemistry, Hôpital Robert Debré, Paris, France",{"openalex":3181,"orcid":3183,"title":3185},{"VOID":3182},"A5009969425",{"VOID":3184},"https:\u002F\u002Forcid.org\u002F0000-0003-2840-1511",{"EN":3186},"Hélène Cavé",{"id":3188,"sortIndex":924,"researcher":23,"roles":3189,"affiliations":3190,"properties":3201},"938b1df4-52d4-4ab9-85a1-44c5c16d8290",[],[3191],{"id":3192,"sortIndex":24,"affiliation":3193,"properties":23},"106e1d75-d517-4f72-9b1c-3b3230cf2916",{"id":3194,"createTime":3195,"updateTime":3195,"relativeEntities":3196,"slug":3197,"properties":3198,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},"51f81385-7ab9-4b3b-8dfc-eb782ffe0000","2024-08-31T23:42:36.233+00:00",[],"Department-of-Haematology-Division-of-Medical-and-Molecular-Genetics-Guy-s-King-s-St-Thomas-School-of-Medicine-University-College-London-Hospitals-London-UK",{"title":3199},{"EN":3200},"Department of Haematology, Division of Medical and Molecular Genetics, Guy's, King's & St Thomas’ School of Medicine, University College London Hospitals, London, UK",{"openalex":3202,"title":3204},{"VOID":3203},"A5089075443",{"EN":3205},"David Grimwade",{"id":3207,"sortIndex":729,"researcher":23,"roles":3208,"affiliations":3209,"properties":3220},"dbce1cce-199c-4c79-8002-a85c2b93d1d0",[],[3210],{"id":3211,"sortIndex":24,"affiliation":3212,"properties":23},"e63f00ca-ed4f-4fb1-8c7c-a76e88d814f4",{"id":3213,"createTime":3214,"updateTime":3214,"relativeEntities":3215,"slug":3216,"properties":3217,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},"cedc53ef-bed5-48cf-b0d9-a39dd91a36ac","2024-08-31T23:42:36.792+00:00",[],"Central-Laboratory-of-Hematology-and-INSERM-U462-H%C3%B4pital-Saint-Louis-Paris-France",{"title":3218},{"EN":3219},"Central Laboratory of Hematology and INSERM U462, Hôpital Saint Louis, Paris, France",{"openalex":3221,"title":3223},{"VOID":3222},"A5103507893",{"EN":3224},"J M Cayuela",{"id":3226,"sortIndex":1512,"researcher":23,"roles":3227,"affiliations":3228,"properties":3239},"7ffd356c-6eeb-4b11-9ea7-8a6e22108916",[],[3229],{"id":3230,"sortIndex":24,"affiliation":3231,"properties":23},"e9ceb4c4-baf9-4b4a-8f56-9031b0e5e267",{"id":3232,"createTime":3233,"updateTime":3233,"relativeEntities":3234,"slug":3235,"properties":3236,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},"ae02683c-74c6-4d51-ad5e-03dad16ee800","2024-08-31T23:42:36.309+00:00",[],"Department-of-Immuno-haematology-Aarhus-University-Hospital-Aarhus-Denmark",{"title":3237},{"EN":3238},"Department of Immuno-haematology, Aarhus University Hospital, Aarhus, Denmark",{"openalex":3240,"orcid":3242,"title":3244},{"VOID":3241},"A5075557171",{"VOID":3243},"https:\u002F\u002Forcid.org\u002F0000-0002-0749-0810",{"EN":3245},"Niels Pallisgaard",{"id":3247,"sortIndex":1094,"researcher":23,"roles":3248,"affiliations":3249,"properties":3260},"fc1c5b4c-862b-4345-b2ae-4616b1dedc05",[],[3250],{"id":3251,"sortIndex":24,"affiliation":3252,"properties":23},"c384af3c-3840-41f6-8535-7a1c2591f8e7",{"id":3253,"createTime":3254,"updateTime":3254,"relativeEntities":3255,"slug":3256,"properties":3257,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},"52cae24f-7f14-4001-baf7-f3b678c80cd4","2024-08-31T23:42:36.401+00:00",[],"Department-of-Hematology-Karolinska-Stockholm-Sweden",{"title":3258},{"EN":3259},"Department of Hematology, Karolinska, Stockholm, Sweden",{"openalex":3261,"title":3263},{"VOID":3262},"A5014414423",{"EN":3264},"Maria Malec",{"id":3266,"sortIndex":518,"researcher":23,"roles":3267,"affiliations":3268,"properties":3280},"d9b054ce-a316-4828-ab16-f033eb0f8bd1",[],[3269],{"id":3270,"sortIndex":24,"affiliation":3271,"properties":23},"f8328e1a-62fd-430c-8e71-acdccac7dec0",{"id":3272,"createTime":3273,"updateTime":3274,"relativeEntities":3275,"slug":3276,"properties":3277,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},"a5c3cf27-a279-43dc-a2cc-c89ba12f2929","2024-01-25T11:40:50.146+00:00","2024-08-31T23:42:36.566+00:00",[],"Department-of-Haematology-University-Hospital-Leuven-Belgium",{"title":3278},{"VI":3279},"Department of Haematology, University Hospital, Leuven, Belgium",{"openalex":3281,"orcid":3283,"title":3285},{"VOID":3282},"A5040466984",{"VOID":3284},"https:\u002F\u002Forcid.org\u002F0000-0002-9902-3696",{"EN":3286},"Joeri L. Aerts",{"id":3288,"sortIndex":205,"researcher":23,"roles":3289,"affiliations":3290,"properties":3301},"c911893c-6712-42c8-99f9-6a87678cdfab",[],[3291],{"id":3292,"sortIndex":24,"affiliation":3293,"properties":23},"f8fbf385-3ff4-4383-9c57-e8cd003298cc",{"id":3294,"createTime":3295,"updateTime":3295,"relativeEntities":3296,"slug":3297,"properties":3298,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},"a25388d7-7e59-44c0-b784-2209cf37d07e","2024-08-31T23:42:36.635+00:00",[],"Pediatric-Clinic-University-of-Milan-Bicocca-San-Gerardo-Hospital-Monza-Italy",{"title":3299},{"EN":3300},"Pediatric Clinic, University of Milan Bicocca, San Gerardo Hospital, Monza, Italy",{"openalex":3302,"orcid":3304,"title":3306},{"VOID":3303},"A5076365826",{"VOID":3305},"https:\u002F\u002Forcid.org\u002F0000-0003-2955-4528",{"EN":3307},"Giovanni Cazzaniga",{"id":3309,"sortIndex":1012,"researcher":23,"roles":3310,"affiliations":3311,"properties":3323},"78502557-31d6-4511-84ba-2f1419873f34",[],[3312],{"id":3313,"sortIndex":24,"affiliation":3314,"properties":23},"6b8cb945-a9d7-44ec-8975-eedecb9f901a",{"id":3315,"createTime":3316,"updateTime":3317,"relativeEntities":3318,"slug":3319,"properties":3320,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},"3c643597-0afb-4dc3-ab5f-1ce0cb5656ea","2023-12-08T18:44:49.430+00:00","2024-08-31T23:42:36.374+00:00",[],"Department-of-Hematology-Hospital-Cl%C3%ADnico-Universitario-Salamanca-Spain",{"title":3321},{"VI":3322},"Department of Hematology, Hospital Clínico Universitario, Salamanca, Spain",{"openalex":3324,"orcid":3326,"title":3328},{"VOID":3325},"A5077463621",{"VOID":3327},"https:\u002F\u002Forcid.org\u002F0000-0001-6637-1072",{"EN":3329},"Douglas F. Easton",{"id":3331,"sortIndex":397,"researcher":23,"roles":3332,"affiliations":3333,"properties":3344},"8a603794-dda6-4923-a760-5d67a788e781",[],[3334],{"id":3335,"sortIndex":24,"affiliation":3336,"properties":23},"7a1d8fa0-1709-4ccd-94f4-e2313efda1a8",{"id":3337,"createTime":3338,"updateTime":3338,"relativeEntities":3339,"slug":3340,"properties":3341,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},"1825aab6-1799-4497-acfd-be92f4f8a178","2024-08-31T23:42:36.723+00:00",[],"Clinical-and-Biological-Science-University-of-Turin-Ospedale-San-Luigi-Gonzaga-Orbassano-Torino-Italy",{"title":3342},{"EN":3343},"Clinical and Biological Science, University of Turin, Ospedale San Luigi Gonzaga, Orbassano-Torino, Italy",{"openalex":3345,"orcid":3346,"title":3347},{"VOID":2329},{"VOID":2331},{"EN":2333},{"id":3349,"sortIndex":689,"researcher":23,"roles":3350,"affiliations":3351,"properties":3362},"7bb466d6-0dd3-4cef-9259-364b791e062e",[],[3352],{"id":3353,"sortIndex":24,"affiliation":3354,"properties":23},"657a6aa9-dc9c-4905-8406-c39bf027d084",{"id":3355,"createTime":3356,"updateTime":3356,"relativeEntities":3357,"slug":3358,"properties":3359,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},"b4d4690b-fdbd-49fc-aebe-f6ba6a4247b9","2024-08-31T23:42:36.836+00:00",[],"Department-of-Medical-Information-University-H%C3%B4pital-Sainte-Marguerite-Biostatistics-Laboratory-Timone-Universit%C3%A9-de-la-M%C3%A9diterran%C3%A9e-Marseille-France",{"title":3360},{"EN":3361},"Department of Medical Information, University Hôpital Sainte Marguerite\u002FBiostatistics Laboratory Timone, Université de la Méditerranée, Marseille, France",{"openalex":3363,"orcid":3365,"title":3367},{"VOID":3364},"A5079002916",{"VOID":3366},"https:\u002F\u002Forcid.org\u002F0000-0003-2619-4432",{"EN":3368},"Vincent Pradel",{"id":3370,"sortIndex":1593,"researcher":23,"roles":3371,"affiliations":3372,"properties":3379},"58a3cb84-2391-4437-bb26-aaf9ee18dd10",[],[3373],{"id":3374,"sortIndex":24,"affiliation":3375,"properties":23},"2e034cce-01ee-4cb6-a465-fb2132e2a4a2",{"id":3130,"createTime":3131,"updateTime":3132,"relativeEntities":3376,"slug":3134,"properties":3377,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},[],{"title":3378},{"VI":3137},{"openalex":3380,"orcid":3381,"title":3382},{"VOID":1193},{"VOID":1195},{"EN":1197},{"id":3384,"sortIndex":947,"researcher":23,"roles":3385,"affiliations":3386,"properties":3393},"b898902b-6a18-43d7-b6b6-1476d339df99",[],[3387],{"id":3388,"sortIndex":24,"affiliation":3389,"properties":23},"323ace07-147a-4283-ae1e-2a58cfcb7b9e",{"id":3355,"createTime":3356,"updateTime":3356,"relativeEntities":3390,"slug":3358,"properties":3391,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},[],{"title":3392},{"EN":3361},{"openalex":3394,"title":3396},{"VOID":3395},"A5019570603",{"EN":3397},"Xavier Thirion",{"id":3399,"sortIndex":24,"researcher":23,"roles":3400,"affiliations":3401,"properties":3408},"9131433a-bda0-4ac0-8b0b-3fc44c09c930",[],[3402],{"id":3403,"sortIndex":24,"affiliation":3404,"properties":23},"73f46a26-6942-4cd8-8117-ffe775d9373b",{"id":3109,"createTime":3110,"updateTime":3110,"relativeEntities":3405,"slug":3112,"properties":3406,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},[],{"title":3407},{"EN":3115},{"openalex":3409,"title":3411},{"VOID":3410},"A5043286121",{"EN":3412},"Jean Gabert",{"id":3414,"sortIndex":69,"researcher":23,"roles":3415,"affiliations":3416,"properties":3428},"f5022dc4-97d6-423d-9186-00e4610f5ec6",[],[3417],{"id":3418,"sortIndex":24,"affiliation":3419,"properties":23},"fa002b54-f4a7-413c-bd5a-2ae7c81e13d7",{"id":3420,"createTime":3421,"updateTime":3422,"relativeEntities":3423,"slug":3424,"properties":3425,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},"1a6bba63-1203-464b-9455-bf0011bb853e","2024-01-13T23:06:30.756+00:00","2024-10-09T19:38:38.875+00:00",[],"Department-of-Medical-Sciences-Uppsala-University-Hospital-Uppsala-Sweden",{"title":3426},{"VI":3427},"Department of Medical Sciences, Uppsala University Hospital, Uppsala, Sweden",{"openalex":3429,"orcid":3430,"title":3431},{"VOID":390},{"VOID":392},{"EN":394},{"id":3433,"sortIndex":375,"researcher":23,"roles":3434,"affiliations":3435,"properties":3446},"ede1f236-506a-4426-9f98-6bf25418a758",[],[3436],{"id":3437,"sortIndex":24,"affiliation":3438,"properties":23},"ca5140e0-6c8f-44cd-b292-3df5e6eb808c",{"id":3439,"createTime":3440,"updateTime":3440,"relativeEntities":3441,"slug":3442,"properties":3443,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},"7b12ca4b-d420-4a05-8d7a-4ffc02454b6d","2024-08-31T23:42:36.985+00:00",[],"Department-of-CEINGE-Department-of-Biochemistry-Medical-Biotechnology-University-Hospital-Federico-II-Naples-Italy",{"title":3444},{"EN":3445},"Department of CEINGE & Department of Biochemistry & Medical Biotechnology, University Hospital ‘Federico II’, Naples, Italy",{"openalex":3447,"orcid":3448,"title":3449},{"VOID":2050},{"VOID":2052},{"EN":2054},{"id":3451,"sortIndex":1453,"researcher":23,"roles":3452,"affiliations":3453,"properties":3465},"cc30160d-2340-4426-8e61-31393f65d4ef",[],[3454],{"id":3455,"sortIndex":24,"affiliation":3456,"properties":23},"77e227d1-98ff-430d-b8a3-97fb489d84d7",{"id":3457,"createTime":3458,"updateTime":3459,"relativeEntities":3460,"slug":3461,"properties":3462,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},"5cb244a1-32db-4a75-9448-fd48c586a352","2024-01-05T13:26:52.291+00:00","2024-09-18T23:35:45.304+00:00",[],"Applied-Biosystems-Foster-City-USA",{"title":3463},{"VI":3464},"Applied Biosystems, Foster City, USA",{"openalex":3466,"title":3468},{"VOID":3467},"A5033687225",{"EN":3469},"W Bi",{"id":3471,"sortIndex":460,"researcher":23,"roles":3472,"affiliations":3473,"properties":3480},"e5122838-4860-4f53-ad38-bc83691925eb",[],[3474],{"id":3475,"sortIndex":24,"affiliation":3476,"properties":23},"22bbb17a-49f8-4f6c-81f8-f9b1d13f3404",{"id":3337,"createTime":3338,"updateTime":3338,"relativeEntities":3477,"slug":3340,"properties":3478,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},[],{"title":3479},{"EN":3343},{"openalex":3481,"title":3483},{"VOID":3482},"A5015279477",{"EN":3484},"Daniela De Micheli",{"url":23,"publisher":3486,"properties":3511},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":3487,"slug":10,"properties":3488,"entityType":21,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24,"subjectFields":3494,"manageAffiliations":3495,"indexDatabases":3496,"url":125,"thumbnailPath":23,"statistic":23,"gsStatistic":23,"type":23,"analyzePriority":23},[],{"country":3489,"issn":3490,"introduce":3491,"eissn":3492,"title":3493},{"VOID":13},{"VOID":15},{"EN":17},{"VOID":19},{"EN":10},[],[],[3497,3504],{"id":84,"indexDatabase":3498,"url":99,"indexYears":23,"academicFieldIds":3503,"indexDatabaseRanking":23},{"id":86,"createTime":87,"updateTime":88,"relativeEntities":3499,"label":3500,"description":3501,"key":95,"publicationTags":3502,"standard":23},[],{"EN":91,"VI":91},{"VI":93,"EN":94},[97,98],[101,102],{"id":104,"indexDatabase":3505,"url":117,"indexYears":118,"academicFieldIds":3510,"indexDatabaseRanking":124},{"id":106,"createTime":107,"updateTime":108,"relativeEntities":3506,"label":3507,"description":3508,"key":114,"publicationTags":3509,"standard":23},[],{"EN":111,"VI":111},{"EN":111,"VI":113},[116],[120,121,122,123],{"volume":3512,"pages":3514,"issue":3516},{"VOID":3513},"17",{"VOID":3515},"2318-2357",{"VOID":3517},"12",1507,{"total":3518,"publishYear":23,"statisticByYear":3520},{"2012":3521,"2013":3522,"2014":3523,"2015":3524,"2016":775,"2017":3525,"2018":1627,"2019":970,"2020":3526,"2021":1627,"2022":563,"2023":440,"2024":709},105,84,75,79,72,74,"2003-12-01",2003,[3530,3534,3538,3542,3546,3550,3553,3557,3560,3564,3568,3572,3576,3580,3584,3588,3592,3596,3600,3604,3608,3612,3616,3619,3623,3627,3631,3635,3639,3643,3647,3651,3655,3659,3663,3666,3669,3673,3677,3681,3685,3689,3693,3697,3701,3705,3709,3713,3716,3720,3723,3727,3731,3735,3739,3743,3747,3751,3755,3759,3763,3766,3770,3774,3778,3782,3786,3790,3794,3797,3800,3804,3807,3811,3815,3819,3823,3826,3830,3834,3837,3841,3844,3848,3852,3856,3860,3864,3868,3872,3876,3880,3884,3888,3892,3895,3898,3902,3906,3910,3914,3918,3921,3924,3928,3931,3935,3939,3943,3946,3950,3954,3957,3960,3964,3967,3971,3974,3978,3981,3985,3988,3992,3996,4000,4004,4008,4012,4016,4020,4024,4027,4031,4035,4039,4043,4047,4051,4055,4059,4063,4067,4071,4074,4078,4082,4086,4089,4093,4097,4101,4105,4109,4113,4117,4121,4125,4129,4133,4137,4141,4145,4149,4153,4156,4160,4164,4168,4172,4176,4180,4184,4188,4192,4196,4200,4204,4208,4212,4216,4220,4223,4227,4231,4235,4239,4243,4247,4251,4255,4259,4263],{"id":23,"text":3531,"url":23,"identifiers":3532},"Lowenberg B, Downing JR, Burnett A . Acute myeloid leukemia. N Engl J Med 1999; 341: 1051–1062.",{"doi":3533},"10.1056\u002FNEJM199909303411407",{"id":23,"text":3535,"url":23,"identifiers":3536},"Verma A, Stock W . Management of adult acute lymphoblastic leukemia: moving toward a risk-adapted approach. Curr Opin Oncol 2001; 13: 14–20.",{"doi":3537},"10.1097\u002F00001622-200101000-00004",{"id":23,"text":3539,"url":23,"identifiers":3540},"Appelbaum FR . Perspectives on the future of chronic myeloid leukemia treatment. Semin Hematol 2001; 38: 35–42.",{"doi":3541},"10.1016\u002FS0037-1963(01)90116-7",{"id":23,"text":3543,"url":23,"identifiers":3544},"Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998; 92: 2322–2333.",{"doi":3545},"10.1182\u002Fblood.V92.7.2322",{"id":23,"text":3547,"url":23,"identifiers":3548},"Groupe FdCH. Cytogenetic abnormalities in adult acute lymphoblastic leukemia: correlations with hematologic finding and outcome. A collaborative study of the Groupe Français de Cytogénétique Hématologique. Blood 1996; 87: 3135–3142.",{"doi":3549},"10.1182\u002Fblood.V87.8.3135.bloodjournal8783135",{"id":23,"text":3551,"url":23,"identifiers":3552},"Nakao M, Yokota S, Iwai T, Kaneko H, Horiike S, Kashima K et al. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia 1996; 10: 1911–1918.",{},{"id":23,"text":3554,"url":23,"identifiers":3555},"Kottaridis PD, Gale RE, Frew ME, Harrison G, Langabeer SE, Belton AA et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 2001; 98: 1752–1759.",{"doi":3556},"10.1182\u002Fblood.V98.6.1752",{"id":23,"text":3558,"url":23,"identifiers":3559},"Abshire TC, Buchanan GR, Jackson JF, Shuster JJ, Brock B, Head D et al. Morphologic, immunologic and cytogenetic studies in children with acute lymphoblastic leukemia at diagnosis and relapse: a Pediatric Oncology Group study. Leukemia 1992; 6: 357–362.",{},{"id":23,"text":3561,"url":23,"identifiers":3562},"Hoelzer D, Thiel E, Loffler H, Buchner T, Ganser A, Heil G et al. Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults. Blood 1988; 71: 123–131.",{"doi":3563},"10.1182\u002Fblood.V71.1.123.123",{"id":23,"text":3565,"url":23,"identifiers":3566},"Liu Yin JA, Wheatley K, Rees JK, Burnett AK . Comparison of ‘sequential’ versus ‘standard’ chemotherapy as re-induction treatment, with or without cyclosporine, in refractory\u002Frelapsed acute myeloid leukaemia (AML): results of the UK Medical Research Council AML-R trial. Br J Haematol 2001; 113: 713–726.",{"doi":3567},"10.1046\u002Fj.1365-2141.2001.02785.x",{"id":23,"text":3569,"url":23,"identifiers":3570},"Estey EH . New drugs for therapy of AML. Leukemia 2002; 16: 306–309.",{"doi":3571},"10.1038\u002Fsj.leu.2402375",{"id":23,"text":3573,"url":23,"identifiers":3574},"Wheatley K, Burnett AK, Goldstone AH, Gray RG, Hann IM, Harrison CJ et al. A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial. United Kingdom Medical Research Council's Adult and Childhood Leukaemia Working Parties. Br J Haematol 1999; 107: 69–79.",{"doi":3575},"10.1046\u002Fj.1365-2141.1999.01684.x",{"id":23,"text":3577,"url":23,"identifiers":3578},"Kantarjian H, Smith T, OBrien S, Beran M, Pierce S, Talpaz M . Prolonged survival in chronic myelogenous leukemia following cytogenetic response to a interferon therapy. Ann Intern Med 1995; 122: 254–261.",{"doi":3579},"10.7326\u002F0003-4819-122-4-199502150-00003",{"id":23,"text":3581,"url":23,"identifiers":3582},"Italian Cooperative Study Group on Chronic Myeloid Leukemia and Italian Group for Bone Marrow Transplantation. Monitoring treatment and survival in chronic myeloid leukemia. J Clin Oncol 1999; 17: 1858–1868.",{"doi":3583},"10.1200\u002FJCO.1999.17.6.1858",{"id":23,"text":3585,"url":23,"identifiers":3586},"Campana D, Pui C-H . Detection of minimal residual disease in acute leukemia: methodologic advances and clinical significance. Blood 1995; 85: 1416–1434.",{"doi":3587},"10.1182\u002Fblood.V85.6.1416.bloodjournal8561416",{"id":23,"text":3589,"url":23,"identifiers":3590},"Szczepanski T, Orfao A, van der Velden VH, San Miguel JF, van Dongen JJ . Minimal residual disease in leukaemia patients. Lancet Oncol 2001; 2: 409–417.",{"doi":3591},"10.1016\u002FS1470-2045(00)00418-6",{"id":23,"text":3593,"url":23,"identifiers":3594},"Cave H, van der Werff ten Bosch J, Suciu S, Guidal C, Waterkeyn C, Otten J et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer – Childhood Leukemia Cooperative Group [see comments]. N Engl J Med 1998; 339: 591–598.",{"doi":3595},"10.1056\u002FNEJM199808273390904",{"id":23,"text":3597,"url":23,"identifiers":3598},"van Dongen JJ, Seriu T, Panzer-Grumayer ER, Biondi A, Pongers-Willemse MJ, Corral L et al. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet 1998; 352: 1731–1738.",{"doi":3599},"10.1016\u002FS0140-6736(98)04058-6",{"id":23,"text":3601,"url":23,"identifiers":3602},"Coustan-Smith E, Behm FG, Sanchez J, Boyett JM, Hancock ML, Raimondi SC et al. Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia. Lancet 1998; 351: 550–554.",{"doi":3603},"10.1016\u002FS0140-6736(97)10295-1",{"id":23,"text":3605,"url":23,"identifiers":3606},"Radich JP, Gehly G, Gooley T, Bryant E, Clift RA, Collins S et al. PCR detection of the BCR-ABL fusion transcript after allogeneic bone marrow transplantation for chronic myeloid leukemia: results and implications in 346 patients. Blood 1995; 85: 2632–2638.",{"doi":3607},"10.1182\u002Fblood.V85.9.2632.bloodjournal8592632",{"id":23,"text":3609,"url":23,"identifiers":3610},"Diverio D, Rossi V, Avvisati G, De Santis S, Pistilli A, Pane F et al. Early detection of relapse by prospective reverse transcriptase-polymerase chain reaction analysis of the PML\u002FRARalpha fusion gene in patients with acute promyelocytic leukemia enrolled in the GIMEMA-AIEOP multicenter ‘AIDA’ trial. GIMEMA-AIEOP Multicenter ‘AIDA’ Trial. Blood 1998; 92: 784–789.",{"doi":3611},"10.1182\u002Fblood.V92.3.784",{"id":23,"text":3613,"url":23,"identifiers":3614},"Lo Coco F, Diverio D, Avvisati G, Petti MC, Meloni G, Pogliani EM et al. Therapy of molecular relapse in acute promyelocytic leukemia. Blood 1999; 94: 2225–2229.",{"doi":3615},"10.1182\u002Fblood.V94.7.2225.419k03_2225_2229",{"id":23,"text":3617,"url":23,"identifiers":3618},"San Miguel J, Van Dongen J, Bartram C, Parreira A, Wormann B, Biondi A et al. In: I. press (ed). Investigation of Minimal Residual Disease (MRD) in Acute Leukemia (AL): International Standardization and Evaluation Cancer research supported under BIOMED1. Amsterdam: Baig SS, 1998, pp 300–306.",{},{"id":23,"text":3620,"url":23,"identifiers":3621},"van Dongen JJ, Macintyre EA, Gabert JA, Delabesse E, Rossi V, Saglio G et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia. Leukemia 1999; 13: 1901–1928.",{"doi":3622},"10.1038\u002Fsj.leu.2401592",{"id":23,"text":3624,"url":23,"identifiers":3625},"Jurlander J, Caligiuri MA, Ruutu T, Baer MR, Strout MP, Oberkircher AR et al. Persistence of the AML1\u002FETO fusion transcript in patients treated with allogeneic bone marrow transplantation for t(8;21) leukemia. Blood 1996; 88: 2183–2191.",{"doi":3626},"10.1182\u002Fblood.V88.6.2183.bloodjournal8862183",{"id":23,"text":3628,"url":23,"identifiers":3629},"Miyamoto T, Nagafuji K, Akashi K, Harada M, Kyo T, Akashi T et al. Persistence of multipotent progenitors expressing AML1\u002FETO transcripts in long-term remission patients with t(8;21) acute myelogenous leukemia. Blood 1996; 87: 4789–4796.",{"doi":3630},"10.1182\u002Fblood.V87.11.4789.bloodjournal87114789",{"id":23,"text":3632,"url":23,"identifiers":3633},"Tobal K, Saunders MJ, Grey MR, Yin JA . Persistence of RAR alpha-PML fusion mRNA detected by reverse transcriptase polymerase chain reaction in patients in long-term remission of acute promyelocytic leukaemia. Br J Haematol 1995; 90: 615–618.",{"doi":3634},"10.1111\u002Fj.1365-2141.1995.tb05592.x",{"id":23,"text":3636,"url":23,"identifiers":3637},"Biernaux C, Loos M, Sels A, Huez G, Stryckmans P . Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals. Blood 1995; 86: 3118–3122.",{"doi":3638},"10.1182\u002Fblood.V86.8.3118.3118",{"id":23,"text":3640,"url":23,"identifiers":3641},"Bose S, Deininger M, Gora-Tybor J, Goldman JM, Melo JV . The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease. Blood 1998; 92: 3362–3367.",{"doi":3642},"10.1182\u002Fblood.V92.9.3362",{"id":23,"text":3644,"url":23,"identifiers":3645},"Zimmermann K, Mannhalter JW . Technical aspects of quantitative competitive PCR. Biotechniques 1996; 21: 268–272, 274–269.",{"doi":3646},"10.2144\u002F96212rv01",{"id":23,"text":3648,"url":23,"identifiers":3649},"Lion T, Henn T, Gaiger A, Kalhs P, Gadner H . Early detection of relapse after bone marrow transplantation in patients with chronic myelogenous leukaemia. Lancet 1993; 341: 275–276.",{"doi":3650},"10.1016\u002F0140-6736(93)92619-5",{"id":23,"text":3652,"url":23,"identifiers":3653},"Hochhaus A, Reiter A, Saussele S, Reichert A, Emig M, Kaeda J et al. Molecular heterogeneity in complete cytogenetic responders after interferon-alpha therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission. German CML Study Group and the UK MRC CML Study Group. Blood 2000; 95: 62–66.",{"doi":3654},"10.1182\u002Fblood.V95.1.62",{"id":23,"text":3656,"url":23,"identifiers":3657},"Laczika K, Novak M, Hilgarth B, Mitterbauer M, Mitterbauer G, Scheidel-Petrovic A et al. Competitive CBFbeta\u002FMYH11 reverse-transcriptase polymerase chain reaction for quantitative assessment of minimal residual disease during postremission therapy in acute myeloid leukemia with inversion(16): a pilot study. J Clin Oncol 1998; 16: 1519–1525.",{"doi":3658},"10.1200\u002FJCO.1998.16.4.1519",{"id":23,"text":3660,"url":23,"identifiers":3661},"Tobal K, Liu Yin JA . Molecular monitoring of minimal residual disease in acute myeloblastic leukemia with t(8;21) by RT-PCR. Leuk Lymphoma 1998; 31: 115–120.",{"doi":3662},"10.3109\u002F10428199809057591",{"id":23,"text":3664,"url":23,"identifiers":3665},"Gabert J . Detection of recurrent translocations using real time PCR; assessment of the technique for diagnosis and detection of minimal residual disease. Haematologica 1999; 84: 107–109.",{},{"id":23,"text":3667,"url":23,"identifiers":3668},"van der Velden V, Hochhaus A, Cazzanigia G, Szczepanski T, Gabert J, van Dongen J . Detection of minimal residual disease in hematopoietic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects. Leukemia 2003; 17: 1013–1034.",{"doi":1775},{"id":23,"text":3670,"url":23,"identifiers":3671},"Mensink E, van de Locht A, Schattenberg A, Linders E, Schaap N, Geurts van Kessel A et al. Quantitation of minimal residual disease in Philadelphia chromosome positive chronic myeloid leukaemia patients using real-time quantitative RT-PCR. Br J Haematol 1998; 102: 768–774.",{"doi":3672},"10.1046\u002Fj.1365-2141.1998.00823.x",{"id":23,"text":3674,"url":23,"identifiers":3675},"Preudhomme C, Revillion F, Merlat A, Hornez L, Roumier C, Duflos-Grardel N et al. Detection of BCR-ABL transcripts in chronic myeloid leukemia (CML) using a ‘real time’ quantitative RT-PCR assay. Leukemia 1999; 13: 957–964.",{"doi":3676},"10.1038\u002Fsj.leu.2401426",{"id":23,"text":3678,"url":23,"identifiers":3679},"Radich JP, Gooley T, Bryant E, Chauncey T, Clift R, Beppu L et al. The significance of bcr-abl molecular detection in chronic myeloid leukemia patients ‘late,’ 18 months or more after transplantation. Blood 2001; 98: 1701–1707.",{"doi":3680},"10.1182\u002Fblood.V98.6.1701",{"id":23,"text":3682,"url":23,"identifiers":3683},"Yokota H, Tsuno NH, Tanaka Y, Fukui T, Kitamura K, Hirai H et al. Quantification of minimal residual disease in patients with e1a2 BCR-ABL-positive acute lymphoblastic leukemia using a real-time RT-PCR assay. Leukemia 2002; 16: 1167–1175.",{"doi":3684},"10.1038\u002Fsj.leu.2402483",{"id":23,"text":3686,"url":23,"identifiers":3687},"Cassinat B, Zassadowski F, Balitrand N, Barbey C, Rain JD, Fenaux P et al. Quantitation of minimal residual disease in acute promyelocytic leukemia patients with t(15;17) translocation using real-time RT-PCR. Leukemia 2000; 14: 324–328.",{"doi":3688},"10.1038\u002Fsj.leu.2401652",{"id":23,"text":3690,"url":23,"identifiers":3691},"Marcucci G, Livak KJ, Bi W, Strout MP, Bloomfield CD, Caligiuri MA . Detection of minimal residual disease in patients with AML1\u002FETO-associated acute myeloid leukemia using a novel quantitative reverse transcription polymerase chain reaction assay. Leukemia 1998; 12: 1482–1489.",{"doi":3692},"10.1038\u002Fsj.leu.2401128",{"id":23,"text":3694,"url":23,"identifiers":3695},"Krauter J, Wattjes MP, Nagel S, Heidenreich O, Krug U, Kafert S et al. Real-time RT-PCR for the detection and quantification of AML1\u002FMTG8 fusion transcripts in t(8;21)-positive AML patients. Br J Haematol 1999; 107: 80–85.",{"doi":3696},"10.1046\u002Fj.1365-2141.1999.01674.x",{"id":23,"text":3698,"url":23,"identifiers":3699},"Sugimoto T, Das H, Imoto S, Murayama T, Gomyo H, Chakraborty S et al. Quantitation of minimal residual disease in t(8;21)-positive acute myelogenous leukemia patients using real-time quantitative RT-PCR. Am J Hematol 2000; 64: 101–106.",{"doi":3700},"10.1002\u002F(SICI)1096-8652(200006)64:2\u003C101::AID-AJH5>3.0.CO;2-X",{"id":23,"text":3702,"url":23,"identifiers":3703},"Marcucci G, Caligiuri MA, Dohner H, Archer KJ, Schlenk RF, Dohner K et al. Quantification of CBFbeta\u002FMYH11 fusion transcript by real time RT-PCR in patients with INV(16) acute myeloid leukemia. Leukemia 2001; 15: 1072–1080.",{"doi":3704},"10.1038\u002Fsj.leu.2402159",{"id":23,"text":3706,"url":23,"identifiers":3707},"Buonamici S, Ottaviani E, Testoni N, Montefusco V, Visani G, Bonifazi F et al. Real-time quantitation of minimal residual disease in inv(16)-positive acute myeloid leukemia may indicate risk for clinical relapse and may identify patients in a curable state. Blood 2002; 99: 443–449.",{"doi":3708},"10.1182\u002Fblood.V99.2.443",{"id":23,"text":3710,"url":23,"identifiers":3711},"Drunat S, Olivi M, Brunie G, Grandchamp B, Vilmer E, Bieche I et al. Quantification of TEL-AML1 transcript for minimal residual disease assessment in childhood acute lymphoblastic leukaemia. Br J Haematol 2001; 114: 281–289.",{"doi":3712},"10.1046\u002Fj.1365-2141.2001.02922.x",{"id":23,"text":3714,"url":23,"identifiers":3715},"Seeger K, Kreuzer KA, Lass U, Taube T, Buchwald D, Eckert C et al. Molecular quantification of response to therapy and remission status in TEL-AML1-positive childhood ALL by real-time reverse transcription polymerase chain reaction. Cancer Res 2001; 61: 2517–2522.",{},{"id":23,"text":3717,"url":23,"identifiers":3718},"Pallisgaard N, Clausen N, Schroder H, Hokland P . Rapid and sensitive minimal residual disease detection in acute leukemia by quantitative real-time RT-PCR exemplified by t(12;21) TEL-AML1 fusion transcript. Genes Chromosomes Cancer 1999; 26: 355–365.",{"doi":3719},"10.1002\u002F(SICI)1098-2264(199912)26:4\u003C355::AID-GCC10>3.0.CO;2-3",{"id":23,"text":3721,"url":23,"identifiers":3722},"Beillard E, Pallisgaard N, Bi W, van der Velden VHJ, Dee R, van der Schoot CE et al. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using ‘real-time’ quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) – A Europe Against Cancer Program. Leukemia 2003, (in press).",{"doi":1757},{"id":23,"text":3724,"url":23,"identifiers":3725},"Livak K, Flood S, Marmaro J, Giusti W, Deetz K . Oligonucleotides with fluorescent dyes at apposite ends provides a quenched probe system useful for detecting PCR product and nucleic acid hybridization. PCR Meth Appl 1995; 4: 357–362.",{"doi":3726},"10.1101\u002Fgr.4.6.357",{"id":23,"text":3728,"url":23,"identifiers":3729},"van der Velden VHJ, Szczepanski T, van Dongen JJM . Polymerase chain reaction, real-time quantitative. In: Brenner S, Miller JH (eds). Encyclopedia of Genetics. London: Academic Press, 2001, pp 1503–1506.",{"doi":3730},"10.1006\u002Frwgn.2001.1726",{"id":23,"text":3732,"url":23,"identifiers":3733},"Saussele S, Weisser A, Muller MC, Emig M, La Rosee P, Paschka P et al. Frequent polymorphism in BCR exon b2 identified in BCR-ABL positive and negative individuals using fluorescent hybridization probes. Leukemia 2000; 14: 2006–2010.",{"doi":3734},"10.1038\u002Fsj.leu.2401929",{"id":23,"text":3736,"url":23,"identifiers":3737},"Mellentin JD, Nourse J, Hunger SP, Smith SD, Cleary ML . Molecular analysis of the t(1;19) breakpoint cluster region in pre-B cell acute lymphoblastic leukemias. Genes Chromosomes Cancer 1990; 2: 239–247.",{"doi":3738},"10.1002\u002Fgcc.2870020313",{"id":23,"text":3740,"url":23,"identifiers":3741},"Nourse J, Mellentin JD, Galili N, Wilkinson J, Stanbridge E, Smith SD et al. Chromosomal translocation t(1;19) results in synthesis of a homeobox fusion mRNA that codes for a potential chimeric transcription factor. Cell 1990; 60: 535–545.",{"doi":3742},"10.1016\u002F0092-8674(90)90657-Z",{"id":23,"text":3744,"url":23,"identifiers":3745},"Kamps MP, Murre C, Sun XH, Baltimore D . A new homeobox gene contributes the DNA binding domain of the t(1;19) translocation protein in pre-B ALL. Cell 1990; 60: 547–555.",{"doi":3746},"10.1016\u002F0092-8674(90)90658-2",{"id":23,"text":3748,"url":23,"identifiers":3749},"Crist WM, Carroll AJ, Shuster JJ, Behm FG, Whitehead M, Vietti TJ et al. Poor prognosis of children with pre-B acute lymphoblastic leukemia is associated with the t(1;19)(q23;p13): a Pediatric Oncology Group study. Blood 1990; 76: 117–122.",{"doi":3750},"10.1182\u002Fblood.V76.1.117.117",{"id":23,"text":3752,"url":23,"identifiers":3753},"Hunger SP, Sun T, Boswell AF, Carroll AJ, McGavran L . Hyperdiploidy and E2A-PBX1 fusion in an adult with t(1;19)+ acute lymphoblastic leukemia: case report and review of the literature. Genes Chromosomes Cancer 1997; 20: 392–398.",{"doi":3754},"10.1002\u002F(SICI)1098-2264(199712)20:4\u003C392::AID-GCC11>3.0.CO;2-P",{"id":23,"text":3756,"url":23,"identifiers":3757},"Borowitz MJ, Hunger SP, Carroll AJ, Shuster JJ, Pullen DJ, Steuber CP et al. Predictability of the t(1;19)(q23;p13) from surface antigen phenotype: implications for screening cases of childhood acute lymphoblastic leukemia for molecular analysis: a Pediatric Oncology Group study. Blood 1993; 82: 1086–1091.",{"doi":3758},"10.1182\u002Fblood.V82.4.1086.1086",{"id":23,"text":3760,"url":23,"identifiers":3761},"Privitera E, Kamps MP, Hayashi Y, Inaba T, Shapiro LH, Raimondi SC et al. Different molecular consequences of the 1;19 chromosomal translocation in childhood B-cell precursor acute lymphoblastic leukemia. Blood 1992; 79: 1781–1788.",{"doi":3762},"10.1182\u002Fblood.V79.7.1781.1781",{"id":23,"text":3764,"url":23,"identifiers":3765},"Privitera E, Luciano A, Ronchetti D, Arico M, Santostasi T, Basso G et al. Molecular variants of the 1;19 chromosomal translocation in pediatric acute lymphoblastic leukemia (ALL). Leukemia 1994; 8: 554–559.",{},{"id":23,"text":3767,"url":23,"identifiers":3768},"Hunger SP, Galili N, Carroll AJ, Crist WM, Link MP, Cleary ML . The t(1;19)(q23;p13) results in consistent fusion of E2A and PBX1 coding sequences in acute lymphoblastic leukemias. Blood 1991; 77: 687–693.",{"doi":3769},"10.1182\u002Fblood.V77.4.687.687",{"id":23,"text":3771,"url":23,"identifiers":3772},"Izraeli S, Kovar H, Gadner H, Lion T . Unexpected heterogeneity in E2A\u002FPBX1 fusion messenger RNA detected by the polymerase chain reaction in pediatric patients with acute lymphoblastic leukemia. Blood 1992; 80: 1413–1417.",{"doi":3773},"10.1182\u002Fblood.V80.6.1413.1413",{"id":23,"text":3775,"url":23,"identifiers":3776},"Van Dijk MA, Voorhoeve PM, Murre C . Pbx1 is converted into a transcriptional activator upon acquiring the N-terminal region of E2A in pre-B-cell acute lymphoblastoid leukemia. Proc Natl Acad Sci USA 1993; 90: 6061–6065.",{"doi":3777},"10.1073\u002Fpnas.90.13.6061",{"id":23,"text":3779,"url":23,"identifiers":3780},"Monica K, LeBrun DP, Dedera DA, Brown R, Cleary ML . Transformation properties of the E2a-Pbx1 chimeric oncoprotein: fusion with E2a is essential, but the Pbx1 homeodomain is dispensable. Mol Cell Biol 1994; 14: 8304–8314.",{"doi":3781},"10.1128\u002FMCB.14.12.8304",{"id":23,"text":3783,"url":23,"identifiers":3784},"Dedera DA, Waller EK, LeBrun DP, Sen-Majumdar A, Stevens ME, Barsh GS et al. Chimeric homeobox gene E2A-PBX1 induces proliferation, apoptosis, and malignant lymphomas in transgenic mice. Cell 1993; 74: 833–843.",{"doi":3785},"10.1016\u002F0092-8674(93)90463-Z",{"id":23,"text":3787,"url":23,"identifiers":3788},"Kamps MP, Baltimore D . E2A-Pbx1, the t(1;19) translocation protein of human pre-B-cell acute lymphocytic leukemia, causes acute myeloid leukemia in mice. Mol Cell Biol 1993; 13: 351–357.",{"doi":3789},"10.1128\u002FMCB.13.1.351",{"id":23,"text":3791,"url":23,"identifiers":3792},"Lanza C, Gottardi E, Gaidano C, Vivenza C, Parziale A, Perfetto F et al. Persistence of E2A\u002FPBX1 transcripts in t(1;19) childhood acute lymphoblastic leukemia: correlation with chamotherapy intensity and clinical outcome. Leukemia Res 1996; 20: 441–443.",{"doi":3793},"10.1016\u002F0145-2126(95)00115-8",{"id":23,"text":3795,"url":23,"identifiers":3796},"Izraeli S, Janssen JW, Haas OA, Harbott J, Brok SF, Walther JU et al. Detection and clinical relevance of genetic abnormalities in pediatric acute lymphoblastic leukemia: a comparison between cytogenetic and polymerase chain reaction analyses. Leukemia 1993; 7: 671–678.",{},{"id":23,"text":3798,"url":23,"identifiers":3799},"Hunger SP, Fall MZ, Camitta BM, Carroll AJ, Link MP, Lauer SJ et al. E2A-PBX1 chimeric transcript status at end of consolidation is not predictive of treatment outcome in childhood acute lymphoblastic leukemias with a t(1;19)(q23;p13): a Pediatric Oncology Group study. Blood 1998; 91: 1021–1028.",{},{"id":23,"text":3801,"url":23,"identifiers":3802},"Privitera E, Rivolta A, Ronchetti D, Mosna G, Giudici G, Biondi A . Reverse transcriptase\u002Fpolymerase chain reaction follow up and minimal residual disease detection in t(1;19)-positive acute lymphoblastic leukaemia. Br J Haematol 1996; 92: 653–658.",{"doi":3803},"10.1046\u002Fj.1365-2141.1996.00366.x",{"id":23,"text":3805,"url":23,"identifiers":3806},"Devaraj PE, Foroni L, Janossy G, Hoffbrand AV, Secker-Walker LM . Expression of the E2A-PBX1 fusion transcripts in t(1;19)(q23;p13) and der(19)t(1;19) at diagnosis and in remission of acute lymphoblastic leukemia with different B lineage immunophenotypes. Leukemia 1995; 9: 821–825.",{},{"id":23,"text":3808,"url":23,"identifiers":3809},"Rowley JD . Molecular genetics in acute leukemia. Leukemia 2000; 14: 513–517.",{"doi":3810},"10.1038\u002Fsj.leu.2401600",{"id":23,"text":3812,"url":23,"identifiers":3813},"Yu BD, Hess JL, Horning SE, Brown GAJ, Korsmeyer SJ . Altered Hox expression and segmental identity in MLL-mutant mice. Nature 1995; 378: 505–508.",{"doi":3814},"10.1038\u002F378505a0",{"id":23,"text":3816,"url":23,"identifiers":3817},"Isnard P, Core N, Naquet P, Djabali M . Altered lymphoid development in mice deficient for the mAF4 proto-oncogene. Blood 2000; 96: 705–710.",{"doi":3818},"10.1182\u002Fblood.V96.2.705",{"id":23,"text":3820,"url":23,"identifiers":3821},"Kersey JH, Wang D, Oberto M . Resistance of t(4;11) (MLL-AF4 fusion gene) leukemias to stress-induced cell death: possible mechanism for extensive extramedullary accumulation of cells and poor prognosis. Leukemia 1998; 12: 1561–1564.",{"doi":3822},"10.1038\u002Fsj.leu.2401148",{"id":23,"text":3824,"url":23,"identifiers":3825},"Uckun FM, Herman-Hatten K, Crotty ML, Sensel MG, Sather HN, Tuel-Ahlgren L et al. Clinical significance of MLL-AF4 fusion transcript expression in the absence of a cytogenetically detectable t(4;11)(q21;q23) chromosomal translocation. Blood 1998; 92: 810–821.",{},{"id":23,"text":3827,"url":23,"identifiers":3828},"Trka J, Zuna J, Hrusak O, Michalova K, Muzikova K, Kalinova M et al. No evidence for MLL\u002FAF4 expression in normal cord blood samples. Blood 1999; 93: 1106–1107, discussion 1108–1110.",{"doi":3829},"10.1182\u002Fblood.V93.3.1106",{"id":23,"text":3831,"url":23,"identifiers":3832},"Kim-Rouille MH, MacGregor A, Wiedemann LM, Greaves MF, Navarrete C . MLL-AF4 gene fusions in normal newborns. Blood 1999; 93: 1107–1108.",{"doi":3833},"10.1182\u002Fblood.V93.3.1107",{"id":23,"text":3835,"url":23,"identifiers":3836},"Cimino G, Elia L, Rapanotti MC, Sprovieri T, Mancini M, Cuneo A et al. A prospective study of residual-disease monitoring of the ALL1\u002FAF4 transcript in patients with t(4;11) acute lymphoblastic leukemia. Blood 2000; 95: 96–101.",{},{"id":23,"text":3838,"url":23,"identifiers":3839},"Romana SP, Poirel H, Leconiat M, Flexor MA, Mauchauffe M, Jonveaux P et al. High frequency of t(12;21) in childhood B-lineage acute lymphoblastic leukemia. Blood 1995; 86: 4263–4269.",{"doi":3840},"10.1182\u002Fblood.V86.11.4263.bloodjournal86114263",{"id":23,"text":3842,"url":23,"identifiers":3843},"Raynaud S, Mauvieux L, Cayuela J, Bastard C, Bilhou-Nabera C, Debuire B et al. TEL\u002FAML1 fusion gene is a rare event in adult acute lymphoblastic leukemia. Leukemia 1996; 10: 1529–1530.",{},{"id":23,"text":3845,"url":23,"identifiers":3846},"Borkhardt A, Cazzaniga G, Viehmann S, Valsecchi MG, Ludwig WD, Burci L et al. Incidence and clinical relevance of TEL\u002FAML1 fusion genes in children with acute lymphoblastic leukemia enrolled in the German and Italian multicenter therapy trials. Associazione Italiana Ematologia Oncologia Pediatrica and the Berlin–Frankfurt–Munster Study Group. Blood 1997; 90: 571–577.",{"doi":3847},"10.1182\u002Fblood.V90.2.571",{"id":23,"text":3849,"url":23,"identifiers":3850},"Heibert SW, Lutterbach B, Durst K, Wang L, Linggi B, Wu S et al. Mechanisms of transcriptional repression by the t(8;21)-, t(12;21)-, and inv(16)-encoded fusion proteins. Cancer Chemother Pharmacol 2001; 48 (Suppl 1): S31–S34.",{"doi":3851},"10.1007\u002Fs002800100302",{"id":23,"text":3853,"url":23,"identifiers":3854},"Satake N, Kobayashi H, Tsunematsu Y, Kawasaki H, Horikoshi Y, Koizumi S et al. Minimal residual disease with TEL-AML1 fusion transcript in childhood acute lymphoblastic leukaemia with t(12;21). Br J Haematol 1997; 97: 607–611.",{"doi":3855},"10.1046\u002Fj.1365-2141.1997.762712.x",{"id":23,"text":3857,"url":23,"identifiers":3858},"Harbott J, Viehmann S, Borkhardt A, Henze G, Lampert F . Incidence of TEL\u002FAML1 fusion gene analyzed consecutively in children with acute lymphoblastic leukemia in relapse. Blood 1997; 90: 4933–4937.",{"doi":3859},"10.1182\u002Fblood.V90.12.4933",{"id":23,"text":3861,"url":23,"identifiers":3862},"Seeger K, Adams HP, Buchwald D, Beyermann B, Kremens B, Niemeyer C et al. TEL-AML1 fusion transcript in relapsed childhood acute lymphoblastic leukaemia. The Berlin–Frankfurt–Munster Study Group. Blood 1998; 91: 1716–1722.",{"doi":3863},"10.1182\u002Fblood.V91.5.1716.1716_1716_1722",{"id":23,"text":3865,"url":23,"identifiers":3866},"Loh ML, Silverman LB, Young ML, Neuberg D, Golub TR, Sallan SE et al. Incidence of TEL\u002FAML1 fusion in children with relapsed acute lymphoblastic leukemia. Blood 1998; 92: 4792–4797.",{"doi":3867},"10.1182\u002Fblood.V92.12.4792",{"id":23,"text":3869,"url":23,"identifiers":3870},"Maloney K, McGavran L, Murphy J, Odom L, Stork L, Wei Q et al. TEL-AML1 fusion identifies a subset of children with standard risk acute lymphoblastic leukemia who have an excellent prognosis when treated with therapy that includes a single delayed intensification. Leukemia 1999; 13: 1708–1712.",{"doi":3871},"10.1038\u002Fsj.leu.2401548",{"id":23,"text":3873,"url":23,"identifiers":3874},"Zuna J, Hrusak O, Kalinova M, Muzikova K, Stary J, Trka J . TEL\u002FAML1 positivity in childhood ALL: average or better prognosis? Czech Paediatric Haematology Working Group. Leukemia 1999; 13: 22–24.",{"doi":3875},"10.1038\u002Fsj.leu.2401256",{"id":23,"text":3877,"url":23,"identifiers":3878},"Cayuela JM, Baruchel A, Orange C, Madani A, Auclerc MF, Daniel MT et al. TEL-AML1 fusion RNA as a new target to detect minimal residual disease in pediatric B-cell precursor acute lymphoblastic leukemia. Blood 1996; 88: 302–308.",{"doi":3879},"10.1182\u002Fblood.V88.1.302.302",{"id":23,"text":3881,"url":23,"identifiers":3882},"Ballerini P, Landman Parker J, Laurendeau I, Olivi M, Vidaud M, Adam M et al. Quantitative analysis of TEL\u002FAML1 fusion transcripts by real-time RT-PCR assay in childhood acute lymphoblastic leukemia. Leukemia 2000; 14: 1526–1528.",{"doi":3883},"10.1038\u002Fsj.leu.2401858",{"id":23,"text":3885,"url":23,"identifiers":3886},"Rosenfeld C, Goutner A, Choquet C, Venuat AM, Kayibanda B, Pico JL et al. Phenotypic characterisation of a unique non-T, non-B acute lymphoblastic leukaemia cell line. Nature 1977; 267: 841–843.",{"doi":3887},"10.1038\u002F267841a0",{"id":23,"text":3889,"url":23,"identifiers":3890},"Groffen J, Stephenson JR, Heisterkamp N, de Klein A, Bartram CR, Grosveld G . Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell 1984; 36: 93–99.",{"doi":3891},"10.1016\u002F0092-8674(84)90077-1",{"id":23,"text":3893,"url":23,"identifiers":3894},"Hoelzer D . Treatment of acute lymphoblastic leukemia. Semin Hematol 1994; 31: 1–15.",{},{"id":23,"text":3896,"url":23,"identifiers":3897},"Cuneo A, Ferrant A, Michaux JL, Demuynck H, Boogaerts M, Louwagie A et al. Philadelphia chromosome-positive acute myeloid leukemia: cytoimmunologic and cytogenetic features. Haematologica 1996; 81: 423–427.",{},{"id":23,"text":3899,"url":23,"identifiers":3900},"Gleissner B, Gokbuget N, Bartram CR, Janssen B, Rieder H, Janssen JW et al. Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis. Blood 2002; 99: 1536–1543.",{"doi":3901},"10.1182\u002Fblood.V99.5.1536",{"id":23,"text":3903,"url":23,"identifiers":3904},"Faderl S, Talpaz M, Estrov Z, O’Brien S, Kurzrock R, Kantarjian HM . The biology of chronic myeloid leukemia. N Engl J Med 1999; 341: 164–172.",{"doi":3905},"10.1056\u002FNEJM199907153410306",{"id":23,"text":3907,"url":23,"identifiers":3908},"Melo JV . The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. Blood 1996; 88: 2375–2384.",{"doi":3909},"10.1182\u002Fblood.V88.7.2375.bloodjournal8872375",{"id":23,"text":3911,"url":23,"identifiers":3912},"Saglio G, Guerrasio A, Rosso C, Zaccaria A, Tassinari A, Serra A et al. New type of Bcr\u002FAbl junction in Philadelphia chromosome-positive chronic myelogenous leukemia. Blood 1990; 76: 1819–1824.",{"doi":3913},"10.1182\u002Fblood.V76.9.1819.1819",{"id":23,"text":3915,"url":23,"identifiers":3916},"Pane F, Frigeri F, Sindona M, Luciano L, Ferrara F, Cimino R et al. Neutrophilic-chronic myeloid leukemia: a distinct disease with a specific molecular marker (BCR\u002FABL with C3\u002FA2 junction). Blood 1996; 88: 2410–2414.",{"doi":3917},"10.1182\u002Fblood.V88.7.2410.bloodjournal8872410",{"id":23,"text":3919,"url":23,"identifiers":3920},"Secker-Walker LM, Craig JM, Hawkins JM, Hoffbrand AV . Philadelphia positive acute lymphoblastic leukemia in adults: age distribution, BCR breakpoint and prognostic significance. Leukemia 1991; 5: 196–199.",{},{"id":23,"text":3922,"url":23,"identifiers":3923},"Melo JV, Myint H, Galton DAG, Goldman JM . P190BCR\u002FABL chronic myeloid leukemia: the missing link with chronic myelomonocytic leukemia? Leukemia 1994; 8: 208–211.",{},{"id":23,"text":3925,"url":23,"identifiers":3926},"Sirard C, Laneuville P, Dick JE . Expression of bcr-abl abrogates factor-dependent growth of human hematopoietic M07E cells by an autocrine mechanism. Blood 1994; 83: 1575–1585.",{"doi":3927},"10.1182\u002Fblood.V83.6.1575.1575",{"id":23,"text":3929,"url":23,"identifiers":3930},"Radich JP, Kopecky KJ, Boldt DH, Head D, Slovak ML, Babu R et al. Detection of BCR-ABL fusion genes in adult acute lymphoblastic leukemia by the polymerase chain reaction. Leukemia 1994; 8: 1688–1695.",{},{"id":23,"text":3932,"url":23,"identifiers":3933},"Brisco MJ, Sykes PJ, Hughes E, Dolman G, Neoh SH, Peng LM et al. Monitoring minimal residual disease in peripheral blood in B-lineage acute lymphoblastic leukaemia. Br J Haematol 1997; 99: 314–319.",{"doi":3934},"10.1046\u002Fj.1365-2141.1997.3723186.x",{"id":23,"text":3936,"url":23,"identifiers":3937},"Annino L, Ferrari A, Lamanda M, Mandelli F, Lo Coco F, Pane F . PCR-detectable transcripts in long-term remission of P190(BCR\u002FABL)-positive acute lymphoblastic leukemia. Blood 2000; 95: 4018–4019.",{"doi":3938},"10.1182\u002Fblood.V95.12.4018",{"id":23,"text":3940,"url":23,"identifiers":3941},"Radich J, Gehly G, Lee A, Avery R, Bryant E, Edmands S et al. Detection of bcr-abl transcripts in Philadelphia chromosome-positive acute lymphoblastic leukemia after marrow transplantation. Blood 1997; 89: 2602–2609.",{"doi":3942},"10.1182\u002Fblood.V89.7.2602",{"id":23,"text":3944,"url":23,"identifiers":3945},"Nowell PC, Hungerford DA . A minute chromosome in human chronic granulocytic leukemia. Science 1960; 132: 1497.",{},{"id":23,"text":3947,"url":23,"identifiers":3948},"de Klein A, van Kessel AG, Grosveld G, Bartram CR, Hagemeijer A, Bootsma D et al. A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia. Nature 1982; 300: 765–767.",{"doi":3949},"10.1038\u002F300765a0",{"id":23,"text":3951,"url":23,"identifiers":3952},"Lugo TG, Pendergast AM, Muller AJ, Witte ON . Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 1990; 247: 1079–1082.",{"doi":3953},"10.1126\u002Fscience.2408149",{"id":23,"text":3955,"url":23,"identifiers":3956},"Hughes TP, O’Shea P, Morgan G, Martiat P, Goldman JM . Persistence of BCR\u002FABL transcripts after BMT for CML detected by PCR reflects a high risk of relapse. Bone Marrow Transplant 1991; 7 (Suppl 2): 23.",{},{"id":23,"text":3958,"url":23,"identifiers":3959},"Radich JP, Gehly G, Gooley T, Bryant E, Clift RA, Collins S et al. Polymerase chain reaction detection of the BCR-ABL fusion transcript after allogeneic marrow transplantation for chronic myeloid leukemia: results and implications in 346 patients. Blood 1995; 85: 2632–2638.",{"doi":3607},{"id":23,"text":3961,"url":23,"identifiers":3962},"Gabert J, Thuret I, Carcassonne Y, Maraninchi D, Mannoni P . Residual bcr\u002Fabl transcripts in chronic myeloid leukaemia. Lancet 1990; 335: 417–418.",{"doi":3963},"10.1016\u002F0140-6736(90)90258-7",{"id":23,"text":3965,"url":23,"identifiers":3966},"Pignon JM, Henni T, Amselem S, Vidaud M, Duquesnoy P, Vernant JP et al. Frequent detection of minimal residual disease by use of the polymerase chain reaction in long-term survivors after bone marrow transplantation for chronic myeloid leukemia. Leukemia 1990; 4: 83–86.",{},{"id":23,"text":3968,"url":23,"identifiers":3969},"Miyamura K, Tahara T, Tanimoto M, Morishita Y, Kawashima K, Morishima Y et al. Long persistent bcr-abl positive transcript detected by polymerase chain reaction after marrow transplant for chronic myelogenous leukemia without clinical relapse: a study of 64 patients. Blood 1993; 81: 1089–1093.",{"doi":3970},"10.1182\u002Fblood.V81.4.1089.1089",{"id":23,"text":3972,"url":23,"identifiers":3973},"van Rhee F, Lin F, Cross NC, Reid CD, Lakhani AK, Szydlo RM et al. Detection of residual leukaemia more than 10 years after allogeneic bone marrow transplantation for chronic myelogenous leukaemia. Bone Marrow Transplant 1994; 14: 609–612.",{},{"id":23,"text":3975,"url":23,"identifiers":3976},"Thompson JD, Brodsky I, Yunis JJ . Molecular quantification of residual disease in chronic myelogenous leukemia after bone marrow transplantation. Blood 1992; 79: 1629–1635.",{"doi":3977},"10.1182\u002Fblood.V79.6.1629.1629",{"id":23,"text":3979,"url":23,"identifiers":3980},"Lion T, Izraeli S, Henn T, Gaiger A, Mor W, Gadner H . Monitoring of residual disease in chronic myelogenous leukemia by quantitative polymerase chain reaction. Leukemia 1992; 6: 495–499.",{},{"id":23,"text":3982,"url":23,"identifiers":3983},"Cross NC, Feng L, Chase A, Bungey J, Hughes TP, Goldman JM . Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation. Blood 1993; 82: 1929–1936.",{"doi":3984},"10.1182\u002Fblood.V82.6.1929.1929",{"id":23,"text":3986,"url":23,"identifiers":3987},"Cross NC . Minimal residual disease in chronic myeloid leukaemia. Hematol Cell Ther 1998; 40: 224–228.",{},{"id":23,"text":3989,"url":23,"identifiers":3990},"Hochhaus A, Lin F, Reiter A, Skladny H, Mason PJ, van Rhee F et al. Quantification of residual disease in chronic myelogenous leukemia patients on interferon-alpha therapy by competitive polymerase chain reaction. Blood 1996; 87: 1549–1555.",{"doi":3991},"10.1182\u002Fblood.V87.4.1549.bloodjournal8741549",{"id":23,"text":3993,"url":23,"identifiers":3994},"Merx K, Muller MC, Kreil S, Lahaye T, Paschka P, Schoch C et al. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha. Leukemia 2002; 16: 1579–1583.",{"doi":3995},"10.1038\u002Fsj.leu.2402680",{"id":23,"text":3997,"url":23,"identifiers":3998},"Stentoft J, Pallisgaard N, Kjeldsen E, Holm MS, Nielsen JL, Hokland P . Kinetics of BCR-ABL fusion transcript levels in chronic myeloid leukemia patients treated with STI571 measured by quantitative real-time polymerase chain reaction. Eur J Haematol 2001; 67: 302–308.",{"doi":3999},"10.1034\u002Fj.1600-0609.2001.00556.x",{"id":23,"text":4001,"url":23,"identifiers":4002},"Emig M, Saussele S, Wittor H, Weisser A, Reiter A, Willer A et al. Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time quantitative RT-PCR. Leukemia 1999; 13: 1825–1832.",{"doi":4003},"10.1038\u002Fsj.leu.2401566",{"id":23,"text":4005,"url":23,"identifiers":4006},"Saffroy R, Lemoine A, Brezillon P, Frenoy N, Delmas B, Goldschmidt E et al. Real-time quantitation of bcr-abl transcripts in haematological malignancies. Eur J Haematol 2000; 65: 258–266.",{"doi":4007},"10.1034\u002Fj.1600-0609.2000.065004258.x",{"id":23,"text":4009,"url":23,"identifiers":4010},"Barbany G, Hagberg A, Olsson-Stromberg U, Simonsson B, Syvanen AC, Landegren U . Manifold-assisted reverse transcription-PCR with real-time detection for measurement of the BCR-ABL fusion transcript in chronic myeloid leukemia patients. Clin Chem 2000; 46: 913–920.",{"doi":4011},"10.1093\u002Fclinchem\u002F46.7.913",{"id":23,"text":4013,"url":23,"identifiers":4014},"Schoch C, Schnittger S, Bursch S, Gerstner D, Hochhaus A, Berger U et al. Comparison of chromosome banding analysis, interphase- and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: a study on 350 cases. Leukemia 2002; 16: 53–59.",{"doi":4015},"10.1038\u002Fsj.leu.2402329",{"id":23,"text":4017,"url":23,"identifiers":4018},"Aplan PD, Lombardi DP, Reaman GH, Sather HN, Hammond GD, Kirsch IR . Involvement of the putative hematopoietic transcription factor SCL in T-cell acute lymphoblastic leukemia. Blood 1992; 79: 1327–1333.",{"doi":4019},"10.1182\u002Fblood.V79.5.1327.1327",{"id":23,"text":4021,"url":23,"identifiers":4022},"Bash RO, Crist WM, Shuster JJ, Link MP, Amylon M, Pullen J et al. Clinical features and outcome of T-cell acute lymphoblastic leukemia in childhood with respect to alterations at the TAL1 locus: a Pediatric Oncology Group study. Blood 1993; 81: 2110–2117.",{"doi":4023},"10.1182\u002Fblood.V81.8.2110.2110",{"id":23,"text":4025,"url":23,"identifiers":4026},"Bernard O, Lecointe N, Jonveaux P, Souyri M, Mauchauffe M, Berger R et al. Two site-specific deletions and t(1;14) translocation restricted to human T-cell acute leukemias disrupt the 5′ part of the tal-1 gene. Oncogene 1991; 6: 1477–1488.",{},{"id":23,"text":4028,"url":23,"identifiers":4029},"Breit TM, Mol EJ, Wolvers-Tettero IL, Ludwig WD, van Wering ER, van Dongen JJ . Site-specific deletions involving the tal-1 and sil genes are restricted to cells of the T cell receptor alpha\u002Fbeta lineage: T cell receptor delta gene deletion mechanism affects multiple genes. J Exp Med 1993; 177: 965–977.",{"doi":4030},"10.1084\u002Fjem.177.4.965",{"id":23,"text":4032,"url":23,"identifiers":4033},"Brown L, Cheng JT, Chen Q, Siciliano MJ, Crist W, Buchanan G et al. Site-specific recombination of the tal-1 gene is a common occurrence in human T cell leukemia. EMBO J 1990; 9: 3343–3351.",{"doi":4034},"10.1002\u002Fj.1460-2075.1990.tb07535.x",{"id":23,"text":4036,"url":23,"identifiers":4037},"Delabesse E, Bernard M, Landman-Parker J, Davi F, Leboeuf D, Varet B et al. Simultaneous SIL-TAL1 RT-PCR detection of all tal(d) deletions and identification of novel tal(d) variants. Br J Haematol 1997; 99: 901–907.",{"doi":4038},"10.1046\u002Fj.1365-2141.1997.4833286.x",{"id":23,"text":4040,"url":23,"identifiers":4041},"Delabesse E, Bernard M, Meyer V, Smit L, Pulford K, Cayuela JM et al. TAL1 expression does not occur in the majority of T-ALL blasts. Br J Haematol 1998; 102: 449–457.",{"doi":4042},"10.1046\u002Fj.1365-2141.1998.00807.x",{"id":23,"text":4044,"url":23,"identifiers":4045},"Begley CG, Green AR . The SCL gene: from case report to critical hematopoietic regulator. Blood 1999; 93: 2760–2770.",{"doi":4046},"10.1182\u002Fblood.V93.9.2760",{"id":23,"text":4048,"url":23,"identifiers":4049},"Begley CG, Aplan PD, Denning SM, Haynes BF, Waldmann TA, Kirsch IR . The gene SCL is expressed during early hematopoiesis and encodes a differentiation-related DNA-binding motif. Proc Natl Acad Sci USA 1989; 86: 10128–10132.",{"doi":4050},"10.1073\u002Fpnas.86.24.10128",{"id":23,"text":4052,"url":23,"identifiers":4053},"Aplan PD, Nakahara K, Orkin SH, Kirsch IR . The SCL gene product: a positive regulator of erythroid differentiation. EMBO J 1992; 11: 4073–4081.",{"doi":4054},"10.1002\u002Fj.1460-2075.1992.tb05500.x",{"id":23,"text":4056,"url":23,"identifiers":4057},"Aplan PD, Lombardi DP, Kirsch IR . Structural characterization of SIL, a gene frequently disrupted in T-cell acute lymphoblastic leukemia. Mol Cell Biol 1991; 11: 5462–5469.",{"doi":4058},"10.1128\u002FMCB.11.11.5462",{"id":23,"text":4060,"url":23,"identifiers":4061},"Chen Q, Cheng JT, Tasi LH, Schneider N, Buchanan G, Carroll A et al. The tal gene undergoes chromosome translocation in T cell leukemia and potentially encodes a helix–loop–helix protein. EMBO J 1990; 9: 415–424.",{"doi":4062},"10.1002\u002Fj.1460-2075.1990.tb08126.x",{"id":23,"text":4064,"url":23,"identifiers":4065},"Huang W, Kuang SQ, Huang QH, Dong S, Zhang T, Gu LJ et al. RT\u002FPCR detection of SIL-TAL-1 fusion mRNA in Chinese T-cell acute lymphoblastic leukemia (T-ALL). Cancer Genet Cytogenet 1995; 81: 76–82.",{"doi":4066},"10.1016\u002FS0165-4608(94)00209-6",{"id":23,"text":4068,"url":23,"identifiers":4069},"Macintyre EA, Smit L, Ritz J, Kirsch IR, Strominger JL . Disruption of the SCL locus in T-lymphoid malignancies correlates with commitment to the T-cell receptor alpha beta lineage. Blood 1992; 80: 1511–1520.",{"doi":4070},"10.1182\u002Fblood.V80.6.1511.1511",{"id":23,"text":4072,"url":23,"identifiers":4073},"Breit TM, Beishuizen A, Ludwig WD, Mol EJ, Adriaansen HJ, van Wering ER et al. tal-1 deletions in T-cell acute lymphoblastic leukemia as PCR target for detection of minimal residual disease. Leukemia 1993; 7: 2004–2011.",{},{"id":23,"text":4075,"url":23,"identifiers":4076},"Pongers-Willemse MJ, Seriu T, Stolz F, d’Aniello E, Gameiro P, Pisa P et al. Primers and protocols for standardized detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin and T cell receptor gene rearrangements and TAL1 deletions as PCR targets: report of the BIOMED-1 CONCERTED ACTION: investigation of minimal residual disease in acute leukemia. Leukemia 1999; 13: 110–118.",{"doi":4077},"10.1038\u002Fsj.leu.2401245",{"id":23,"text":4079,"url":23,"identifiers":4080},"Chen X, Pan Q, Stow P, Behm FG, Goorha R, Pui CH et al. Quantification of minimal residual disease in T-lineage acute lymphoblastic leukemia with the TAL-1 deletion using a standardized real-time PCR assay. Leukemia 2001; 15: 166–170.",{"doi":4081},"10.1038\u002Fsj.leu.2402000",{"id":23,"text":4083,"url":23,"identifiers":4084},"Rowley JD, Golomb HM, Dougherty C . 15\u002F17 translocation, a consistent chromosomal change in acute promyelocytic leukaemia. Lancet 1977; 1: 549–550.",{"doi":4085},"10.1016\u002FS0140-6736(77)91415-5",{"id":23,"text":4087,"url":23,"identifiers":4088},"Biondi A, Rambaldi A . Acute promyelocytic leukemia. In: Henderson ES, Lister TA, Greaves MS (eds), Leukemia, 7th edn, Chap. 23. Philadelphia: WB Saunders, 2002, pp 529–543.",{},{"id":23,"text":4090,"url":23,"identifiers":4091},"Longo L, Pandolfi PP, Biondi A, Rambaldi A, Mencarelli A, Lo Coco F et al. Rearrangements and aberrant expression of the retinoic acid receptor alpha gene in acute promyelocytic leukemias. J Exp Med 1990; 172: 1571–1575.",{"doi":4092},"10.1084\u002Fjem.172.6.1571",{"id":23,"text":4094,"url":23,"identifiers":4095},"Borrow J, Goddard AD, Sheer D, Solomon E . Molecular analysis of acute promyelocytic leukemia breakpoint cluster region on chromosome 17. Science 1990; 249: 1577–1580.",{"doi":4096},"10.1126\u002Fscience.2218500",{"id":23,"text":4098,"url":23,"identifiers":4099},"de The H, Chomienne C, Lanotte M, Degos L, Dejean A . The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus. Nature 1990; 347: 558–561.",{"doi":4100},"10.1038\u002F347558a0",{"id":23,"text":4102,"url":23,"identifiers":4103},"Lemons RS, Eilender D, Waldmann RA, Rebentisch M, Frej AK, Ledbetter DH et al. Cloning and characterization of the t(15;17) translocation breakpoint region in acute promyelocytic leukemia. Genes Chromosomes Cancer 1990; 2: 79–87.",{"doi":4104},"10.1002\u002Fgcc.2870020202",{"id":23,"text":4106,"url":23,"identifiers":4107},"Petkovich M, Brand NJ, Krust A, Chambon P . A human retinoic acid receptor which belongs to the family of nuclear receptors. Nature 1987; 330: 444–450.",{"doi":4108},"10.1038\u002F330444a0",{"id":23,"text":4110,"url":23,"identifiers":4111},"Giguere V, Ong ES, Segui P, Evans RM . Identification of a receptor for the morphogen retinoic acid. Nature 1987; 330: 624–629.",{"doi":4112},"10.1038\u002F330624a0",{"id":23,"text":4114,"url":23,"identifiers":4115},"Zelent A, Guidez F, Melnick A, Waxman S, Licht JD . Translocations of the RARalpha gene in acute promyelocytic leukemia. Oncogene 2001; 20: 7186–7203.",{"doi":4116},"10.1038\u002Fsj.onc.1204766",{"id":23,"text":4118,"url":23,"identifiers":4119},"Grimwade D . The pathogenesis of acute promyelocytic leukaemia: evaluation of the role of molecular diagnosis and monitoring in the management of the disease. Br J Haematol 1999; 106: 591–613.",{"doi":4120},"10.1046\u002Fj.1365-2141.1999.01501.x",{"id":23,"text":4122,"url":23,"identifiers":4123},"Reiter A, Sauβele S, Grimwade D, Wiesmels JL, Segal M, Lafage-Pochitaloff M et al. Genomic anatomy of the reciprocal translocation t(15;17) in acute promyelocytic leukemia. Gene Chromosome Cancer 2003; 36: 175–188.",{"doi":4124},"10.1002\u002Fgcc.10154",{"id":23,"text":4126,"url":23,"identifiers":4127},"Lo Coco F, Diverio D, Pandolfi PP, Biondi A, Rossi V, Avvisati G et al. Molecular evaluation of residual disease as a predictor of relapse in acute promyelocytic leukaemia. Lancet 1992; 340: 1437–1438.",{"doi":4128},"10.1016\u002F0140-6736(92)92625-P",{"id":23,"text":4130,"url":23,"identifiers":4131},"Burnett AK, Grimwade D, Solomon E, Wheatley K, Goldstone AH . Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: result of the Randomized MRC Trial. Blood 1999; 93: 4131–4143.",{"doi":4132},"10.1182\u002Fblood.V93.12.4131",{"id":23,"text":4134,"url":23,"identifiers":4135},"Slack JL, Bi W, Livak KJ, Beaubier N, Yu M, Clark M et al. Pre-clinical validation of a novel, highly sensitive assay to detect PML-RARalpha mRNA using real-time reverse-transcription polymerase chain reaction. J Mol Diagn 2001; 3: 141–149.",{"doi":4136},"10.1016\u002FS1525-1578(10)60665-4",{"id":23,"text":4138,"url":23,"identifiers":4139},"Visani G, Buonamici S, Malagola M, Isidori A, Piccaluga PP, Martinelli G et al. Pulsed ATRA as single therapy restores long-term remission in PML-RARalpha-positive acute promyelocytic leukemia patients: real time quantification of minimal residual disease. A pilot study. Leukemia 2001; 15: 1696–1700.",{"doi":4140},"10.1038\u002Fsj.leu.2402266",{"id":23,"text":4142,"url":23,"identifiers":4143},"Kwong YL, Au WY, Chim CS, Pang A, Suen C, Liang R . Arsenic trioxide- and idarubicin-induced remissions in relapsed acute promyelocytic leukaemia: clinicopathological and molecular features of a pilot study. Am J Hematol 2001; 66: 274–279.",{"doi":4144},"10.1002\u002Fajh.1057",{"id":23,"text":4146,"url":23,"identifiers":4147},"Gallagher RE, Li YP, Rao S, Paietta E, Andersen J, Etkind P et al. Characterization of acute promyelocytic leukemia cases with PML-RAR alpha break\u002Ffusion sites in PML exon 6: identification of a subgroup with decreased in vitro responsiveness to all-trans retinoic acid. Blood 1995; 86: 1540–1547.",{"doi":4148},"10.1182\u002Fblood.V86.4.1540.bloodjournal8641540",{"id":23,"text":4150,"url":23,"identifiers":4151},"Grimwade D, Howe K, Langabeer S, Davies L, Oliver F, Walker H et al. Establishing the presence of the t(15;17) in suspected acute promyelocytic leukaemia: cytogenetic, molecular and PML immunofluorescence assessment of patients entered into the M.R.C. ATRA trial. M.R.C. Adult Leukaemia Working Party. Br J Haematol 1996; 94: 557–573.",{"doi":4152},"10.1046\u002Fj.1365-2141.1996.d01-1004.x",{"id":23,"text":4154,"url":23,"identifiers":4155},"Slack JL, Willman CL, Andersen JW, Li YP, Viswanatha DS, Bloomfield CD et al. Molecular analysis and clinical outcome of adult APL patients with the type V PML-RARalpha isoform: results from intergroup protocol 0129. Blood 2000; 95: 398–403.",{},{"id":23,"text":4157,"url":23,"identifiers":4158},"Lanotte M, Martin-Thouvenin V, Najman S, Balerini P, Valensi F, Berger R . NB4, a maturation inducible cell line with t(15;17) marker isolated from a human acute promyelocytic leukemia (M3). Blood 1991; 77: 1080–1086.",{"doi":4159},"10.1182\u002Fblood.V77.5.1080.1080",{"id":23,"text":4161,"url":23,"identifiers":4162},"Rowe D, Cotterill SJ, Ross FM, Bunyan DJ, Vickers SJ, Bryon J et al. Cytogenetically cryptic AML1-ETO and CBF beta-MYH11 gene rearrangements: incidence in 412 cases of acute myeloid leukaemia. Br J Haematol 2000; 111: 1051–1056.",{"doi":4163},"10.1046\u002Fj.1365-2141.2000.02474.x",{"id":23,"text":4165,"url":23,"identifiers":4166},"Liu P, Hajra A, Wijmenga C, Collins F . Molecular pathogenesis of the chromosome16 inversion in the M4Eo subtype of acute myeloid leukemia. Blood 1995; 85: 2289–2302.",{"doi":4167},"10.1182\u002Fblood.V85.9.2289.bloodjournal8592289",{"id":23,"text":4169,"url":23,"identifiers":4170},"Claxton DF, Liu P, Hsu HB, Marlton P, Hester J, Collins F et al. Detection of fusion transcripts generated by the inversion 16 chromosome in acute myeloid leukemia. Blood 1994; 83: 1750–1756.",{"doi":4171},"10.1182\u002Fblood.V83.7.1750.1750",{"id":23,"text":4173,"url":23,"identifiers":4174},"Hébert J, Cayuela JM, Daniel MT, Berger R, Sigaux F . Detection of minimal residual disease in acute myelomonocytic leukemia with abnormal marrow eosinophils by nested polymerase chain reaction with allele specific amplification. Blood 1994; 84: 2291–2296.",{"doi":4175},"10.1182\u002Fblood.V84.7.2291.2291",{"id":23,"text":4177,"url":23,"identifiers":4178},"Poirel H, Radford-Weiss I, Rack K, Troussard X, Veil A, Valensi F et al. Detection of the chromosome 16 CBFβ-MHY11 fusion transcript in myelomonocytic leukemias. Blood 1995; 85: 1313–1322.",{"doi":4179},"10.1182\u002Fblood.V85.5.1313.bloodjournal8551313",{"id":23,"text":4181,"url":23,"identifiers":4182},"Costello R, Sainty D, Lecine P, Cusenier A, Mozziconacci MJ, Arnoulet C et al. Detection of CBFbeta\u002FMYH11 fusion transcripts in acute myeloid leukemia: heterogeneity of cytological and molecular characteristics. Leukemia 1997; 11: 644–650.",{"doi":4183},"10.1038\u002Fsj.leu.2400629",{"id":23,"text":4185,"url":23,"identifiers":4186},"Burnett AK, Goldstone AH, Stevens RM, Hann IM, Rees JK, Gray RG et al. Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial. UK Medical Research Council Adult and Children's Leukaemia Working Parties. Lancet 1998; 351: 700–708.",{"doi":4187},"10.1016\u002FS0140-6736(97)09214-3",{"id":23,"text":4189,"url":23,"identifiers":4190},"Burnett AK, Wheatley K, Goldstone AH, Stevens RF, Hann IM, Rees JHK et al. The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the MRC AML10 trial. Br J Heamatol 2002; 118: 385–400.",{"doi":4191},"10.1046\u002Fj.1365-2141.2002.03724.x",{"id":23,"text":4193,"url":23,"identifiers":4194},"Marcucci G, Caligiuri MA, Bloomfield CD . Defining the ‘absence’ of the CBFbeta\u002FMYH11 fusion transcript in patients with acute myeloid leukemia and inversion of chromosome 16 to predict long-term complete remission: a call for definitions. Blood 1997; 90: 5022–5024.",{"doi":4195},"10.1182\u002Fblood.V90.12.5022b",{"id":23,"text":4197,"url":23,"identifiers":4198},"Costello R, Sainty D, Blaise D, Gastaut JA, Poirel H, Buzyn-Veil A et al. Prognosis value of residual disease monitoring by polymerase chain reaction in patients with CBF beta\u002FMYH11-positive acute myeloblastic leukemia [letter]. Blood 1997; 89: 2222–2223.",{"doi":4199},"10.1182\u002Fblood.V89.6.2222",{"id":23,"text":4201,"url":23,"identifiers":4202},"Evans PA, Short MA, Jack AS, Norfolk DR, Child JA, Shiach CR et al. Detection and quantitation of the CBFbeta\u002FMYH11 transcripts associated with the inv(16) in presentation and follow-up samples from patients with AML. Leukemia 1997; 11: 364–369.",{"doi":4203},"10.1038\u002Fsj.leu.2400578",{"id":23,"text":4205,"url":23,"identifiers":4206},"Krauter J, Hoellge W, Wattjes MP, Nagel S, Heidenreich O, Bunjes D et al. Detection and quantification of CBFB\u002FMYH11 fusion transcripts in patients with inv(16)-positive acute myeloblastic leukemia by real-time RT-PCR. Genes Chromosomes Cancer 2001; 30: 342–348.",{"doi":4207},"10.1002\u002Fgcc.1100",{"id":23,"text":4209,"url":23,"identifiers":4210},"Guerrasio A, Pilatrino C, De Micheli D, Cilloni D, Serra A, Gottardi E et al. Assessment of minimal residual disease (MRD) in CBFbeta\u002FMYH11-positive acute myeloid leukemias by qualitative and quantitative RT-PCR amplification of fusion transcripts. Leukemia 2002; 16: 1176–1181.",{"doi":4211},"10.1038\u002Fsj.leu.2402478",{"id":23,"text":4213,"url":23,"identifiers":4214},"Friedman AD . Leukemogenesis by CBF oncoproteins. Leukemia 1999; 13: 1932–1942.",{"doi":4215},"10.1038\u002Fsj.leu.2401590",{"id":23,"text":4217,"url":23,"identifiers":4218},"Nucifora G, Larson RA, Rowley JD . Persistence of the t(8;21) translocation in patients with AML-M2 in long-term remission patients. Blood 1993; 82: 712–715.",{"doi":4219},"10.1182\u002Fblood.V82.3.712.712",{"id":23,"text":4221,"url":23,"identifiers":4222},"Kusec R, Laczika K, Knobl P, Friedl J, Greinix H, Kahls P et al. AML1\u002FETO fusion mRNA can be detected in remission blood samples of all patients with t(8;21) acute myeloid leukemia after chemotherapy or autologous bone marrow transplantation. Leukemia 1994; 8: 735–739.",{},{"id":23,"text":4224,"url":23,"identifiers":4225},"Miyamoto T, Weissman IL, Akashi K . AML1\u002FETO-expressing nonleukemic stem cells in acute myelogenous leukemia with 8;21 chromosomal translocation. Proc Natl Acad Sci USA 2000; 97: 7521–7526.",{"doi":4226},"10.1073\u002Fpnas.97.13.7521",{"id":23,"text":4228,"url":23,"identifiers":4229},"Morschhauser F, Cayuela JM, Martini S, Baruchel A, Rousselot P, Socie G et al. Evaluation of minimal residual disease using reverse-transcription polymerase chain reaction in t(8;21) acute myeloid leukemia: a multicenter study of 51 patients. J Clin Oncol 2000; 18: 788–794.",{"doi":4230},"10.1200\u002FJCO.2000.18.4.788",{"id":23,"text":4232,"url":23,"identifiers":4233},"Muto A, Mori S, Matsushita H, Awaya N, Ueno H, Takayama N et al. Serial quantification of minimal residual disease of t(8;21) acute myelogenous leukaemia with RT-competitive PCR assay. Br J Haematol 1996; 95: 85–94.",{"doi":4234},"10.1046\u002Fj.1365-2141.1996.d01-1877.x",{"id":23,"text":4236,"url":23,"identifiers":4237},"Tobal K, Yin JA . Monitoring of minimal residual disease by quantitative reverse transcriptase-polymerase chain reaction for AML1-MTG8 transcripts in AML-M2 with t(8; 21). Blood 1996; 88: 3704–3709.",{"doi":4238},"10.1182\u002Fblood.V88.10.3704.bloodjournal88103704",{"id":23,"text":4240,"url":23,"identifiers":4241},"Tobal K, Newton J, Macheta M, Chang J, Morgenstern G, Evans PA et al. Molecular quantitation of minimal residual disease in acute myeloid leukemia with t(8;21) can identify patients in durable remission and predict clinical relapse. Blood 2000; 95: 815–819.",{"doi":4242},"10.1182\u002Fblood.V95.3.815.003k30_815_819",{"id":23,"text":4244,"url":23,"identifiers":4245},"Kondo M, Kudo K, Kimura H, Inaba J, Kato K, Kojima S et al. Real-time quantitative reverse transcription-polymerase chain reaction for the detection of AML1-MTG8 fusion transcripts in t(8;21)-positive acute myelogenous leukemia. Leuk Res 2000; 24: 951–956.",{"doi":4246},"10.1016\u002FS0145-2126(00)00071-0",{"id":23,"text":4248,"url":23,"identifiers":4249},"Fujimaki S, Funato T, Harigae H, Imaizumi M, Suzuki H, Kaneko Y et al. A quantitative reverse transcriptase polymerase chain reaction method for the detection of leukaemic cells with t(8;21) in peripheral blood. Eur J Haematol 2000; 64: 252–258.",{"doi":4250},"10.1034\u002Fj.1600-0609.2000.90091.x",{"id":23,"text":4252,"url":23,"identifiers":4253},"Asou H, Tashiro S, Hamamoto K, Otsuji A, Kita K, Kamada N . Establishment of a human acute myeloid leukemia cell line (Kasumi-1) with 8;21 chromosome translocation. Blood 1991; 77: 2031–2036.",{"doi":4254},"10.1182\u002Fblood.V77.9.2031.2031",{"id":23,"text":4256,"url":23,"identifiers":4257},"Hochhaus A, Weisser A, La Rosee P, Emig M, Muller MC, Saussele S et al. Detection and quantification of residual disease in chronic myelogenous leukemia. Leukemia 2000; 14: 998–1005.",{"doi":4258},"10.1038\u002Fsj.leu.2401811",{"id":23,"text":4260,"url":23,"identifiers":4261},"Wattjes MP, Krauter J, Nagel S, Heidenreich O, Ganser A, Heil G . Comparison of nested competitive RT-PCR and real-time RT-PCR for the detection and quantification of AML1\u002FMTG8 fusion transcripts in t(8;21) positive acute myelogenous leukemia. Leukemia 2000; 14: 329–335.",{"doi":4262},"10.1038\u002Fsj.leu.2401679",{"id":23,"text":4264,"url":23,"identifiers":4265},"Livak KJ, Schmittgen TD . Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001; 25: 402–408.",{"doi":4266},"10.1006\u002Fmeth.2001.1262",{"id":4268,"createTime":4269,"updateTime":4269,"relativeEntities":4270,"slug":4271,"properties":4272,"entityType":150,"verifyStatus":151,"verifyTime":4285,"verifyNote":152,"syncStatus":22,"languages":4286,"translateLanguages":23,"viewCount":24,"primaryUrl":4287,"fullTextUrl":23,"authors":4288,"publicationType":1646,"publisherRelationship":4518,"citationCount":1572,"citationInfo":4551,"publishDate":4553,"publishYear":4554,"citationAnalyzeStatus":22,"lastCitationAnalyze":23,"indexDatabases":23,"openAccess":23,"references":4555,"isForceReanalyzing":1780},"9d2d5373-98f1-4bd7-9195-f8e9e1885ea7","2024-09-22T23:31:57.899+00:00",[],"MicroRNA-signatures-characterize-multiple-myeloma-patients",{"mag":4273,"keywords":4275,"openalex":4276,"abstract":4278,"title":4279,"pm":4281,"doi":4283},{"VOID":4274},"2148941906",{},{"VOID":4277},"W2148941906",{},{"EN":4280},"MicroRNA signatures characterize multiple myeloma patients",{"VOID":4282},"21701488",{"VOID":4284},"10.1038\u002Fleu.2011.147","2024-09-22T23:31:57.898+00:00",[154],"https:\u002F\u002Fwww.nature.com\u002Farticles\u002Fleu2011147",[4289,4311,4333,4350,4365,4380,4395,4410,4425,4447,4467,4488,4503],{"id":4290,"sortIndex":69,"researcher":23,"roles":4291,"affiliations":4292,"properties":4304},"8a75713a-f67e-4993-bf59-8eb0e6819d6f",[],[4293],{"id":4294,"sortIndex":24,"affiliation":4295,"properties":23},"335f19ba-7fca-4e63-bfbc-8c73cdd38b40",{"id":4296,"createTime":4297,"updateTime":4298,"relativeEntities":4299,"slug":4300,"properties":4301,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},"b14a6f2b-c5d5-4d1e-95b0-460fdb6ff113","2024-01-11T12:28:18.701+00:00","2024-12-28T04:46:01.754+00:00",[],"Department-of-Clinical-Genetics-Erasmus-MC-Rotterdam-The-Netherlands",{"title":4302},{"VI":4303},"Department of Clinical Genetics, Erasmus MC, Rotterdam, The Netherlands",{"openalex":4305,"orcid":4307,"title":4309},{"VOID":4306},"A5079893077",{"VOID":4308},"https:\u002F\u002Forcid.org\u002F0000-0003-2280-7617",{"EN":4310},"H. Berna Beverloo",{"id":4312,"sortIndex":460,"researcher":23,"roles":4313,"affiliations":4314,"properties":4326},"178a121f-f55e-4098-b6ec-b89124b1db39",[],[4315],{"id":4316,"sortIndex":24,"affiliation":4317,"properties":23},"e6812837-6014-442a-a921-cb215cac6eb0",{"id":4318,"createTime":4319,"updateTime":4320,"relativeEntities":4321,"slug":4322,"properties":4323,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},"52dd4457-cd38-498f-bd9b-acab5baed9e1","2024-01-03T15:35:41.075+00:00","2024-10-05T22:27:56.592+00:00",[],"Department-of-Hematology-Erasmus-MC-Rotterdam-The-Netherlands",{"title":4324},{"VI":4325},"Department of Hematology, Erasmus MC, Rotterdam, The Netherlands",{"openalex":4327,"orcid":4329,"title":4331},{"VOID":4328},"A5002972322",{"VOID":4330},"https:\u002F\u002Forcid.org\u002F0000-0002-0808-2237",{"EN":4332},"Pieter Sonneveld",{"id":4334,"sortIndex":1593,"researcher":23,"roles":4335,"affiliations":4336,"properties":4343},"507316bd-f084-44fd-a1b2-4b6967a558e2",[],[4337],{"id":4338,"sortIndex":24,"affiliation":4339,"properties":23},"653986af-c67f-4d40-a93f-00ecee9369b1",{"id":4318,"createTime":4319,"updateTime":4320,"relativeEntities":4340,"slug":4322,"properties":4341,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},[],{"title":4342},{"VI":4325},{"openalex":4344,"orcid":4346,"title":4348},{"VOID":4345},"A5006394021",{"VOID":4347},"https:\u002F\u002Forcid.org\u002F0000-0002-3703-1762",{"EN":4349},"Rowan Kuiper",{"id":4351,"sortIndex":518,"researcher":23,"roles":4352,"affiliations":4353,"properties":4360},"76663fdb-3aa2-4939-9846-5d2cb230a775",[],[4354],{"id":4355,"sortIndex":24,"affiliation":4356,"properties":23},"5f125a2c-eb67-4cb2-8302-b222a88380d9",{"id":4318,"createTime":4319,"updateTime":4320,"relativeEntities":4357,"slug":4322,"properties":4358,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},[],{"title":4359},{"VI":4325},{"openalex":4361,"title":4363},{"VOID":4362},"A5033811992",{"EN":4364},"Mojca Jongen‐Lavrencic",{"id":4366,"sortIndex":205,"researcher":23,"roles":4367,"affiliations":4368,"properties":4375},"eb07c766-d207-4196-9318-8e8e721c3b1e",[],[4369],{"id":4370,"sortIndex":24,"affiliation":4371,"properties":23},"a49f7d5c-32fc-48cb-86ed-70c77a6cdacc",{"id":4318,"createTime":4319,"updateTime":4320,"relativeEntities":4372,"slug":4322,"properties":4373,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},[],{"title":4374},{"VI":4325},{"openalex":4376,"title":4378},{"VOID":4377},"A5103502229",{"EN":4379},"Justine Peeters",{"id":4381,"sortIndex":924,"researcher":23,"roles":4382,"affiliations":4383,"properties":4390},"182760d4-6b69-418a-aa0d-32a68e0e6e63",[],[4384],{"id":4385,"sortIndex":24,"affiliation":4386,"properties":23},"54480e29-55c7-43d9-b008-d58d4797d2ae",{"id":4318,"createTime":4319,"updateTime":4320,"relativeEntities":4387,"slug":4322,"properties":4388,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},[],{"title":4389},{"VI":4325},{"openalex":4391,"title":4393},{"VOID":4392},"A5080712446",{"EN":4394},"Annemiek Broyl",{"id":4396,"sortIndex":24,"researcher":23,"roles":4397,"affiliations":4398,"properties":4405},"22a17e67-069f-4b3f-b0a6-c380a0b98b97",[],[4399],{"id":4400,"sortIndex":24,"affiliation":4401,"properties":23},"583cf3f9-dab7-4264-b69c-4590eebae257",{"id":4318,"createTime":4319,"updateTime":4320,"relativeEntities":4402,"slug":4322,"properties":4403,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},[],{"title":4404},{"VI":4325},{"openalex":4406,"title":4408},{"VOID":4407},"A5031487599",{"EN":4409},"Sophie L. Corthals",{"id":4411,"sortIndex":1453,"researcher":23,"roles":4412,"affiliations":4413,"properties":4420},"cb9527d5-3b00-4fe0-a4fc-3058aa5a3a6f",[],[4414],{"id":4415,"sortIndex":24,"affiliation":4416,"properties":23},"276c7f81-e9aa-4e58-8cfe-f52e033fe033",{"id":4318,"createTime":4319,"updateTime":4320,"relativeEntities":4417,"slug":4322,"properties":4418,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},[],{"title":4419},{"VI":4325},{"openalex":4421,"title":4423},{"VOID":4422},"A5049532216",{"EN":4424},"Yvonne de Knegt",{"id":4426,"sortIndex":375,"researcher":23,"roles":4427,"affiliations":4428,"properties":4440},"dfc2cad8-bc91-40d6-bbe2-e8e321fd264e",[],[4429],{"id":4430,"sortIndex":24,"affiliation":4431,"properties":23},"62417f59-5fe9-4cb9-b8ad-0c5f1d351b3f",{"id":4432,"createTime":4433,"updateTime":4434,"relativeEntities":4435,"slug":4436,"properties":4437,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},"c677cb73-3276-4efc-9677-c3781a4499a2","2023-11-26T07:25:58.739+00:00","2024-12-01T14:33:07.668+00:00",[],"Department-of-Hematology-VU-University-Medical-Center-Amsterdam-The-Netherlands",{"title":4438},{"VI":4439},"Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands",{"openalex":4441,"orcid":4443,"title":4445},{"VOID":4442},"A5083385949",{"VOID":4444},"https:\u002F\u002Forcid.org\u002F0000-0002-5011-1820",{"EN":4446},"Sonja Zweegman",{"id":4448,"sortIndex":1216,"researcher":23,"roles":4449,"affiliations":4450,"properties":4462},"a307d5d9-81a4-4c9a-96ad-6423f30c2c7d",[],[4451],{"id":4452,"sortIndex":24,"affiliation":4453,"properties":23},"65994a45-192f-4959-b46f-d1ed24859139",{"id":4454,"createTime":4455,"updateTime":4456,"relativeEntities":4457,"slug":4458,"properties":4459,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},"a76a4311-69a2-4286-81dc-078634bf69e0","2024-01-05T00:29:48.207+00:00","2024-09-22T23:31:58.009+00:00",[],"Department-of-Hematology-University-Medical-Center-Utrecht-The-Netherlands",{"title":4460},{"VI":4461},"Department of Hematology, University Medical Center, Utrecht, The Netherlands",{"openalex":4463,"title":4465},{"VOID":4464},"A5058429057",{"EN":4466},"Henk M. Lokhorst",{"id":4468,"sortIndex":1512,"researcher":23,"roles":4469,"affiliations":4470,"properties":4481},"1b454e6a-0bf1-4176-a6df-0dd7bcbadb1a",[],[4471],{"id":4472,"sortIndex":24,"affiliation":4473,"properties":23},"c5d2e47b-7023-4148-88ac-67000f06376e",{"id":4474,"createTime":4475,"updateTime":4475,"relativeEntities":4476,"slug":4477,"properties":4478,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},"1f8ea75c-8960-4f3c-b69f-c951029570d3","2024-09-22T23:31:57.964+00:00",[],"Department-of-Trials-Statistics-HOVON-Data-Center-Erasmus-MC-Rotterdam-The-Netherlands",{"title":4479},{"EN":4480},"Department of Trials & Statistics-HOVON Data Center, Erasmus MC, Rotterdam, The Netherlands",{"openalex":4482,"orcid":4484,"title":4486},{"VOID":4483},"A5012101669",{"VOID":4485},"https:\u002F\u002Forcid.org\u002F0000-0001-6414-2671",{"EN":4487},"Bronno van der Holt",{"id":4489,"sortIndex":729,"researcher":23,"roles":4490,"affiliations":4491,"properties":4498},"23d547ef-307e-4d4e-9bac-da87d1e78c08",[],[4492],{"id":4493,"sortIndex":24,"affiliation":4494,"properties":23},"9a487cfd-9a68-470a-b187-118c27d3566b",{"id":4474,"createTime":4475,"updateTime":4475,"relativeEntities":4495,"slug":4477,"properties":4496,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},[],{"title":4497},{"EN":4480},{"openalex":4499,"title":4501},{"VOID":4500},"A5062591567",{"EN":4502},"Laila el Jarari",{"id":4504,"sortIndex":500,"researcher":23,"roles":4505,"affiliations":4506,"properties":4513},"e64b437d-7405-4ad6-85f8-2eae3ffe6b2b",[],[4507],{"id":4508,"sortIndex":24,"affiliation":4509,"properties":23},"e13ca42a-aba6-4cf0-9f37-f50621484dd1",{"id":4318,"createTime":4319,"updateTime":4320,"relativeEntities":4510,"slug":4322,"properties":4511,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},[],{"title":4512},{"VI":4325},{"openalex":4514,"title":4516},{"VOID":4515},"A5010814415",{"EN":4517},"Su Ming Sun",{"url":23,"publisher":4519,"properties":4544},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":4520,"slug":10,"properties":4521,"entityType":21,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24,"subjectFields":4527,"manageAffiliations":4528,"indexDatabases":4529,"url":125,"thumbnailPath":23,"statistic":23,"gsStatistic":23,"type":23,"analyzePriority":23},[],{"country":4522,"issn":4523,"introduce":4524,"eissn":4525,"title":4526},{"VOID":13},{"VOID":15},{"EN":17},{"VOID":19},{"EN":10},[],[],[4530,4537],{"id":84,"indexDatabase":4531,"url":99,"indexYears":23,"academicFieldIds":4536,"indexDatabaseRanking":23},{"id":86,"createTime":87,"updateTime":88,"relativeEntities":4532,"label":4533,"description":4534,"key":95,"publicationTags":4535,"standard":23},[],{"EN":91,"VI":91},{"VI":93,"EN":94},[97,98],[101,102],{"id":104,"indexDatabase":4538,"url":117,"indexYears":118,"academicFieldIds":4543,"indexDatabaseRanking":124},{"id":106,"createTime":107,"updateTime":108,"relativeEntities":4539,"label":4540,"description":4541,"key":114,"publicationTags":4542,"standard":23},[],{"EN":111,"VI":111},{"EN":111,"VI":113},[116],[120,121,122,123],{"volume":4545,"pages":4547,"issue":4549},{"VOID":4546},"25",{"VOID":4548},"1784-1789",{"VOID":4550},"11",{"total":1572,"publishYear":23,"statisticByYear":4552},{"2012":1512,"2013":69,"2014":375,"2015":205,"2016":205,"2017":924,"2018":1453,"2019":924,"2020":500,"2021":1453,"2022":500,"2023":1453,"2024":1593},"2011-11-01",2011,[4556,4560,4564,4568,4572,4575,4579,4583,4587],{"id":23,"text":4557,"url":23,"identifiers":4558},"Gutiérrez NC, Sarasquete ME, Misiewicz-Krzeminska I, Delgado M, De Las Rivas J, Ticona FV et al. Deregulation of microRNA expression in the different genetic subtypes of multiple myeloma and correlation with gene expression profiling. Leukemia 2010; 24: 629–637.",{"doi":4559},"10.1038\u002Fleu.2009.274",{"id":23,"text":4561,"url":23,"identifiers":4562},"Lionetti M, Biasiolo M, Agnelli L, Todoerti K, Mosca L, Fabris S et al. Identification of microRNA expression patterns and definition of a microRNA\u002FmRNA regulatory network in distinct molecular groups of multiple myeloma. Blood 2009; 114: e20–e26.",{"doi":4563},"10.1182\u002Fblood-2009-08-237495",{"id":23,"text":4565,"url":23,"identifiers":4566},"Pichiorri F, Suh SS, Ladetto M, Kuehl M, Palumbo T, Drandi D et al. MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. Proc Natl Acad Sci USA 2008; 105: 12885–12890.",{"doi":4567},"10.1073\u002Fpnas.0806202105",{"id":23,"text":4569,"url":23,"identifiers":4570},"O’Donnell KA, Wentzel EA, Zeller KI, Dang CV, Mendell JT . c-Myc-regulated microRNAs modulate E2F1 expression. Nature 2005; 435: 839–843.",{"doi":4571},"10.1038\u002Fnature03677",{"id":23,"text":4573,"url":23,"identifiers":4574},"Benjamini Y, Hochberg Y . Controlling the false discovery rate: a powerful apporach to multiple testing. J Roy Statist Soc Ser B (Methodological) 1995; 57: 289–300.",{},{"id":23,"text":4576,"url":23,"identifiers":4577},"Pichiorri F, Suh SS, Rocci A, De Luca L, Taccioli C, Santhanam R et al. Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53\u002FMDM2 autoregulatory loop in multiple myeloma development. Cancer Cell 2010; 18: 367–381.",{"doi":4578},"10.1016\u002Fj.ccr.2010.09.005",{"id":23,"text":4580,"url":23,"identifiers":4581},"Asangani IA, Rasheed SA, Nikolova DA, Leupold JH, Colburn NH, Post S et al. MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene 2008; 27: 2128–2136.",{"doi":4582},"10.1038\u002Fsj.onc.1210856",{"id":23,"text":4584,"url":23,"identifiers":4585},"Loffler D, Brocke-Heidrich K, Pfeifer G, Stocsits C, Hackermuller J, Kretzschmar AK et al. Interleukin-6 dependent survival of multiple myeloma cells involves the Stat3-mediated induction of microRNA-21 through a highly conserved enhancer. Blood 2007; 110: 1330–1333.",{"doi":4586},"10.1182\u002Fblood-2007-03-081133",{"id":23,"text":4588,"url":23,"identifiers":4589},"Oh J, Takahashi R, Kondo S, Mizoguchi A, Adachi E, Sasahara RM et al. The membrane-anchored MMP inhibitor RECK is a key regulator of extracellular matrix integrity and angiogenesis. Cell 2001; 107: 789–800.",{"doi":4590},"10.1016\u002FS0092-8674(01)00597-9",{"id":4592,"createTime":4593,"updateTime":4593,"relativeEntities":4594,"slug":4595,"properties":4596,"entityType":150,"verifyStatus":151,"verifyTime":4609,"verifyNote":152,"syncStatus":22,"languages":4610,"translateLanguages":23,"viewCount":24,"primaryUrl":4611,"fullTextUrl":23,"authors":4612,"publicationType":1646,"publisherRelationship":4844,"citationCount":904,"citationInfo":4876,"publishDate":4878,"publishYear":4879,"citationAnalyzeStatus":22,"lastCitationAnalyze":23,"indexDatabases":23,"openAccess":23,"references":4880,"isForceReanalyzing":1780},"572b5411-0d84-4dc1-928e-4f24fbe37e0e","2024-09-22T23:31:40.196+00:00",[],"Oncolytic-virotherapy-for-multiple-myeloma-using-a-tumour-specific-double-deleted-vaccinia-virus",{"mag":4597,"keywords":4599,"openalex":4600,"abstract":4602,"title":4603,"pm":4605,"doi":4607},{"VOID":4598},"2080122207",{},{"VOID":4601},"W2080122207",{},{"EN":4604},"Oncolytic virotherapy for multiple myeloma using a tumour-specific double-deleted vaccinia virus",{"VOID":4606},"18509356",{"VOID":4608},"10.1038\u002Fleu.2008.120","2024-09-22T23:31:40.195+00:00",[154],"https:\u002F\u002Fwww.nature.com\u002Farticles\u002Fleu2008120",[4613,4635,4652,4667,4687,4702,4717,4732,4749,4766,4799,4827],{"id":4614,"sortIndex":24,"researcher":23,"roles":4615,"affiliations":4616,"properties":4628},"74f976fd-dc15-4694-b2ee-a597c19eb16f",[],[4617],{"id":4618,"sortIndex":24,"affiliation":4619,"properties":23},"83691231-ac9d-4b23-a870-b782ef389a70",{"id":4620,"createTime":4621,"updateTime":4622,"relativeEntities":4623,"slug":4624,"properties":4625,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},"21c1d242-e2c9-478e-980d-1accc5297e0e","2024-04-15T20:07:17.393+00:00","2024-09-22T23:31:40.212+00:00",[],"Division-of-Experimental-Therapeutics-Toronto-General-Research-Institute-Toronto-Canada",{"title":4626},{"EN":4627},"Division of Experimental Therapeutics, Toronto General Research Institute, Toronto, Canada",{"openalex":4629,"orcid":4631,"title":4633},{"VOID":4630},"A5039221601",{"VOID":4632},"https:\u002F\u002Forcid.org\u002F0000-0002-7426-5146",{"EN":4634},"Hui Deng",{"id":4636,"sortIndex":500,"researcher":23,"roles":4637,"affiliations":4638,"properties":4645},"58765707-3bbc-4a27-a9cf-404c333eef1c",[],[4639],{"id":4640,"sortIndex":24,"affiliation":4641,"properties":23},"d2b7ade5-5a44-4d66-b80f-150f1e178758",{"id":4620,"createTime":4621,"updateTime":4622,"relativeEntities":4642,"slug":4624,"properties":4643,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},[],{"title":4644},{"EN":4627},{"openalex":4646,"orcid":4648,"title":4650},{"VOID":4647},"A5062243169",{"VOID":4649},"https:\u002F\u002Forcid.org\u002F0000-0002-8284-3372",{"EN":4651},"Nan Tang",{"id":4653,"sortIndex":69,"researcher":23,"roles":4654,"affiliations":4655,"properties":4662},"30ab9690-f67c-4fe5-825d-e395a9d336d6",[],[4656],{"id":4657,"sortIndex":24,"affiliation":4658,"properties":23},"5e67a599-bf1b-4ac6-b73e-279e0196cb80",{"id":4620,"createTime":4621,"updateTime":4622,"relativeEntities":4659,"slug":4624,"properties":4660,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},[],{"title":4661},{"EN":4627},{"openalex":4663,"title":4665},{"VOID":4664},"A5020853459",{"EN":4666},"Gillian Sleep",{"id":4668,"sortIndex":375,"researcher":23,"roles":4669,"affiliations":4670,"properties":4682},"29e29796-d4f4-4c81-bda1-1174cf60a3d3",[],[4671],{"id":4672,"sortIndex":24,"affiliation":4673,"properties":23},"eb4f5ab3-a389-48c2-a4c8-fdb1e6871d2e",{"id":4674,"createTime":4675,"updateTime":4676,"relativeEntities":4677,"slug":4678,"properties":4679,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},"5af537d9-b49c-4b69-b291-0f9f89c1a114","2024-02-13T14:06:22.830+00:00","2024-09-22T23:31:40.278+00:00",[],"Department-of-Medical-Oncology-and-Hematology-University-Health-Network-Toronto-Canada",{"title":4680},{"VI":4681},"Department of Medical Oncology and Hematology, University Health Network, Toronto, Canada",{"openalex":4683,"title":4685},{"VOID":4684},"A5000842608",{"EN":4686},"Stewart Ak",{"id":4688,"sortIndex":1593,"researcher":23,"roles":4689,"affiliations":4690,"properties":4697},"3586a830-072d-4d24-a8bc-b6b5d6e31bae",[],[4691],{"id":4692,"sortIndex":24,"affiliation":4693,"properties":23},"9c48515c-07d1-484c-99ad-4614d8676bfa",{"id":4620,"createTime":4621,"updateTime":4622,"relativeEntities":4694,"slug":4624,"properties":4695,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},[],{"title":4696},{"EN":4627},{"openalex":4698,"title":4700},{"VOID":4699},"A5019854782",{"EN":4701},"Sverstiuk Ae",{"id":4703,"sortIndex":518,"researcher":23,"roles":4704,"affiliations":4705,"properties":4712},"4ae887e8-84df-4d1d-a778-418f746649de",[],[4706],{"id":4707,"sortIndex":24,"affiliation":4708,"properties":23},"aede1e0d-bba7-4b81-aa60-469919af7c35",{"id":4620,"createTime":4621,"updateTime":4622,"relativeEntities":4709,"slug":4624,"properties":4710,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},[],{"title":4711},{"EN":4627},{"openalex":4713,"title":4715},{"VOID":4714},"A5105803658",{"EN":4716},"McCart Ja",{"id":4718,"sortIndex":205,"researcher":23,"roles":4719,"affiliations":4720,"properties":4727},"f4e60035-b821-4707-a455-225875f4eb03",[],[4721],{"id":4722,"sortIndex":24,"affiliation":4723,"properties":23},"ba16e0d4-cdb4-4c61-ab09-2d03653a4229",{"id":4674,"createTime":4675,"updateTime":4676,"relativeEntities":4724,"slug":4678,"properties":4725,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},[],{"title":4726},{"VI":4681},{"openalex":4728,"title":4730},{"VOID":4729},"A5006530399",{"EN":4731},"Yang Xz",{"id":4733,"sortIndex":1512,"researcher":23,"roles":4734,"affiliations":4735,"properties":4742},"e8124b78-5e88-4712-b5d4-2fddb5da577c",[],[4736],{"id":4737,"sortIndex":24,"affiliation":4738,"properties":23},"a2955871-2c4c-4677-9054-3167daf18ce2",{"id":4620,"createTime":4621,"updateTime":4622,"relativeEntities":4739,"slug":4624,"properties":4740,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},[],{"title":4741},{"EN":4627},{"openalex":4743,"orcid":4745,"title":4747},{"VOID":4744},"A5103046088",{"VOID":4746},"https:\u002F\u002Forcid.org\u002F0000-0002-6865-1542",{"EN":4748},"Richard D. Head",{"id":4750,"sortIndex":924,"researcher":23,"roles":4751,"affiliations":4752,"properties":4759},"54e00f70-33e4-4a8e-a6cd-41f4807da2ec",[],[4753],{"id":4754,"sortIndex":24,"affiliation":4755,"properties":23},"88e2985c-4729-4204-802f-ceb484237611",{"id":4620,"createTime":4621,"updateTime":4622,"relativeEntities":4756,"slug":4624,"properties":4757,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},[],{"title":4758},{"EN":4627},{"openalex":4760,"orcid":4762,"title":4764},{"VOID":4761},"A5057784359",{"VOID":4763},"https:\u002F\u002Forcid.org\u002F0000-0001-5400-2552",{"EN":4765},"E Baig",{"id":4767,"sortIndex":729,"researcher":23,"roles":4768,"affiliations":4769,"properties":4792},"ab3458aa-47cb-45fb-88ad-df7c3830024e",[],[4770,4781],{"id":4771,"sortIndex":500,"affiliation":4772,"properties":23},"383871f1-ee59-4fa2-943e-e63d7c53d94e",{"id":4773,"createTime":4774,"updateTime":4775,"relativeEntities":4776,"slug":4777,"properties":4778,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},"164037b0-0233-4be9-a49e-34da68fb2504","2024-01-17T04:26:05.862+00:00","2024-12-26T01:13:51.051+00:00",[],"Department-of-Laboratory-Medicine-and-Pathobiology-University-of-Toronto-Toronto-Canada",{"title":4779},{"VI":4780},"Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada",{"id":4782,"sortIndex":24,"affiliation":4783,"properties":23},"f2ad9d32-358f-49c8-8914-abad2d72b331",{"id":4784,"createTime":4785,"updateTime":4786,"relativeEntities":4787,"slug":4788,"properties":4789,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},"04ccfb97-3a60-4dd5-88a2-a5569e762f07","2024-09-22T23:31:40.287+00:00","2025-06-11T18:01:58.729+00:00",[],"Centre-For-Modeling-Human-Disease-Samuel-Lunenfeld-Research-Institute-Mount-Sinai-Hospital-Toronto-Canada",{"title":4790},{"EN":4791},"Centre For Modeling Human Disease, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Canada",{"openalex":4793,"orcid":4795,"title":4797},{"VOID":4794},"A5075162277",{"VOID":4796},"https:\u002F\u002Forcid.org\u002F0000-0002-2232-0967",{"EN":4798},"Colin McKerlie",{"id":4800,"sortIndex":1216,"researcher":23,"roles":4801,"affiliations":4802,"properties":4820},"3088af01-c2b5-4c50-990c-f4f22a42a204",[],[4803,4809],{"id":4804,"sortIndex":24,"affiliation":4805,"properties":23},"a3c7f90d-ebc8-40da-9f23-98a4192407d3",{"id":4674,"createTime":4675,"updateTime":4676,"relativeEntities":4806,"slug":4678,"properties":4807,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},[],{"title":4808},{"VI":4681},{"id":4810,"sortIndex":500,"affiliation":4811,"properties":23},"1a7eb362-ee45-4032-a228-95131aaafe49",{"id":4812,"createTime":4813,"updateTime":4814,"relativeEntities":4815,"slug":4816,"properties":4817,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},"0ad0a7a5-7ed0-48c8-814b-393ab3591139","2023-12-31T03:41:10.803+00:00","2025-06-11T23:42:36.959+00:00",[],"Department-of-Medicine-University-of-Toronto-Toronto-Canada",{"title":4818},{"VI":4819},"Department of Medicine, University of Toronto, Toronto, Canada",{"openalex":4821,"orcid":4823,"title":4825},{"VOID":4822},"A5082712392",{"VOID":4824},"https:\u002F\u002Forcid.org\u002F0000-0001-7952-6352",{"EN":4826},"Suzanne Trudel",{"id":4828,"sortIndex":1453,"researcher":23,"roles":4829,"affiliations":4830,"properties":4837},"1b4fb376-c56c-4d84-b018-8a71fe1dbdfb",[],[4831],{"id":4832,"sortIndex":24,"affiliation":4833,"properties":23},"361eb954-e09c-4cfa-8a5b-22edae2d32d4",{"id":4620,"createTime":4621,"updateTime":4622,"relativeEntities":4834,"slug":4624,"properties":4835,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},[],{"title":4836},{"EN":4627},{"openalex":4838,"orcid":4840,"title":4842},{"VOID":4839},"A5024981525",{"VOID":4841},"https:\u002F\u002Forcid.org\u002F0000-0002-1735-1494",{"EN":4843},"Nikhil Mehta",{"url":23,"publisher":4845,"properties":4870},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":4846,"slug":10,"properties":4847,"entityType":21,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24,"subjectFields":4853,"manageAffiliations":4854,"indexDatabases":4855,"url":125,"thumbnailPath":23,"statistic":23,"gsStatistic":23,"type":23,"analyzePriority":23},[],{"country":4848,"issn":4849,"introduce":4850,"eissn":4851,"title":4852},{"VOID":13},{"VOID":15},{"EN":17},{"VOID":19},{"EN":10},[],[],[4856,4863],{"id":84,"indexDatabase":4857,"url":99,"indexYears":23,"academicFieldIds":4862,"indexDatabaseRanking":23},{"id":86,"createTime":87,"updateTime":88,"relativeEntities":4858,"label":4859,"description":4860,"key":95,"publicationTags":4861,"standard":23},[],{"EN":91,"VI":91},{"VI":93,"EN":94},[97,98],[101,102],{"id":104,"indexDatabase":4864,"url":117,"indexYears":118,"academicFieldIds":4869,"indexDatabaseRanking":124},{"id":106,"createTime":107,"updateTime":108,"relativeEntities":4865,"label":4866,"description":4867,"key":114,"publicationTags":4868,"standard":23},[],{"EN":111,"VI":111},{"EN":111,"VI":113},[116],[120,121,122,123],{"volume":4871,"pages":4873,"issue":4875},{"VOID":4872},"22",{"VOID":4874},"2261-2264",{"VOID":3517},{"total":904,"publishYear":23,"statisticByYear":4877},{"2012":924,"2013":500,"2014":500,"2015":1593,"2016":500,"2017":69,"2018":924,"2020":500,"2021":924,"2022":500,"2024":1593},"2008-12-01",2008,[4881,4885,4889,4893,4896,4900,4904,4908,4912,4916,4919],{"id":23,"text":4882,"url":23,"identifiers":4883},"Coffey MC, Strong JE, Forsyth PA, Lee PW . Reovirus therapy of tumors with activated Ras pathway. Science 1998; 282: 1332–1334.",{"doi":4884},"10.1126\u002Fscience.282.5392.1332",{"id":23,"text":4886,"url":23,"identifiers":4887},"Stojdl DF, Lichty B, Knowles S, Marius R, Atkins H, Sonenberg N et al. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nature Med 2000; 6: 821–825.",{"doi":4888},"10.1038\u002F77558",{"id":23,"text":4890,"url":23,"identifiers":4891},"Martuza RL, Malick A, Markert JM, Ruffner KL, Coen DM . Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 1991; 252: 854–856.",{"doi":4892},"10.1126\u002Fscience.1851332",{"id":23,"text":4894,"url":23,"identifiers":4895},"McCart JA, Ward JM, Lee J, Hu Y, Alexander HR, Libutti SK et al. Systemic cancer therapy with a tumor selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes. Cancer Res 2001; 61: 8751–8757.",{},{"id":23,"text":4897,"url":23,"identifiers":4898},"Jounaidi Y, Doloff JC, Waxman DJ . Conditionally replicating adenoviruses for cancer treatment. Curr Cancer Drug Targets 2007; 7: 285–301.",{"doi":4899},"10.2174\u002F156800907780618301",{"id":23,"text":4901,"url":23,"identifiers":4902},"Peng KW, Ahmann GJ, Pham L, Greipp PR, Russell SJ . Systemic therapy of myeloma xenografts by an attenuated measles virus. Blood 2001; 98: 2002–2007.",{"doi":4903},"10.1182\u002Fblood.V98.7.2002",{"id":23,"text":4905,"url":23,"identifiers":4906},"Peng KW, Donovan KA, Schneider U, Cattaneo R, Lust JA, Russell SJ . Oncolytic measles virus displaying a single chain antibody against CD38, a myeloma cell marker. Blood 2001; 101: 2557–2562.",{"doi":4907},"10.1182\u002Fblood-2002-07-2195",{"id":23,"text":4909,"url":23,"identifiers":4910},"Lichty BD, Stojdl DF, Taylor RA, Miller L, Frenkel I, Atkins H et al. Vesicular stomatitis virus: a potential therapeutic virus for the treatment of hematological malignancy. Hum Gene Ther 2004; 15: 821–831.",{"doi":4911},"10.1089\u002Fhum.2004.15.821",{"id":23,"text":4913,"url":23,"identifiers":4914},"Au GG, Lincz LF, Enno A, Shafren DR . Oncolytic Coxsackievirus A21 as a novel therapy for multiple myeloma. Br J Haematol 2007; 137: 133–141.",{"doi":4915},"10.1111\u002Fj.1365-2141.2007.06550.x",{"id":23,"text":4917,"url":23,"identifiers":4918},"Mitsiades CS, Mitsiades NS, Bronson RT, Chauhan D, Munshi N, Treon SP et al. Fluorescence imaging of multiple myeloma cells in a clinically relevant SCID\u002FNOD in vivo model: biologic and clinical implications. Cancer Res 2003; 63: 6689–6696.",{},{"id":23,"text":4920,"url":23,"identifiers":4921},"Moss B . Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. Proc Natl Acad Sci USA 1996; 93: 11341–11348.",{"doi":4922},"10.1073\u002Fpnas.93.21.11341",{"id":4924,"createTime":4925,"updateTime":4925,"relativeEntities":4926,"slug":4927,"properties":4928,"entityType":150,"verifyStatus":151,"verifyTime":4925,"verifyNote":152,"syncStatus":22,"languages":4941,"translateLanguages":23,"viewCount":24,"primaryUrl":4942,"fullTextUrl":23,"authors":4943,"publicationType":1646,"publisherRelationship":5015,"citationCount":563,"citationInfo":5047,"publishDate":5049,"publishYear":5050,"citationAnalyzeStatus":22,"lastCitationAnalyze":23,"indexDatabases":23,"openAccess":23,"references":5051,"isForceReanalyzing":1780},"2e433a59-d505-4e74-ac4d-bd5c4a97a077","2024-09-11T23:24:29.276+00:00",[],"Abnormal-mRNA-expression-of-ASPP-members-in-leukemia-cell-lines",{"mag":4929,"keywords":4931,"openalex":4932,"abstract":4934,"title":4935,"pm":4937,"doi":4939},{"VOID":4930},"2027791090",{},{"VOID":4933},"W2027791090",{},{"EN":4936},"Abnormal mRNA expression of ASPP members in leukemia cell lines",{"VOID":4938},"14973501",{"VOID":4940},"10.1038\u002Fsj.leu.2403300",[154],"https:\u002F\u002Fwww.nature.com\u002Farticles\u002F2403300",[4944,4966,4981,4998],{"id":4945,"sortIndex":500,"researcher":23,"roles":4946,"affiliations":4947,"properties":4959},"12f9a305-754a-4497-b12d-b9227e5bdbb1",[],[4948],{"id":4949,"sortIndex":24,"affiliation":4950,"properties":23},"0231f1d3-aa11-41da-af8b-bbfcc866c6de",{"id":4951,"createTime":4952,"updateTime":4953,"relativeEntities":4954,"slug":4955,"properties":4956,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},"19fa1194-40e7-47f6-a9f8-db20a7ed410a","2024-01-03T08:57:26.944+00:00","2024-09-11T23:24:29.298+00:00",[],"Department-of-Laboratory-Medicine-Southwest-Hospital-Third-Military-Medical-University-Chongqing-People-s-Republic-of-China",{"title":4957},{"VI":4958},"Department of Laboratory Medicine, Southwest Hospital, Third Military Medical University, Chongqing, People's Republic of China",{"openalex":4960,"orcid":4962,"title":4964},{"VOID":4961},"A5024645432",{"VOID":4963},"https:\u002F\u002Forcid.org\u002F0000-0002-8636-183X",{"EN":4965},"Yun Zhang",{"id":4967,"sortIndex":1593,"researcher":23,"roles":4968,"affiliations":4969,"properties":4976},"1829e21e-a733-4128-91d9-9258f6df525d",[],[4970],{"id":4971,"sortIndex":24,"affiliation":4972,"properties":23},"c325fd5e-1e8b-4b95-8c8e-7423a0d86cf0",{"id":4951,"createTime":4952,"updateTime":4953,"relativeEntities":4973,"slug":4955,"properties":4974,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},[],{"title":4975},{"VI":4958},{"openalex":4977,"title":4979},{"VOID":4978},"A5054043747",{"EN":4980},"Zhang Xb",{"id":4982,"sortIndex":1453,"researcher":23,"roles":4983,"affiliations":4984,"properties":4991},"51b97cd3-b5a4-4e1d-94f9-d2df06483a85",[],[4985],{"id":4986,"sortIndex":24,"affiliation":4987,"properties":23},"ebe747f6-81d4-4ff8-bbe4-ae5057743379",{"id":4951,"createTime":4952,"updateTime":4953,"relativeEntities":4988,"slug":4955,"properties":4989,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},[],{"title":4990},{"VI":4958},{"openalex":4992,"orcid":4994,"title":4996},{"VOID":4993},"A5037280231",{"VOID":4995},"https:\u002F\u002Forcid.org\u002F0000-0001-5352-8843",{"EN":4997},"Yang Xiang",{"id":4999,"sortIndex":24,"researcher":23,"roles":5000,"affiliations":5001,"properties":5008},"93fec7d4-ea7b-4355-b8fa-8f339b20b0b9",[],[5002],{"id":5003,"sortIndex":24,"affiliation":5004,"properties":23},"48f990de-115d-4794-ab1a-ec957a23309a",{"id":4951,"createTime":4952,"updateTime":4953,"relativeEntities":5005,"slug":4955,"properties":5006,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},[],{"title":5007},{"VI":4958},{"openalex":5009,"orcid":5011,"title":5013},{"VOID":5010},"A5100399047",{"VOID":5012},"https:\u002F\u002Forcid.org\u002F0000-0002-2301-0768",{"EN":5014},"Zhao‐Jun Liu",{"url":23,"publisher":5016,"properties":5041},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":5017,"slug":10,"properties":5018,"entityType":21,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24,"subjectFields":5024,"manageAffiliations":5025,"indexDatabases":5026,"url":125,"thumbnailPath":23,"statistic":23,"gsStatistic":23,"type":23,"analyzePriority":23},[],{"country":5019,"issn":5020,"introduce":5021,"eissn":5022,"title":5023},{"VOID":13},{"VOID":15},{"EN":17},{"VOID":19},{"EN":10},[],[],[5027,5034],{"id":84,"indexDatabase":5028,"url":99,"indexYears":23,"academicFieldIds":5033,"indexDatabaseRanking":23},{"id":86,"createTime":87,"updateTime":88,"relativeEntities":5029,"label":5030,"description":5031,"key":95,"publicationTags":5032,"standard":23},[],{"EN":91,"VI":91},{"VI":93,"EN":94},[97,98],[101,102],{"id":104,"indexDatabase":5035,"url":117,"indexYears":118,"academicFieldIds":5040,"indexDatabaseRanking":124},{"id":106,"createTime":107,"updateTime":108,"relativeEntities":5036,"label":5037,"description":5038,"key":114,"publicationTags":5039,"standard":23},[],{"EN":111,"VI":111},{"EN":111,"VI":113},[116],[120,121,122,123],{"volume":5042,"pages":5044,"issue":5046},{"VOID":5043},"18",{"VOID":5045},"880-880",{"VOID":2542},{"total":563,"publishYear":23,"statisticByYear":5048},{"2012":1453,"2013":924,"2014":1453,"2015":1453,"2017":1453,"2018":1593,"2019":500,"2020":500,"2022":500,"2023":500},"2004-04-01",2004,[5052,5056,5060,5064,5068],{"id":23,"text":5053,"url":23,"identifiers":5054},"Bergamaschi D, Samuels Y, O'Neil NJ et al. iASPP oncoprotein is a key inhibitor of p53 conserved from worm to human. Nat Genet 2003; 33: 162–167.",{"doi":5055},"10.1038\u002Fng1070",{"id":23,"text":5057,"url":23,"identifiers":5058},"Samuels-Lev Y, O'Connor DJ, Bergamaschi D et al. ASPP proteins specifically stimulate the apoptotic function of p53. Mol Cell 2001; 8: 781–794.",{"doi":5059},"10.1016\u002FS1097-2765(01)00367-7",{"id":23,"text":5061,"url":23,"identifiers":5062},"Lane D . How cells choose to die. Nature 2001; 414: 25.",{"doi":5063},"10.1038\u002F35102132",{"id":23,"text":5065,"url":23,"identifiers":5066},"Gresham D . Cheating death. Nat Rev Mol Cell Biol 2003; 4: 87.",{"doi":5067},"10.1038\u002Fnrm1040",{"id":23,"text":5069,"url":23,"identifiers":5070},"P53 mutation database. http:\u002F\u002Fp53.curie.fr.",{},{"id":5072,"createTime":5073,"updateTime":5073,"relativeEntities":5074,"slug":5075,"properties":5076,"entityType":150,"verifyStatus":151,"verifyTime":5073,"verifyNote":152,"syncStatus":22,"languages":5091,"translateLanguages":23,"viewCount":24,"primaryUrl":5092,"fullTextUrl":23,"authors":5093,"publicationType":1646,"publisherRelationship":5289,"citationCount":5322,"citationInfo":5323,"publishDate":5325,"publishYear":5326,"citationAnalyzeStatus":22,"lastCitationAnalyze":23,"indexDatabases":23,"openAccess":23,"references":5327,"isForceReanalyzing":1780},"8f0d0281-9ce8-47bd-9c9e-706170929eaa","2024-09-12T23:20:56.242+00:00",[],"Bone-marrow-mesenchymal-stem-cells-are-abnormal-in-multiple-myeloma",{"mag":5077,"keywords":5079,"pmc":5080,"openalex":5082,"abstract":5084,"title":5085,"pm":5087,"doi":5089},{"VOID":5078},"2048064990",{},{"VOID":5081},"2346535",{"VOID":5083},"W2048064990",{},{"EN":5086},"Bone marrow mesenchymal stem cells are abnormal in multiple myeloma",{"VOID":5088},"17344918",{"VOID":5090},"10.1038\u002Fsj.leu.2404621",[154],"https:\u002F\u002Fwww.nature.com\u002Farticles\u002F2404621",[5094,5113,5134,5149,5170,5187,5206,5221,5236,5253,5270],{"id":5095,"sortIndex":500,"researcher":23,"roles":5096,"affiliations":5097,"properties":5108},"024263eb-e3ad-49c4-b61d-221238438544",[],[5098],{"id":5099,"sortIndex":24,"affiliation":5100,"properties":23},"82ba74ed-43e9-47ec-a4e7-088a09167dd6",{"id":5101,"createTime":5102,"updateTime":5102,"relativeEntities":5103,"slug":5104,"properties":5105,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},"2d345d01-e1c4-410f-b5cf-e1ec6b072ee0","2024-09-12T23:20:56.299+00:00",[],"INSERM-U475-Montpellier-nd-CHU-Montpellier-Institute-of-Research-in-Biotherapy-France-France",{"title":5106},{"EN":5107},"INSERM U475, Montpellier nd CHU Montpellier, Institute of Research in Biotherapy France, France",{"openalex":5109,"title":5111},{"VOID":5110},"A5041691512",{"EN":5112},"Karène Mahtouk",{"id":5114,"sortIndex":375,"researcher":23,"roles":5115,"affiliations":5116,"properties":5127},"58b15260-634c-4463-8b53-473d7ebab032",[],[5117],{"id":5118,"sortIndex":24,"affiliation":5119,"properties":23},"16bea293-b051-44c1-8c4a-039b3f666fa1",{"id":5120,"createTime":5121,"updateTime":5121,"relativeEntities":5122,"slug":5123,"properties":5124,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},"d1a0fa99-b4d9-4b8b-878a-ee102dbfa98e","2024-09-12T23:20:56.384+00:00",[],"Groupe-d-Etude-des-Cellules-Souches-M%C3%A9senchymateuses-Toulouse-France",{"title":5125},{"EN":5126},"Groupe d'Etude des Cellules Souches Mésenchymateuses, Toulouse, France",{"openalex":5128,"orcid":5130,"title":5132},{"VOID":5129},"A5053209026",{"VOID":5131},"https:\u002F\u002Forcid.org\u002F0000-0002-9652-4380",{"EN":5133},"Philippe Bourin",{"id":5135,"sortIndex":729,"researcher":23,"roles":5136,"affiliations":5137,"properties":5144},"d22ead53-4d3d-4b52-a077-dbc95f7c8838",[],[5138],{"id":5139,"sortIndex":24,"affiliation":5140,"properties":23},"e266f94d-9a0f-4b29-9298-4cc234b2af9b",{"id":5101,"createTime":5102,"updateTime":5102,"relativeEntities":5141,"slug":5104,"properties":5142,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},[],{"title":5143},{"EN":5107},{"openalex":5145,"title":5147},{"VOID":5146},"A5018942492",{"EN":5148},"Bernard Klein",{"id":5150,"sortIndex":1593,"researcher":23,"roles":5151,"affiliations":5152,"properties":5163},"684ede3a-2be8-4487-a9da-a8421197ca39",[],[5153],{"id":5154,"sortIndex":24,"affiliation":5155,"properties":23},"d4af1456-06f9-4e03-bd9a-0ea989631c4a",{"id":5156,"createTime":5157,"updateTime":5157,"relativeEntities":5158,"slug":5159,"properties":5160,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},"8c4f2f90-cee6-4a13-9234-07aa2dc995df","2024-09-12T23:20:56.263+00:00",[],"Service-d-h%C3%A9matologie-CHU-Purpan-Toulouse-France-France",{"title":5161},{"EN":5162},"Service d'hématologie CHU Purpan Toulouse France, France",{"openalex":5164,"orcid":5166,"title":5168},{"VOID":5165},"A5025996929",{"VOID":5167},"https:\u002F\u002Forcid.org\u002F0000-0002-0136-9665",{"EN":5169},"Michel Attal",{"id":5171,"sortIndex":924,"researcher":23,"roles":5172,"affiliations":5173,"properties":5180},"9d88e225-1041-4646-b5db-ea1771d54eed",[],[5174],{"id":5175,"sortIndex":24,"affiliation":5176,"properties":23},"41f5025d-4c6e-4547-a17d-53b36d7d691e",{"id":5156,"createTime":5157,"updateTime":5157,"relativeEntities":5177,"slug":5159,"properties":5178,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},[],{"title":5179},{"EN":5162},{"openalex":5181,"orcid":5183,"title":5185},{"VOID":5182},"A5037455697",{"VOID":5184},"https:\u002F\u002Forcid.org\u002F0000-0001-8462-6198",{"EN":5186},"Anne Huynh",{"id":5188,"sortIndex":1453,"researcher":23,"roles":5189,"affiliations":5190,"properties":5201},"378c20d2-f8eb-415b-8a22-24be7c7d21c7",[],[5191],{"id":5192,"sortIndex":24,"affiliation":5193,"properties":23},"080119fe-8f7b-4cb8-82cf-7f2583984ae5",{"id":5194,"createTime":5195,"updateTime":5195,"relativeEntities":5196,"slug":5197,"properties":5198,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},"63ec797f-889d-4a6d-b089-3fb315b1c5c7","2024-09-12T23:20:56.285+00:00",[],"Etablissement-Fran%C3%A7ais-du-Sang-Pyr%C3%A9n%C3%A9es-M%C3%A9diterran%C3%A9e-Toulouse-France-France",{"title":5199},{"EN":5200},"Etablissement Français du Sang Pyrénées-Méditerranée Toulouse France, France",{"openalex":5202,"title":5204},{"VOID":5203},"A5050241340",{"EN":5205},"Mélanie Gadelorge",{"id":5207,"sortIndex":1216,"researcher":23,"roles":5208,"affiliations":5209,"properties":5216},"7a7812b4-3a71-4f16-a463-52c0233ce71f",[],[5210],{"id":5211,"sortIndex":24,"affiliation":5212,"properties":23},"32241a42-9714-465f-850f-70fdd42dc441",{"id":5101,"createTime":5102,"updateTime":5102,"relativeEntities":5213,"slug":5104,"properties":5214,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},[],{"title":5215},{"EN":5107},{"openalex":5217,"title":5219},{"VOID":5218},"A5105779380",{"EN":5220},"Thierry Rème",{"id":5222,"sortIndex":69,"researcher":23,"roles":5223,"affiliations":5224,"properties":5231},"57f6dad1-81c7-4182-942a-c572eaa79cf5",[],[5225],{"id":5226,"sortIndex":24,"affiliation":5227,"properties":23},"fd89e363-1c84-42ec-bc9b-3efe933577a8",{"id":5156,"createTime":5157,"updateTime":5157,"relativeEntities":5228,"slug":5159,"properties":5229,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},[],{"title":5230},{"EN":5162},{"openalex":5232,"title":5234},{"VOID":5233},"A5089065399",{"EN":5235},"Clotaire Danho",{"id":5237,"sortIndex":24,"researcher":23,"roles":5238,"affiliations":5239,"properties":5246},"33de6ebf-2342-427a-b0e1-1756626ae037",[],[5240],{"id":5241,"sortIndex":24,"affiliation":5242,"properties":23},"a5c5b7c9-0a2a-458e-b392-e6b5fc7ac981",{"id":5194,"createTime":5195,"updateTime":5195,"relativeEntities":5243,"slug":5197,"properties":5244,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},[],{"title":5245},{"EN":5200},{"openalex":5247,"orcid":5249,"title":5251},{"VOID":5248},"A5030565933",{"VOID":5250},"https:\u002F\u002Forcid.org\u002F0000-0003-1580-6106",{"EN":5252},"Jill Corre",{"id":5254,"sortIndex":1512,"researcher":23,"roles":5255,"affiliations":5256,"properties":5263},"df31e0fa-4ee6-4d81-9d41-de24cbc1f82f",[],[5257],{"id":5258,"sortIndex":24,"affiliation":5259,"properties":23},"5dfbe8aa-c7d7-4888-8376-89003fce8b3d",{"id":5194,"createTime":5195,"updateTime":5195,"relativeEntities":5260,"slug":5197,"properties":5261,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},[],{"title":5262},{"EN":5200},{"openalex":5264,"orcid":5266,"title":5268},{"VOID":5265},"A5043152532",{"VOID":5267},"https:\u002F\u002Forcid.org\u002F0000-0002-7739-6168",{"EN":5269},"Sandrine Fleury‐Cappellesso",{"id":5271,"sortIndex":205,"researcher":23,"roles":5272,"affiliations":5273,"properties":5284},"c62e1279-8051-47b0-bba1-afcc496ab111",[],[5274],{"id":5275,"sortIndex":24,"affiliation":5276,"properties":23},"b68282d8-3807-418f-b224-5c8dcfad23f6",{"id":5277,"createTime":5278,"updateTime":5278,"relativeEntities":5279,"slug":5280,"properties":5281,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},"44b812ed-8ff5-4000-986d-fa1288f0b501","2024-09-12T23:20:56.348+00:00",[],"UMR-5018-UPS-CNRS-Toulouse-France-France",{"title":5282},{"EN":5283},"UMR 5018 UPS CNRS Toulouse France, France",{"openalex":5285,"title":5287},{"VOID":5286},"A5082986407",{"EN":5288},"Patrick Laharrague",{"url":23,"publisher":5290,"properties":5315},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":5291,"slug":10,"properties":5292,"entityType":21,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24,"subjectFields":5298,"manageAffiliations":5299,"indexDatabases":5300,"url":125,"thumbnailPath":23,"statistic":23,"gsStatistic":23,"type":23,"analyzePriority":23},[],{"country":5293,"issn":5294,"introduce":5295,"eissn":5296,"title":5297},{"VOID":13},{"VOID":15},{"EN":17},{"VOID":19},{"EN":10},[],[],[5301,5308],{"id":84,"indexDatabase":5302,"url":99,"indexYears":23,"academicFieldIds":5307,"indexDatabaseRanking":23},{"id":86,"createTime":87,"updateTime":88,"relativeEntities":5303,"label":5304,"description":5305,"key":95,"publicationTags":5306,"standard":23},[],{"EN":91,"VI":91},{"VI":93,"EN":94},[97,98],[101,102],{"id":104,"indexDatabase":5309,"url":117,"indexYears":118,"academicFieldIds":5314,"indexDatabaseRanking":124},{"id":106,"createTime":107,"updateTime":108,"relativeEntities":5310,"label":5311,"description":5312,"key":114,"publicationTags":5313,"standard":23},[],{"EN":111,"VI":111},{"EN":111,"VI":113},[116],[120,121,122,123],{"volume":5316,"pages":5318,"issue":5320},{"VOID":5317},"21",{"VOID":5319},"1079-1088",{"VOID":5321},"5",310,{"total":5322,"publishYear":23,"statisticByYear":5324},{"2012":647,"2013":991,"2014":1117,"2015":1094,"2016":397,"2017":1200,"2018":860,"2019":947,"2020":1012,"2021":860,"2022":689,"2023":460,"2024":729},"2007-05-01",2007,[5328,5332,5336,5340,5344,5348,5352,5356,5360,5364,5368,5372,5376,5380,5384,5388,5392,5396,5400,5404,5408,5412,5416,5420,5424,5427,5431,5435,5439,5443,5447,5451,5455,5459,5463,5467,5471,5475,5479,5483,5487,5491,5495,5499,5503,5507,5511,5515,5519,5522,5526,5529,5533,5537],{"id":23,"text":5329,"url":23,"identifiers":5330},"Liotta LA, Kohn EC . The microenvironment of the tumour–host interface. Nature 2001; 411: 375–379.",{"doi":5331},"10.1038\u002F35077241",{"id":23,"text":5333,"url":23,"identifiers":5334},"Bhowmick NA, Neilson EG, Moses HL . Stromal fibroblasts in cancer initiation and progression. Nature 2004; 432: 332–337.",{"doi":5335},"10.1038\u002Fnature03096",{"id":23,"text":5337,"url":23,"identifiers":5338},"Maffini MV, Soto AM, Calabro JM, Ucci AA, Sonnenschein C . The stroma as a crucial target in rat mammary gland carcinogenesis. J Cell Sci 2004; 117: 1495–1502.",{"doi":5339},"10.1242\u002Fjcs.01000",{"id":23,"text":5341,"url":23,"identifiers":5342},"Allinen M, Beroukhim R, Cai L, Brennan C, Lahti-Domenici J, Huang H et al. Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell 2004; 6: 17–32.",{"doi":5343},"10.1016\u002Fj.ccr.2004.06.010",{"id":23,"text":5345,"url":23,"identifiers":5346},"Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996; 335: 91–97.",{"doi":5347},"10.1056\u002FNEJM199607113350204",{"id":23,"text":5349,"url":23,"identifiers":5350},"Attal M, Harousseau JL, Facon T, Guilhot F, Doyen C, Fuzibet JG et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003; 349: 2495–2502.",{"doi":5351},"10.1056\u002FNEJMoa032290",{"id":23,"text":5353,"url":23,"identifiers":5354},"Berenson JR . Myeloma bone disease. Best Pract Res Clin Haematol 2005; 18: 653–672.",{"doi":5355},"10.1016\u002Fj.beha.2005.03.001",{"id":23,"text":5357,"url":23,"identifiers":5358},"Silvestris F, Cafforio P, Tucci M, Grinello D, Dammacco F . Upregulation of osteoblast apoptosis by malignant plasma cells: a role in myeloma bone disease. Br J Haematol 2003; 122: 39–52.",{"doi":5359},"10.1046\u002Fj.1365-2141.2003.04374.x",{"id":23,"text":5361,"url":23,"identifiers":5362},"Silvestris F, Cafforio P, Calvani N, Dammacco F . Impaired osteoblastogenesis in myeloma bone disease: role of upregulated apoptosis by cytokines and malignant plasma cells. Br J Haematol 2004; 126: 475–486.",{"doi":5363},"10.1111\u002Fj.1365-2141.2004.05084.x",{"id":23,"text":5365,"url":23,"identifiers":5366},"Tian E, Zhan F, Walker R, Rasmussen E, Ma Y, Barlogie B et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 2003; 349: 2483–2494.",{"doi":5367},"10.1056\u002FNEJMoa030847",{"id":23,"text":5369,"url":23,"identifiers":5370},"Oshima T, Abe M, Asano J, Hara T, Kitazoe K, Sekimoto E et al. Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2. Blood 2005; 106: 3160–3165.",{"doi":5371},"10.1182\u002Fblood-2004-12-4940",{"id":23,"text":5373,"url":23,"identifiers":5374},"Mahtouk K, Hose D, Reme T, De Vos J, Jourdan M, Moreaux J et al. Expression of EGF-family receptors and amphiregulin in multiple myeloma Amphiregulin is a growth factor for myeloma cells. Oncogene 2005; 24: 3512–3524.",{"doi":5375},"10.1038\u002Fsj.onc.1208536",{"id":23,"text":5377,"url":23,"identifiers":5378},"Uchiyama H, Barut BA, Mohrbacher AF, Chauhan D, Anderson KC . Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion. Blood 1993; 82: 3712–3720.",{"doi":5379},"10.1182\u002Fblood.V82.12.3712.3712",{"id":23,"text":5381,"url":23,"identifiers":5382},"Zhang XG, Bataille R, Widjenes J, Klein B . Interleukin-6 dependence of advanced malignant plasma cell dyscrasias. Cancer 1992; 69: 1373–1376.",{"doi":5383},"10.1002\u002F1097-0142(19920315)69:6\u003C1373::AID-CNCR2820690612>3.0.CO;2-1",{"id":23,"text":5385,"url":23,"identifiers":5386},"Gupta D, Treon SP, Shima Y, Hideshima T, Podar K, Tai YT et al. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia 2001; 15: 1950–1961.",{"doi":5387},"10.1038\u002Fsj.leu.2402295",{"id":23,"text":5389,"url":23,"identifiers":5390},"Michigami T, Shimizu N, Williams PJ, Niewolna M, Dallas SL, Mundy GR et al. Cell–cell contact between marrow stromal cells and myeloma cells via VCAM-1 and alpha(4)beta(1)-integrin enhances production of osteoclast-stimulating activity. Blood 2000; 96: 1953–1960.",{"doi":5391},"10.1182\u002Fblood.V96.5.1953",{"id":23,"text":5393,"url":23,"identifiers":5394},"Barille-Nion S, Barlogie B, Bataille R, Bergsagel PL, Epstein J, Fenton RG et al. Advances in biology and therapy of multiple myeloma. Hematology 2003, 248–278.",{"doi":5395},"10.1182\u002Fasheducation-2003.1.248",{"id":23,"text":5397,"url":23,"identifiers":5398},"Hayashi T, Hideshima T, Anderson KC . Novel therapies for multiple myeloma. Br J Haematol 2003; 120: 10–17.",{"doi":5399},"10.1046\u002Fj.1365-2141.2003.03929.x",{"id":23,"text":5401,"url":23,"identifiers":5402},"Gregoretti MG, Gottardi D, Ghia P, Bergui L, Merico F, Marchsio PC et al. Characterization of bone marrow stromal cells from multiple myeloma. Leuk Res 1994; 18: 675–682.",{"doi":5403},"10.1016\u002F0145-2126(94)90067-1",{"id":23,"text":5405,"url":23,"identifiers":5406},"Caligaris-Cappio F, Bergui L, Gregoretti MG, Gaidano G, Gaboli M, Schena M et al. Role of bone marrow stromal cells in the growth of human multiple myeloma. Blood 1991; 77: 2688–2693.",{"doi":5407},"10.1182\u002Fblood.V77.12.2688.2688",{"id":23,"text":5409,"url":23,"identifiers":5410},"Wallace SR, Oken MM, Lunetta KL, Panoskaltsis-Mortari A, Masellis AM . Abnormalities of bone marrow mesenchymal stem cells in multiple myeloma patients. Cancer 2001; 91: 1219–1230.",{"doi":5411},"10.1002\u002F1097-0142(20010401)91:7\u003C1219::AID-CNCR1122>3.0.CO;2-1",{"id":23,"text":5413,"url":23,"identifiers":5414},"Calabro A, Oken MM, Hascall VC, Masellis AM . Characterization of hyaluronan synthetase expression and hyaluronan synthesis in bone marrow mesenchymal progenitor cells: predominant expression of HAS1 mRNA and up-regulated hyaluronan synthesis in bone marrow cells derived from multiple myeloma patients. Blood 2002; 100: 2578–2585.",{"doi":5415},"10.1182\u002Fblood-2002-01-0030",{"id":23,"text":5417,"url":23,"identifiers":5418},"Vincent T, Jourdan M, Sy MS, Klein B, Mechti N . Hyaluronic acid induces survival and proliferation of human myeloma cells through an interleukin-6-mediated pathway involving the phosphorylation of retinoblastoma protein. J Biol Chem 2001; 276: 14728–14736.",{"doi":5419},"10.1074\u002Fjbc.M003965200",{"id":23,"text":5421,"url":23,"identifiers":5422},"Zhang XG, Gaillard JP, Robillard N, Lu ZY, Gu ZJ, Jourdan M et al. Reproducible obtaining of human myeloma cell lines as a model for tumor stem cell study in human multiple myeloma. Blood 1994; 83: 3654–3663.",{"doi":5423},"10.1182\u002Fblood.V83.12.3654.3654",{"id":23,"text":5425,"url":23,"identifiers":5426},"Harashima A, Matsuo Y, Nishizaki C, Kozuka T, Fukuda S, Sezaki T et al. Human bone marrow stroma-dependent myeloma sister cell lines MOLP-6 and MOLP-7 derived from a patient with multiple myeloma. Human Cell 2000; 13: 43–54.",{},{"id":23,"text":5428,"url":23,"identifiers":5429},"Schecroun N, Delloye Ch . In vitro growth and osteoblastic differentiation of human bone marrow stromal cells supported by autologous plasma. Bone 2004; 35: 517–524.",{"doi":5430},"10.1016\u002Fj.bone.2004.03.029",{"id":23,"text":5432,"url":23,"identifiers":5433},"Gregory CA, Gunn WG, Peister A, Prockop DJ . An Alizarin red-based assay of mineralization by adherent cells in culture: comparison with cetylpyridinium chloride extraction. Anal Biochem 2004; 329: 77–84.",{"doi":5434},"10.1016\u002Fj.ab.2004.02.002",{"id":23,"text":5436,"url":23,"identifiers":5437},"Wijdenes J, Clement C, Klein B, Morel-Fourrier B, Vita N, Ferrara P et al. Human recombinant dimeric IL-6 binds to its receptor as detected by anti-IL-6 monoclonal antibodies. Mol Immunol 1991; 28: 1183–1192.",{"doi":5438},"10.1016\u002F0161-5890(91)90004-4",{"id":23,"text":5440,"url":23,"identifiers":5441},"Liu WM, Mei R, Di X, Ryder TB, Hubbell E, Dee S et al. Analysis of high density expression microarrays with signed-rank call algorithms. Bioinformatics 2002; 18: 1593–1599.",{"doi":5442},"10.1093\u002Fbioinformatics\u002F18.12.1593",{"id":23,"text":5444,"url":23,"identifiers":5445},"Eisen MB, Spellman PT, Brown PO, Botstein D . Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 1998; 95: 14863–14868.",{"doi":5446},"10.1073\u002Fpnas.95.25.14863",{"id":23,"text":5448,"url":23,"identifiers":5449},"Tarte K, Zhan F, De Vos J, Klein B, Shaughnessy Jr J . Gene expression profiling of plasma cells and plasmablasts: toward a better understanding of the late stages of B-cell differentiation. Blood 2003; 102: 592–600.",{"doi":5450},"10.1182\u002Fblood-2002-10-3161",{"id":23,"text":5452,"url":23,"identifiers":5453},"Hu M, Yao J, Cai L, Bachman KE, van den Brule F, Velculescu V et al. Distinct epigenetic changes in the stromal cells of breast cancers. Nat Genet 2005; 37: 899–905.",{"doi":5454},"10.1038\u002Fng1596",{"id":23,"text":5456,"url":23,"identifiers":5457},"De Vos J, Hose D, Reme T, Tarte K, Moreaux J, Mahtouk K et al. Microarray-based understanding of normal and malignant plasma cells. Immunol Rev 2006; 210: 86–104.",{"doi":5458},"10.1111\u002Fj.0105-2896.2006.00362.x",{"id":23,"text":5460,"url":23,"identifiers":5461},"Lacy MQ, Donovan KA, Heimbach JK, Ahmann GJ, Lust JA . Comparison of interleukin-1 beta expression by in situ hybridization in monoclonal gammopathy of undetermined significance and multiple myeloma. Blood 1999; 93: 300–305.",{"doi":5462},"10.1182\u002Fblood.V93.1.300",{"id":23,"text":5464,"url":23,"identifiers":5465},"Costes V, Portier M, Lu ZY, Rossi JF, Bataille R, Klein B . Interleukin-1 in multiple myeloma: producer cells and their role in the control of IL-6 production. Br J Haematol 1998; 103: 1152–1160.",{"doi":5466},"10.1046\u002Fj.1365-2141.1998.01101.x",{"id":23,"text":5468,"url":23,"identifiers":5469},"Gunn WG, Conley A, Deininger L, Olson SD, Prockop DJ, Gregory CA . A crosstalk between myeloma cells and marrow stromal cells stimulates production of DKK1 and IL-6: a potential role in the development of lytic bone disease and tumor progression in multiple myeloma. Stem Cells 2005; 24: 986–991.",{"doi":5470},"10.1634\u002Fstemcells.2005-0220",{"id":23,"text":5472,"url":23,"identifiers":5473},"Giuliani N, Colla S, Rizzoli V . Angiogenic switch in multiple myeloma. Hematology 2004; 9: 377–381.",{"doi":5474},"10.1080\u002F10245330400018524",{"id":23,"text":5476,"url":23,"identifiers":5477},"Le Jan S, Amy C, Cazes A, Monnot C, Lamande N, Favier J et al. Angiopoietin-like 4 is a proangiogenic factor produced during ischemia and in conventional renal cell carcinoma. Am J Pathol 2003; 162: 1521–1528.",{"doi":5478},"10.1016\u002FS0002-9440(10)64285-X",{"id":23,"text":5480,"url":23,"identifiers":5481},"Bajou K, Maillard C, Jost M, Lijnen RH, Gils A, Declerck P et al. Host-derived plasminogen activator inhibitor-1 (PAI-1) concentration is critical for in vivo tumoral angiogenesis and growth. Oncogene 2004; 23: 6986–6990.",{"doi":5482},"10.1038\u002Fsj.onc.1207859",{"id":23,"text":5484,"url":23,"identifiers":5485},"Maillard C, Jost M, Romer MU, Brunner N, Houard X, Lejeune A et al. Host plasminogen activator inhibitor-1 promotes human skin carcinoma progression in a stage-dependent manner. Neoplasia 2005; 7: 57–66.",{"doi":5486},"10.1593\u002Fneo.04406",{"id":23,"text":5488,"url":23,"identifiers":5489},"Reinisch N, Kirchmair R, Kahler CM, Hogue-Angeletti R, Fischer-Colbrie R, Winkler H et al. Attraction of human monocytes by the neuropeptide secretoneurin. FEBS Lett 1993; 334: 41–44.",{"doi":5490},"10.1016\u002F0014-5793(93)81676-Q",{"id":23,"text":5492,"url":23,"identifiers":5493},"Starnes T, Broxmeyer HE, Robertson MJ, Hromas R . Cutting edge: IL-17D, a novel member of the IL-17 family, stimulates cytokine production and inhibits hemopoiesis. J Immunol 2002; 169: 642–646.",{"doi":5494},"10.4049\u002Fjimmunol.169.2.642",{"id":23,"text":5496,"url":23,"identifiers":5497},"Jaubert J, Jaubert F, Martin N, Washburn LL, Lee BK, Eicher EM et al. Three new allelic mouse mutations that cause skeletal overgrowth involve the natriuretic peptide receptor C gene (Npr3). Proc Natl Acad Sci USA 1999; 96: 10278–10283.",{"doi":5498},"10.1073\u002Fpnas.96.18.10278",{"id":23,"text":5500,"url":23,"identifiers":5501},"French DM, Kaul RJ, D'Souza AL, Crowley CW, Bao M, Frantz GD et al. WISP-1 is an osteoblastic regulator expressed during skeletal development and fracture repair. Am J Pathol 2004; 165: 855–867.",{"doi":5502},"10.1016\u002FS0002-9440(10)63348-2",{"id":23,"text":5504,"url":23,"identifiers":5505},"Grey A, Banovic T, Naot D, Hill B, Callon K, Reid I et al. Lysophosphatidic acid is an osteoblast mitogen whose proliferative actions involve G(i) proteins and protein kinase C, but not P42\u002F44 mitogen-activated protein kinases. Endocrinology 2001; 142: 1098–1106.",{"doi":5506},"10.1210\u002Fendo.142.3.8011",{"id":23,"text":5508,"url":23,"identifiers":5509},"Grey A, Chen Q, Callon K, Xu X, Reid IR, Cornish J . The phospholipids sphingosine-1-phosphate and lysophosphatidic acid prevent apoptosis in osteoblastic cells via a signaling pathway involving G(i) proteins and phosphatidylinositol-3 kinase. Endocrinology 2002; 143: 4755–4763.",{"doi":5510},"10.1210\u002Fen.2002-220347",{"id":23,"text":5512,"url":23,"identifiers":5513},"Contos JJ, Fukushima N, Weiner JA, Kaushal D, Chun J . Requirement for the LPA1 lysophosphatidic acid receptor gene in normal suckling behavior. Proc Natl Acad Sci USA 2000; 97: 13384–13389.",{"doi":5514},"10.1073\u002Fpnas.97.24.13384",{"id":23,"text":5516,"url":23,"identifiers":5517},"Böttner M, Suter-Crazzolara C, Schober A, Unsicker K . Expression of a novel member of the TGF-beta superfamily, growth\u002Fdifferentiation factor-15\u002Fmacrophage-inhibiting cytokine-1 (GDF15\u002FMIC-1) in adult rat tissues. Cell Tissue Res 1999; 297: 103–110.",{"doi":5518},"10.1007\u002Fs004410051337",{"id":23,"text":5520,"url":23,"identifiers":5521},"Moore AG, Brown DA, Fairlie WD, Bauskin AR, Brown PK, Munier ML et al. The transforming growth factor-β superfamily cytokine macrophage inhibitory cytokine-1 is present in high concentrations in the serum of pregnant women. J Clin Endocrinol Metab 2000; 85: 4781–4788.",{},{"id":23,"text":5523,"url":23,"identifiers":5524},"Koopmann J, Buckhaults P, Brown DA, Zahurak ML, Sato N, Fukushima N et al. Serum macrophage inhibitory cytokine 1 as a marker of pancreatic and other periampullary cancers. Clin Cancer Res 2004; 10: 2386–2392.",{"doi":5525},"10.1158\u002F1078-0432.CCR-03-0165",{"id":23,"text":5527,"url":23,"identifiers":5528},"Brown DA, Ward RL, Buckhaults P, Liu T, Romans KE, Hawkins NJ et al. MIC-1 serum level and genotype: associations with progress and prognosis of colorectal carcinoma. Clin Cancer Res 2003; 9: 2642–2650.",{},{"id":23,"text":5530,"url":23,"identifiers":5531},"Basil CF, Zhao Y, Zavaglia K, Jin P, Panelli MC, Voiculescu S et al. Common cancer biomarkers. Cancer Res 2006; 66: 2953–2961.",{"doi":5532},"10.1158\u002F0008-5472.CAN-05-3433",{"id":23,"text":5534,"url":23,"identifiers":5535},"Subramaniam S, Strelau J, Unsicker K . Growth differentiation factor-15 prevents low potassium-induced cell death of cerebellar granule neurons by differential regulation of Akt and ERK pathways. J Biol Chem 2003; 278: 8904–8912.",{"doi":5536},"10.1074\u002Fjbc.M210037200",{"id":23,"text":5538,"url":23,"identifiers":5539},"Liu T, Bauskin AR, Zaunders J, Brown DA, Pankhurst S, Russell PJ et al. Macrophage inhibitory cytokine 1 reduces cell adhesion and induces apoptosis in prostate cancer cells. Cancer Res 2003; 63: 5034–5040.",{},{"id":5541,"createTime":5542,"updateTime":5542,"relativeEntities":5543,"slug":5544,"properties":5545,"entityType":150,"verifyStatus":151,"verifyTime":5542,"verifyNote":152,"syncStatus":22,"languages":5558,"translateLanguages":23,"viewCount":24,"primaryUrl":5559,"fullTextUrl":23,"authors":5560,"publicationType":1646,"publisherRelationship":5776,"citationCount":5807,"citationInfo":5808,"publishDate":5810,"publishYear":5050,"citationAnalyzeStatus":22,"lastCitationAnalyze":23,"indexDatabases":23,"openAccess":23,"references":5811,"isForceReanalyzing":1780},"feb50a05-8c46-4656-b26c-7e44c9aa8ae4","2024-09-02T23:14:40.127+00:00",[],"BAG3-protein-regulates-stress-induced-apoptosis-in-normal-and-neoplastic-leukocytes",{"mag":5546,"keywords":5548,"openalex":5549,"abstract":5551,"title":5552,"pm":5554,"doi":5556},{"VOID":5547},"2002271685",{},{"VOID":5550},"W2002271685",{},{"EN":5553},"BAG3 protein regulates stress-induced apoptosis in normal and neoplastic leukocytes",{"VOID":5555},"14628070",{"VOID":5557},"10.1038\u002Fsj.leu.2403219",[154],"https:\u002F\u002Fwww.nature.com\u002Farticles\u002F2403219",[5561,5581,5600,5621,5642,5663,5678,5695,5710,5727,5742,5759],{"id":5562,"sortIndex":1216,"researcher":23,"roles":5563,"affiliations":5564,"properties":5576},"65d4c375-b152-4024-9f10-3caf4f699014",[],[5565],{"id":5566,"sortIndex":24,"affiliation":5567,"properties":23},"4cf74d4d-3b3c-4dbc-ad77-9ae0d97e8888",{"id":5568,"createTime":5569,"updateTime":5570,"relativeEntities":5571,"slug":5572,"properties":5573,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},"00793682-97e0-4d39-9937-54d9faca092f","2024-09-02T23:14:40.541+00:00","2025-06-11T13:58:20.219+00:00",[],"Dipartimento-di-Medicina-Sperimentale-e-Clinica-DMSC-University-of-Catanzaro-Italy",{"title":5574},{"EN":5575},"Dipartimento di Medicina Sperimentale e Clinica (DMSC) University of Catanzaro, Italy",{"openalex":5577,"title":5579},{"VOID":5578},"A5065413978",{"EN":5580},"Salvatore Venuta",{"id":5582,"sortIndex":69,"researcher":23,"roles":5583,"affiliations":5584,"properties":5595},"e487f54c-a132-4f0c-bead-d0e92e8cc529",[],[5585],{"id":5586,"sortIndex":24,"affiliation":5587,"properties":23},"e7ec8d60-d5c0-4bec-9afb-c6b41016422c",{"id":5588,"createTime":5589,"updateTime":5589,"relativeEntities":5590,"slug":5591,"properties":5592,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},"16d2d8f9-b9f5-4531-91a6-ec73dc9640bb","2024-09-02T23:14:40.482+00:00",[],"Dipartimento-di-Scienze-e-Tecnologie-per-l-Ambiente-ed-il-Territorio-DiSTAT-University-of-Molise-Italy",{"title":5593},{"EN":5594},"Dipartimento di Scienze e Tecnologie per l'Ambiente ed il Territorio (DiSTAT) University of Molise, Italy",{"openalex":5596,"title":5598},{"VOID":5597},"A5073799068",{"EN":5599},"T. Amelio",{"id":5601,"sortIndex":924,"researcher":23,"roles":5602,"affiliations":5603,"properties":5614},"2dbd7c5e-ca98-4536-846b-33e5b3ee732d",[],[5604],{"id":5605,"sortIndex":24,"affiliation":5606,"properties":23},"e1763675-0204-4d9c-b4eb-75f0b4f9aff7",{"id":5607,"createTime":5608,"updateTime":5608,"relativeEntities":5609,"slug":5610,"properties":5611,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},"a1e47efb-e28f-4b10-a93a-12ffbce772dd","2024-09-02T23:14:40.211+00:00",[],"Dipartimento-di-Scienze-Farmaceutiche-DIFARMA-University-of-Salerno-Italy",{"title":5612},{"EN":5613},"Dipartimento di Scienze Farmaceutiche (DIFARMA) University of Salerno, Italy",{"openalex":5615,"orcid":5617,"title":5619},{"VOID":5616},"A5049706232",{"VOID":5618},"https:\u002F\u002Forcid.org\u002F0000-0002-9197-4833",{"EN":5620},"Rosa Lerose",{"id":5622,"sortIndex":24,"researcher":23,"roles":5623,"affiliations":5624,"properties":5635},"03d2ea04-05b5-4ea7-9177-c99a93e08a98",[],[5625],{"id":5626,"sortIndex":24,"affiliation":5627,"properties":23},"e917e16e-e601-45d7-aa0f-37ec88d7fff3",{"id":5628,"createTime":5629,"updateTime":5629,"relativeEntities":5630,"slug":5631,"properties":5632,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},"e0190b3d-cea5-4676-be2e-2b7d9781cdcd","2024-09-02T23:14:40.149+00:00",[],"Tumour-Institute-Fondazione-Sen-Pascale-Naples-Italy",{"title":5633},{"EN":5634},"Tumour Institute “Fondazione Sen. Pascale” Naples, Italy",{"openalex":5636,"orcid":5638,"title":5640},{"VOID":5637},"A5072585277",{"VOID":5639},"https:\u002F\u002Forcid.org\u002F0000-0002-0916-4015",{"EN":5641},"Patrizia Bonelli",{"id":5643,"sortIndex":1453,"researcher":23,"roles":5644,"affiliations":5645,"properties":5656},"593a18ab-9122-4c40-bedd-1f22190dc21c",[],[5646],{"id":5647,"sortIndex":24,"affiliation":5648,"properties":23},"bdc96fc2-2fd2-4db9-8278-19a05225dfb3",{"id":5649,"createTime":5650,"updateTime":5650,"relativeEntities":5651,"slug":5652,"properties":5653,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},"5cf263c3-ed76-4cb4-aa54-89f0dce3d991","2024-09-02T23:14:40.343+00:00",[],"Dipartimento-di-Biochimica-e-Biotecnologie-Mediche-DBBM-and-Area-di-Ematologia-DACM-University-of-Naples-Federico-II-Italy",{"title":5654},{"EN":5655},"Dipartimento di Biochimica e Biotecnologie Mediche (DBBM) and Area di Ematologia (DACM) University of Naples ‘Federico II’, Italy",{"openalex":5657,"orcid":5659,"title":5661},{"VOID":5658},"A5047387182",{"VOID":5660},"https:\u002F\u002Forcid.org\u002F0000-0001-5557-7307",{"EN":5662},"Maria Fiammetta Romano",{"id":5664,"sortIndex":729,"researcher":23,"roles":5665,"affiliations":5666,"properties":5673},"32c6f746-55f8-457e-92bd-2dae950b8703",[],[5667],{"id":5668,"sortIndex":24,"affiliation":5669,"properties":23},"ed716617-fe6f-4b9b-a7b7-2f0d3a00cfdd",{"id":5588,"createTime":5589,"updateTime":5589,"relativeEntities":5670,"slug":5591,"properties":5671,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},[],{"title":5672},{"EN":5594},{"openalex":5674,"title":5676},{"VOID":5675},"A5069128731",{"EN":5677},"Gianluca Martire",{"id":5679,"sortIndex":500,"researcher":23,"roles":5680,"affiliations":5681,"properties":5688},"6d844dfe-d60a-4d2f-9201-9cda252c74ce",[],[5682],{"id":5683,"sortIndex":24,"affiliation":5684,"properties":23},"91d8391e-6301-4a5c-80a7-6fe5d71dff03",{"id":5607,"createTime":5608,"updateTime":5608,"relativeEntities":5685,"slug":5610,"properties":5686,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},[],{"title":5687},{"EN":5613},{"openalex":5689,"orcid":5691,"title":5693},{"VOID":5690},"A5042599468",{"VOID":5692},"https:\u002F\u002Forcid.org\u002F0000-0002-6945-5295",{"EN":5694},"Antonello Petrella",{"id":5696,"sortIndex":1512,"researcher":23,"roles":5697,"affiliations":5698,"properties":5705},"c9ec6419-c0e9-4619-a8a7-52dfc69da4ff",[],[5699],{"id":5700,"sortIndex":24,"affiliation":5701,"properties":23},"f4de8599-442e-4480-90e8-cba7f4391b55",{"id":5607,"createTime":5608,"updateTime":5608,"relativeEntities":5702,"slug":5610,"properties":5703,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},[],{"title":5704},{"EN":5613},{"openalex":5706,"title":5708},{"VOID":5707},"A5057427562",{"EN":5709},"Maria Gabriella Pagliuca",{"id":5711,"sortIndex":518,"researcher":23,"roles":5712,"affiliations":5713,"properties":5720},"9ee7b7ff-2de7-43a3-a5de-cfd277c153db",[],[5714],{"id":5715,"sortIndex":24,"affiliation":5716,"properties":23},"9433096c-9844-436a-8294-964e340a2d33",{"id":5607,"createTime":5608,"updateTime":5608,"relativeEntities":5717,"slug":5610,"properties":5718,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},[],{"title":5719},{"EN":5613},{"openalex":5721,"orcid":5723,"title":5725},{"VOID":5722},"A5078050436",{"VOID":5724},"https:\u002F\u002Forcid.org\u002F0000-0002-0193-6826",{"EN":5726},"Alessia Leone",{"id":5728,"sortIndex":205,"researcher":23,"roles":5729,"affiliations":5730,"properties":5737},"841244bf-7962-44dc-9119-6d3180d65bd1",[],[5731],{"id":5732,"sortIndex":24,"affiliation":5733,"properties":23},"6e2f9146-e7ad-49d6-8463-62bd9f13c437",{"id":5607,"createTime":5608,"updateTime":5608,"relativeEntities":5734,"slug":5610,"properties":5735,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},[],{"title":5736},{"EN":5613},{"openalex":5738,"title":5740},{"VOID":5739},"A5087277477",{"EN":5741},"Michelina Festa",{"id":5743,"sortIndex":375,"researcher":23,"roles":5744,"affiliations":5745,"properties":5752},"5f26e714-1f81-4c73-94b1-35c849c2da6f",[],[5746],{"id":5747,"sortIndex":24,"affiliation":5748,"properties":23},"647139df-6df4-400f-a56b-a3dfb6ebc305",{"id":5607,"createTime":5608,"updateTime":5608,"relativeEntities":5749,"slug":5610,"properties":5750,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},[],{"title":5751},{"EN":5613},{"openalex":5753,"orcid":5755,"title":5757},{"VOID":5754},"A5001382285",{"VOID":5756},"https:\u002F\u002Forcid.org\u002F0000-0002-7835-359X",{"EN":5758},"Maria Caterina Turco",{"id":5760,"sortIndex":1593,"researcher":23,"roles":5761,"affiliations":5762,"properties":5769},"62003b53-b64c-4a58-9a06-2841983988e1",[],[5763],{"id":5764,"sortIndex":24,"affiliation":5765,"properties":23},"00e91a83-8faa-4372-a57f-1303e5e32a6e",{"id":5607,"createTime":5608,"updateTime":5608,"relativeEntities":5766,"slug":5610,"properties":5767,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},[],{"title":5768},{"EN":5613},{"openalex":5770,"orcid":5772,"title":5774},{"VOID":5771},"A5055822030",{"VOID":5773},"https:\u002F\u002Forcid.org\u002F0000-0001-6675-0857",{"EN":5775},"Alessandra Rosati",{"url":23,"publisher":5777,"properties":5802},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":5778,"slug":10,"properties":5779,"entityType":21,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24,"subjectFields":5785,"manageAffiliations":5786,"indexDatabases":5787,"url":125,"thumbnailPath":23,"statistic":23,"gsStatistic":23,"type":23,"analyzePriority":23},[],{"country":5780,"issn":5781,"introduce":5782,"eissn":5783,"title":5784},{"VOID":13},{"VOID":15},{"EN":17},{"VOID":19},{"EN":10},[],[],[5788,5795],{"id":84,"indexDatabase":5789,"url":99,"indexYears":23,"academicFieldIds":5794,"indexDatabaseRanking":23},{"id":86,"createTime":87,"updateTime":88,"relativeEntities":5790,"label":5791,"description":5792,"key":95,"publicationTags":5793,"standard":23},[],{"EN":91,"VI":91},{"VI":93,"EN":94},[97,98],[101,102],{"id":104,"indexDatabase":5796,"url":117,"indexYears":118,"academicFieldIds":5801,"indexDatabaseRanking":124},{"id":106,"createTime":107,"updateTime":108,"relativeEntities":5797,"label":5798,"description":5799,"key":114,"publicationTags":5800,"standard":23},[],{"EN":111,"VI":111},{"EN":111,"VI":113},[116],[120,121,122,123],{"volume":5803,"pages":5804,"issue":5806},{"VOID":5043},{"VOID":5805},"358-360",{"VOID":1679},87,{"total":5807,"publishYear":23,"statisticByYear":5809},{"2012":1512,"2013":1216,"2014":924,"2015":729,"2016":1593,"2017":1593,"2018":924,"2020":924,"2021":1453,"2022":1593,"2023":500,"2024":1593},"2004-02-01",[5812,5816,5820,5824,5828,5832,5835,5839,5843,5847,5851,5855,5859,5863,5867,5870,5874,5878,5882,5886,5890],{"id":23,"text":5813,"url":23,"identifiers":5814},"Takayama S, Xie Z, Reed JC . An evolutionary conserved family of Hsp70\u002Fhsc70 molecular chaperone regulators. J Biol Chem 1999; 274: 781–786.",{"doi":5815},"10.1074\u002Fjbc.274.2.781",{"id":23,"text":5817,"url":23,"identifiers":5818},"Takayama S, Reed JC . Molecular chaperone targeting and regulation by BAG family proteins. Nat Cell Biol 2001; 3: E237–E241.",{"doi":5819},"10.1038\u002Fncb1001-e237",{"id":23,"text":5821,"url":23,"identifiers":5822},"Lee J-H, Takahashi T, Yasuhara N, Inazawa J, Kamada S, Tsujimoto Y . Bis, a Bcl-2-binding protein that synergizes with Bcl-2 in preventing cell death. Oncogene 1999; 18: 6183–6190.",{"doi":5823},"10.1038\u002Fsj.onc.1203043",{"id":23,"text":5825,"url":23,"identifiers":5826},"Doong H, Price J, Kim YS, Gasbarre C, Probst J, Liotta LA et al. CAIR-1\u002FBAG-3 forms an EGF-regulated ternary complex with phospholipase C-gamma and Hsp70\u002FHsc70. Oncogene 2000; 19: 4385–4395.",{"doi":5827},"10.1038\u002Fsj.onc.1203797",{"id":23,"text":5829,"url":23,"identifiers":5830},"Antoku K, Maser RS, Scully Jr WJ, Delach SM, Johnson DE . Isolation of Bcl-2-binding proteins that exhibit homology with BAG-1 and suppressor of death domains protein. Biochem Biophys Res Commun 2001; 286: 1003–1010.",{"doi":5831},"10.1006\u002Fbbrc.2001.5512",{"id":23,"text":5833,"url":23,"identifiers":5834},"Doong H, Vrailas A, Kohn EC . What's in the ‘BAG’? A functional domain analysis of the BAG-family proteins. Cancer Lett 2002; 188: 25–32.",{},{"id":23,"text":5836,"url":23,"identifiers":5837},"Mosser DD, Caron AW, Bourget L, Denis-Larose C, Masiie B . Role of the human heat shock protein hsp70 in protection against stress-induced apoptosis. Mol Cell Biol 1997; 17: 5317–5327.",{"doi":5838},"10.1128\u002FMCB.17.9.5317",{"id":23,"text":5840,"url":23,"identifiers":5841},"Jaattela M, Wissing D, Kokholm K, Kallunki T, Egeblad M . Hsp70 exerts its anti-apoptotic function downstream of caspase-3-like proteases. EMBO J 1998; 17: 6124–6134.",{"doi":5842},"10.1093\u002Femboj\u002F17.21.6124",{"id":23,"text":5844,"url":23,"identifiers":5845},"Li CY, Lee JS, Ko YG, Kim JL, Seo JS . Heat shock protein 70 inhibits apoptosis downstream of cytochrome c release and upstream of caspase-3 activation. J Biol Chem 2000; 275: 25665–25671.",{"doi":5846},"10.1074\u002Fjbc.M906383199",{"id":23,"text":5848,"url":23,"identifiers":5849},"Creagh EM, Carmody RJ, Cotter TG . Heat shock protein 70 inhibits caspase-dependent and –independent apoptosis in Jurkat T cells. Exp Cell Res 2000; 257: 58–66.",{"doi":5850},"10.1006\u002Fexcr.2000.4856",{"id":23,"text":5852,"url":23,"identifiers":5853},"Beere HM, Wolf BB, Cain K, Mosser DD, Mahboubi A, Kuwana T et al. Heat-shock protein 70 inhibits apoptosis by preventing recruitment of procaspase-9 to the Apaf-1 apoptosome. Nat Cell Biol 2000; 2: 469–475.",{"doi":5854},"10.1038\u002F35019501",{"id":23,"text":5856,"url":23,"identifiers":5857},"Saleh A, Srinivasula SM, Balkir L, Robbins PD, Alnemri ES . Negative regulation of the Apaf-1 apoptosome by Hsp70. Nat Cell Biol 2000; 2: 476–483.",{"doi":5858},"10.1038\u002F35019510",{"id":23,"text":5860,"url":23,"identifiers":5861},"Mosser DD, Caron AW, Bourget L, Meriin AB, Sherman MY, Morimoto RI et al. The chaperone function of hsp70 is required for protection against stress- induced apoptosis. Mol Cell Biol 2002; 20: 7146–7159.",{"doi":5862},"10.1128\u002FMCB.20.19.7146-7159.2000",{"id":23,"text":5864,"url":23,"identifiers":5865},"Ravagnan L, Gurbuxani S, Susin SA, Maisse C, Daugas E, Zamzami N et al. Heat-shock protein 70 antagonizes apoptosis-inducing factor. Nat Cell Biol 2001; 3: 839–843.",{"doi":5866},"10.1038\u002Fncb0901-839",{"id":23,"text":5868,"url":23,"identifiers":5869},"Beere HM . Stressed to death: regulation of apoptotic signaling pathways by the heat shock proteins. Sci STKE 2001; 93: RE1.",{},{"id":23,"text":5871,"url":23,"identifiers":5872},"Romano MF, Festa M, Pagliuca G, Lerose R, Bisogni R, Chiurazzi F et al. BAG3 protein controls B-chronic lymphocytic leukemia cell apoptosis. Cell Death Differ 2003; 10: 383–385.",{"doi":5873},"10.1038\u002Fsj.cdd.4401167",{"id":23,"text":5875,"url":23,"identifiers":5876},"Benhar M, Engelberg D, Levitzki A . ROS, stress-activated kinases and stress signaling in cancer. EMBO Rep 2002; 3: 420–425.",{"doi":5877},"10.1093\u002Fembo-reports\u002Fkvf094",{"id":23,"text":5879,"url":23,"identifiers":5880},"Herr I, Debatin KM . Cellular stress response and apoptosis in cancer therapy. Blood 2001; 98: 2603–2614.",{"doi":5881},"10.1182\u002Fblood.V98.9.2603",{"id":23,"text":5883,"url":23,"identifiers":5884},"O'Neill S, O'Neill AJ, Conroy E, Brady HR, Fizpatrick JM, Watson RW . Altered caspase expression results in delayed neutrophil apoptosis in acute pancreatitis. J Leukoc Biol. 2000; 68: 15–20.",{"doi":5885},"10.1189\u002Fjlb.68.1.15",{"id":23,"text":5887,"url":23,"identifiers":5888},"Pagliuca MG, Lerose R, Cigliano S, Leone A . Regulation by heavy metals and temperature of the human BAG-3 gene, a modulator of Hsp70 activity. FEBS Lett. 2003; 541: 11–15.",{"doi":5889},"10.1016\u002FS0014-5793(03)00274-6",{"id":23,"text":5891,"url":23,"identifiers":5892},"Doong H, Rizzo K, Fang S, Kulpa V, Weissman AM, Kohn EC . CAIR-1\u002FBAG-3 Abrogates Heat Shock protein-70 chaperone complex-mediated protein degradation: Accumulation OF poly-ubiquitinated Hsp90 client proteins. J Biol Chem 2003; 178: 28490–28500.",{"doi":5893},"10.1074\u002Fjbc.M209682200",{"id":5895,"createTime":5896,"updateTime":5896,"relativeEntities":5897,"slug":5898,"properties":5899,"entityType":150,"verifyStatus":22,"verifyTime":5896,"verifyNote":5912,"syncStatus":22,"languages":5913,"translateLanguages":23,"viewCount":24,"primaryUrl":5914,"fullTextUrl":23,"authors":5915,"publicationType":1646,"publisherRelationship":6062,"citationCount":6095,"citationInfo":6096,"publishDate":6098,"publishYear":6099,"citationAnalyzeStatus":22,"lastCitationAnalyze":23,"indexDatabases":23,"openAccess":23,"references":6100,"isForceReanalyzing":1780},"683f7b3d-238a-46b7-af6e-16ccfa98316e","2024-09-19T23:08:39.917+00:00",[],"Frequency-and-clinical-significance-of-BCR-ABL-mutations-in-patients-with-chronic-myeloid-leukemia-treated-with-imatinib-mesylate",{"mag":5900,"keywords":5902,"openalex":5903,"abstract":5905,"title":5906,"pm":5908,"doi":5910},{"VOID":5901},"2075786831",{},{"VOID":5904},"W2075786831",{},{"EN":5907},"Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate",{"VOID":5909},"16855631",{"VOID":5911},"10.1038\u002Fsj.leu.2404318","Author affiliation is blank",[154],"https:\u002F\u002Fwww.nature.com\u002Farticles\u002F2404318",[5916,5927,5938,5959,5970,5981,5989,6000,6011,6022,6031,6040,6051],{"id":5917,"sortIndex":1216,"researcher":23,"roles":5918,"affiliations":5919,"properties":5920},"1c800ac7-f89e-4fc9-b40d-4f2481aeb838",[],[],{"openalex":5921,"orcid":5923,"title":5925},{"VOID":5922},"A5061285204",{"VOID":5924},"https:\u002F\u002Forcid.org\u002F0000-0002-6919-0231",{"EN":5926},"Francis J. Giles",{"id":5928,"sortIndex":729,"researcher":23,"roles":5929,"affiliations":5930,"properties":5931},"955397c0-981f-4721-a782-13dee30d7fa7",[],[],{"openalex":5932,"orcid":5934,"title":5936},{"VOID":5933},"A5061026876",{"VOID":5935},"https:\u002F\u002Forcid.org\u002F0000-0002-3631-2482",{"EN":5937},"Guillermo Garcia‐Manero",{"id":5939,"sortIndex":24,"researcher":23,"roles":5940,"affiliations":5941,"properties":5952},"75cbc089-e623-4914-8370-ee84aca234d5",[],[5942],{"id":5943,"sortIndex":24,"affiliation":5944,"properties":23},"d91d9bec-1cc3-4a15-912a-affa3bc19d2a",{"id":5945,"createTime":5946,"updateTime":5946,"relativeEntities":5947,"slug":5948,"properties":5949,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},"439ec936-3341-40a2-be7f-b6ff4fc212ad","2024-09-19T23:08:39.939+00:00",[],"Department-of-Leukemia-The-University-of-Texas-UT-MD-Anderson-Cancer-Center-Houston-TX-77030-USA-",{"title":5950},{"EN":5951},"Department of Leukemia, The University of Texas, UT MD Anderson Cancer Center, Houston, TX 77030, USA.",{"openalex":5953,"orcid":5955,"title":5957},{"VOID":5954},"A5049385583",{"VOID":5956},"https:\u002F\u002Forcid.org\u002F0000-0003-4465-6119",{"EN":5958},"Elias Jabbour",{"id":5960,"sortIndex":69,"researcher":23,"roles":5961,"affiliations":5962,"properties":5963},"d4f25491-bd9a-4ab9-a539-eac77e504a81",[],[],{"openalex":5964,"orcid":5966,"title":5968},{"VOID":5965},"A5015144369",{"VOID":5967},"https:\u002F\u002Forcid.org\u002F0000-0001-5017-0356",{"EN":5969},"Xian Zhou",{"id":5971,"sortIndex":1453,"researcher":23,"roles":5972,"affiliations":5973,"properties":5974},"ccd315e7-97a9-4659-89ea-ecea960ad294",[],[],{"openalex":5975,"orcid":5977,"title":5979},{"VOID":5976},"A5011529063",{"VOID":5978},"https:\u002F\u002Forcid.org\u002F0000-0003-3361-3981",{"EN":5980},"Moshe Talpaz",{"id":5982,"sortIndex":500,"researcher":23,"roles":5983,"affiliations":5984,"properties":5985},"287b8946-08c8-4c69-b8da-6b675583ef2d",[],[],{"openalex":5986,"orcid":5987,"title":5988},{"VOID":1944},{"VOID":1946},{"EN":1948},{"id":5990,"sortIndex":1593,"researcher":23,"roles":5991,"affiliations":5992,"properties":5993},"dfdba2f9-0655-41da-a381-59e30c13a438",[],[],{"openalex":5994,"orcid":5996,"title":5998},{"VOID":5995},"A5070451207",{"VOID":5997},"https:\u002F\u002Forcid.org\u002F0000-0002-4688-3780",{"EN":5999},"Dan Jones",{"id":6001,"sortIndex":460,"researcher":23,"roles":6002,"affiliations":6003,"properties":6004},"321764cf-3874-48e0-8cd5-aec9d83dd141",[],[],{"openalex":6005,"orcid":6007,"title":6009},{"VOID":6006},"A5015101485",{"VOID":6008},"https:\u002F\u002Forcid.org\u002F0000-0002-8636-1071",{"EN":6010},"Jorge E. Cortés",{"id":6012,"sortIndex":518,"researcher":23,"roles":6013,"affiliations":6014,"properties":6015},"b117e253-0179-45d0-a6ad-4822d38a562f",[],[],{"openalex":6016,"orcid":6018,"title":6020},{"VOID":6017},"A5085521139",{"VOID":6019},"https:\u002F\u002Forcid.org\u002F0000-0002-6912-8569",{"EN":6021},"Srđan Verstovšek",{"id":6023,"sortIndex":924,"researcher":23,"roles":6024,"affiliations":6025,"properties":6026},"5458299b-6e66-4b64-a8a2-3cc84a34f9d9",[],[],{"openalex":6027,"title":6029},{"VOID":6028},"A5004557741",{"EN":6030},"Neby Bekele",{"id":6032,"sortIndex":375,"researcher":23,"roles":6033,"affiliations":6034,"properties":6035},"4b70d94a-cd9e-4b50-8094-b679c645d47f",[],[],{"openalex":6036,"title":6038},{"VOID":6037},"A5057701424",{"EN":6039},"Mary Beth Rios",{"id":6041,"sortIndex":205,"researcher":23,"roles":6042,"affiliations":6043,"properties":6044},"0a5cd075-32e8-4a1e-8427-aeb01aa578f6",[],[],{"openalex":6045,"orcid":6047,"title":6049},{"VOID":6046},"A5073079562",{"VOID":6048},"https:\u002F\u002Forcid.org\u002F0000-0002-7133-0221",{"EN":6050},"Rajyalakshmi Luthra",{"id":6052,"sortIndex":1512,"researcher":23,"roles":6053,"affiliations":6054,"properties":6055},"1d7aef31-dd55-46c6-9486-82656b4c2ce9",[],[],{"openalex":6056,"orcid":6058,"title":6060},{"VOID":6057},"A5102743501",{"VOID":6059},"https:\u002F\u002Forcid.org\u002F0000-0003-3386-6540",{"EN":6061},"Susan O’Brien",{"url":23,"publisher":6063,"properties":6088},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":6064,"slug":10,"properties":6065,"entityType":21,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24,"subjectFields":6071,"manageAffiliations":6072,"indexDatabases":6073,"url":125,"thumbnailPath":23,"statistic":23,"gsStatistic":23,"type":23,"analyzePriority":23},[],{"country":6066,"issn":6067,"introduce":6068,"eissn":6069,"title":6070},{"VOID":13},{"VOID":15},{"EN":17},{"VOID":19},{"EN":10},[],[],[6074,6081],{"id":84,"indexDatabase":6075,"url":99,"indexYears":23,"academicFieldIds":6080,"indexDatabaseRanking":23},{"id":86,"createTime":87,"updateTime":88,"relativeEntities":6076,"label":6077,"description":6078,"key":95,"publicationTags":6079,"standard":23},[],{"EN":91,"VI":91},{"VI":93,"EN":94},[97,98],[101,102],{"id":104,"indexDatabase":6082,"url":117,"indexYears":118,"academicFieldIds":6087,"indexDatabaseRanking":124},{"id":106,"createTime":107,"updateTime":108,"relativeEntities":6083,"label":6084,"description":6085,"key":114,"publicationTags":6086,"standard":23},[],{"EN":111,"VI":111},{"EN":111,"VI":113},[116],[120,121,122,123],{"volume":6089,"pages":6091,"issue":6093},{"VOID":6090},"20",{"VOID":6092},"1767-1773",{"VOID":6094},"10",384,{"total":6095,"publishYear":23,"statisticByYear":6097},{"2012":1157,"2013":991,"2014":1032,"2015":1200,"2016":860,"2017":1012,"2018":397,"2019":518,"2020":729,"2021":729,"2022":729,"2023":205,"2024":924},"2006-10-01",2006,[6101,6105,6109,6111,6115,6119,6123,6127,6130,6134,6138,6142,6146,6150,6154,6158,6162,6166,6169,6172,6175,6178,6181,6185,6188,6192,6196,6199,6203,6207,6211,6215],{"id":23,"text":6102,"url":23,"identifiers":6103},"Goldman JM, Melo JV . Chronic myeloid leukemia – advances in biology and new approaches to treatment. N Engl J Med 2003; 349: 1451–1464.",{"doi":6104},"10.1056\u002FNEJMra020777",{"id":23,"text":6106,"url":23,"identifiers":6107},"Cortes J, Talpaz M, O’Brien S, Jones D, Luthra R, Shan J et al. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate. Clin Cancer Res 2005; 11: 3425–3432.",{"doi":6108},"10.1158\u002F1078-0432.CCR-04-2139",{"id":23,"text":1731,"url":23,"identifiers":6110},{"doi":1733},{"id":23,"text":6112,"url":23,"identifiers":6113},"Hochhaus A, Kreil S, Corbin AS, La Rosee P, Muller MC, Lahaye T et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 2002; 16: 2190–2196.",{"doi":6114},"10.1038\u002Fsj.leu.2402741",{"id":23,"text":6116,"url":23,"identifiers":6117},"Gambacorti-Passerini CB, Gunby RH, Piazza R, Galietta A, Rostagno R, Scapozza L . Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias. Lancet Oncol 2003; 4: 75–85.",{"doi":6118},"10.1016\u002FS1470-2045(03)00979-3",{"id":23,"text":6120,"url":23,"identifiers":6121},"Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001; 293: 876–880.",{"doi":6122},"10.1126\u002Fscience.1062538",{"id":23,"text":6124,"url":23,"identifiers":6125},"Branford S, Rudzki Z, Walsh S, Parkinson I, Grigg A, Szer J et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood 2003; 102: 276–283.",{"doi":6126},"10.1182\u002Fblood-2002-09-2896",{"id":23,"text":6128,"url":23,"identifiers":6129},"Gambacorti-Passerini C, Zucchetti M, Russo D, Frapolli R, Verga M, Bungaro S et al. Alpha1 acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients. Clin Cancer Res 200; 9: 625–632.",{},{"id":23,"text":6131,"url":23,"identifiers":6132},"Donato NJ, Wu JY, Stapley J, Lin H, Arlinghaus R, Aggarwal BB et al. Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia. Cancer Res 2004; 64: 672–677.",{"doi":6133},"10.1158\u002F0008-5472.CAN-03-1484",{"id":23,"text":6135,"url":23,"identifiers":6136},"Donato NJ, Wu JY, Stapley J, Gallick G, Lin H, Arlinghaus R et al. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 2003; 101: 690–698.",{"doi":6137},"10.1182\u002Fblood.V101.2.690",{"id":23,"text":6139,"url":23,"identifiers":6140},"Branford S, Rudzki Z, Walsh S, Grigg A, Arthur C, Taylor K et al. High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR\u002FABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood 2002; 99: 3472–3475.",{"doi":6141},"10.1182\u002Fblood.V99.9.3472",{"id":23,"text":6143,"url":23,"identifiers":6144},"Soverini S, Martinelli G, Rosti G, Bassi S, Amabile M, Poerio A et al. ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA working party on chronic myeloid leukemia. J Clin Oncol 2005; 23: 4100–4109.",{"doi":6145},"10.1200\u002FJCO.2005.05.531",{"id":23,"text":6147,"url":23,"identifiers":6148},"Nardi V, Azam M, Daley GQ . Mechanisms and implications of imatinib resistance mutations in BCR-ABL. Curr Opin Hematol 2004; 11: 35–43.",{"doi":6149},"10.1097\u002F00062752-200401000-00006",{"id":23,"text":6151,"url":23,"identifiers":6152},"Corbin AS, Rosee PL, Stoffregen EP, Druker BJ, Deininger MW . Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib. Blood 2003; 101: 4611–4614.",{"doi":6153},"10.1182\u002Fblood-2002-12-3659",{"id":23,"text":6155,"url":23,"identifiers":6156},"Branford S, Rudzki Z, Parkinson I, Grigg A, Taylor K, Seymour JF et al. Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations. Blood 2004; 104: 2926–2932.",{"doi":6157},"10.1182\u002Fblood-2004-03-1134",{"id":23,"text":6159,"url":23,"identifiers":6160},"Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002; 346: 645–652.",{"doi":6161},"10.1056\u002FNEJMoa011573",{"id":23,"text":6163,"url":23,"identifiers":6164},"Kantarjian HM, Cortes J, O’Brien S, Giles FJ, Albitar M, Rios MB et al. Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. Blood 2002; 99: 3547–3553.",{"doi":6165},"10.1182\u002Fblood.V99.10.3547",{"id":23,"text":6167,"url":23,"identifiers":6168},"Kantarjian HM, O’Brien S, Cortes JE, Smith TL, Rios MB, Shan J et al. Treatment of Philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate. Clin Cancer Res 2002; 8: 2167–2176.",{},{"id":23,"text":6170,"url":23,"identifiers":6171},"Kantarjian HM, Talpaz M, O’Brien S, Smith TL, Giles FJ, Faderl S et al. Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results. Clin Cancer Res 2002; 8: 2177–2187.",{},{"id":23,"text":6173,"url":23,"identifiers":6174},"Kantarjian HM, Smith T, O’Brien S, Beran M, Pierce S, Talpaz M et al. Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-therapy. Ann Int Med 1995; 122: 254–261.",{"doi":3579},{"id":23,"text":6176,"url":23,"identifiers":6177},"Snedecor G, Cochran W . Statistical Methods. 7th edn. Iowa State University Press, Ames, Iowa, 1980.",{},{"id":23,"text":6179,"url":23,"identifiers":6180},"Agresti A . Categorical Data Analysis. 2nd edn. John Wiley & Sons Inc. Hoboken, NJ, 1990.",{},{"id":23,"text":6182,"url":23,"identifiers":6183},"Kaplan EL, Maier P . Non-parametric estimation from incomplete observations. J Am Stat Assoc 1965; 53: 457–481.",{"doi":6184},"10.1080\u002F01621459.1958.10501452",{"id":23,"text":6186,"url":23,"identifiers":6187},"Cox DR . Regression models and life tables. J R Stat Soc 1972; 34: 187–220.",{},{"id":23,"text":6189,"url":23,"identifiers":6190},"Cortes J, Giles F, O’Brien S, Thomas D, Garcia-Manero G, Rios MB et al. Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-{alpha}. Blood 2003; 102: 83–86.",{"doi":6191},"10.1182\u002Fblood-2003-01-0025",{"id":23,"text":6193,"url":23,"identifiers":6194},"Kantarjian H, Talpaz M, O’Brien S, Garcia-Manero G, Verstovsek S, Giles F et al. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood 2004; 103: 2873–2878.",{"doi":6195},"10.1182\u002Fblood-2003-11-3800",{"id":23,"text":6197,"url":23,"identifiers":6198},"Soverini S, Martinelli G, Rosti G, Bassi S, Amabile M, Poerio A et al. ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the gimema working party on chronic myeloid leukemia. J Clin Oncol 2005, JCO.2005.2005.2531.",{"doi":6145},{"id":23,"text":6200,"url":23,"identifiers":6201},"Shah NP, Nicoll JM, Nagar B, Gorre ME, Paquette RL, Kuriyan J et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002; 2: 117–125.",{"doi":6202},"10.1016\u002FS1535-6108(02)00096-X",{"id":23,"text":6204,"url":23,"identifiers":6205},"Willis S, Lange T, Demehri S, Otto S, Crossman L, Niederwieser D et al. High sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy. Blood 2005, 2005-2003-1036.",{"doi":6206},"10.1182\u002Fblood-2005-03-1036",{"id":23,"text":6208,"url":23,"identifiers":6209},"Jabbour E, Cortes J, Kantarjian HM, Giralt S, Jones D, Jones R et al. Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after BCR-ABL kinase mutation-related imatinib failure. Blood 2006 [E-pub ahead of print (April 6, 2006)].",{"doi":6210},"10.1182\u002Fblood-2006-02-001933",{"id":23,"text":6212,"url":23,"identifiers":6213},"Roche-Lestienne C, Lai JL, Darre S, Facon T, Preudhomme C . A mutation conferring resistance to imatinib at the time of diagnosis of chronic myelogenous leukemia. N Engl J Med 2003; 348: 2265–2266.",{"doi":6214},"10.1056\u002FNEJMc035089",{"id":23,"text":6216,"url":23,"identifiers":6217},"O’Hare T, Walters DK, Stoffregen EP, Jia T, Manley PW, Mestan J et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 2005; 65: 4500–4505.",{"doi":6218},"10.1158\u002F0008-5472.CAN-05-0259",{"id":6220,"createTime":6221,"updateTime":6221,"relativeEntities":6222,"slug":6223,"properties":6224,"entityType":150,"verifyStatus":22,"verifyTime":6221,"verifyNote":5912,"syncStatus":22,"languages":6237,"translateLanguages":23,"viewCount":24,"primaryUrl":6238,"fullTextUrl":23,"authors":6239,"publicationType":1646,"publisherRelationship":6293,"citationCount":182,"citationInfo":6326,"publishDate":6328,"publishYear":6329,"citationAnalyzeStatus":22,"lastCitationAnalyze":23,"indexDatabases":23,"openAccess":23,"references":6330,"isForceReanalyzing":1780},"2a6d0cd5-217d-4d75-98b6-3cebf15d813a","2024-09-19T23:08:37.129+00:00",[],"Choosing-the-best-treatment-strategy-for-chronic-myeloid-leukemia-patients-resistant-to-imatinib-weighing-the-efficacy-and-safety-of-individual-drugs-with-BCR-ABL-mutations-and-patient-history",{"mag":6225,"keywords":6227,"openalex":6228,"abstract":6230,"title":6231,"pm":6233,"doi":6235},{"VOID":6226},"2021188441",{},{"VOID":6229},"W2021188441",{},{"EN":6232},"Choosing the best treatment strategy for chronic myeloid leukemia patients resistant to imatinib: weighing the efficacy and safety of individual drugs with BCR-ABL mutations and patient history",{"VOID":6234},"19798095",{"VOID":6236},"10.1038\u002Fleu.2009.193",[154],"https:\u002F\u002Fwww.nature.com\u002Farticles\u002Fleu2009193",[6240,6258,6269,6277,6285],{"id":6241,"sortIndex":24,"researcher":23,"roles":6242,"affiliations":6243,"properties":6254},"6ba6ebae-3442-4ad3-9941-4713dd06aa57",[],[6244],{"id":6245,"sortIndex":24,"affiliation":6246,"properties":23},"a87f3878-a84d-4727-ae16-c31b426f87c4",{"id":6247,"createTime":6248,"updateTime":6248,"relativeEntities":6249,"slug":6250,"properties":6251,"entityType":68,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24},"a3120f02-aa98-4be9-8b3c-78ee4f44cc53","2024-09-19T23:08:37.146+00:00",[],"Department-of-Leukemia-The-University-of-Texas-MD-Anderson-Cancer-Center-1515-Holcombe-Blvd-Unit-423-Houston-TX-77030-USA-ejabbour-mdanderson-org",{"title":6252},{"EN":6253},"Department of Leukemia, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Unit 423, Houston, TX 77030, USA. ejabbour@mdanderson.org",{"openalex":6255,"orcid":6256,"title":6257},{"VOID":5954},{"VOID":5956},{"EN":5958},{"id":6259,"sortIndex":1453,"researcher":23,"roles":6260,"affiliations":6261,"properties":6262},"6ee382c9-1f7a-41ef-8973-b554312cec6c",[],[],{"openalex":6263,"orcid":6265,"title":6267},{"VOID":6264},"A5070260720",{"VOID":6266},"https:\u002F\u002Forcid.org\u002F0000-0002-6758-7809",{"EN":6268},"Paul La Rosée",{"id":6270,"sortIndex":500,"researcher":23,"roles":6271,"affiliations":6272,"properties":6273},"8787a70f-9bd7-4319-9f74-6d413d33e012",[],[],{"openalex":6274,"orcid":6275,"title":6276},{"VOID":786},{"VOID":788},{"EN":790},{"id":6278,"sortIndex":924,"researcher":23,"roles":6279,"affiliations":6280,"properties":6281},"601c0fe5-a091-49e8-ba04-bfba13d516c9",[],[],{"openalex":6282,"orcid":6283,"title":6284},{"VOID":1944},{"VOID":1946},{"EN":1948},{"id":6286,"sortIndex":1593,"researcher":23,"roles":6287,"affiliations":6288,"properties":6289},"08e53155-c6ca-4f27-b68f-6b3f6f64d394",[],[],{"openalex":6290,"orcid":6291,"title":6292},{"VOID":6006},{"VOID":6008},{"EN":6010},{"url":23,"publisher":6294,"properties":6319},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":6295,"slug":10,"properties":6296,"entityType":21,"verifyStatus":22,"verifyTime":23,"verifyNote":23,"syncStatus":22,"languages":23,"translateLanguages":23,"viewCount":24,"subjectFields":6302,"manageAffiliations":6303,"indexDatabases":6304,"url":125,"thumbnailPath":23,"statistic":23,"gsStatistic":23,"type":23,"analyzePriority":23},[],{"country":6297,"issn":6298,"introduce":6299,"eissn":6300,"title":6301},{"VOID":13},{"VOID":15},{"EN":17},{"VOID":19},{"EN":10},[],[],[6305,6312],{"id":84,"indexDatabase":6306,"url":99,"indexYears":23,"academicFieldIds":6311,"indexDatabaseRanking":23},{"id":86,"createTime":87,"updateTime":88,"relativeEntities":6307,"label":6308,"description":6309,"key":95,"publicationTags":6310,"standard":23},[],{"EN":91,"VI":91},{"VI":93,"EN":94},[97,98],[101,102],{"id":104,"indexDatabase":6313,"url":117,"indexYears":118,"academicFieldIds":6318,"indexDatabaseRanking":124},{"id":106,"createTime":107,"updateTime":108,"relativeEntities":6314,"label":6315,"description":6316,"key":114,"publicationTags":6317,"standard":23},[],{"EN":111,"VI":111},{"EN":111,"VI":113},[116],[120,121,122,123],{"volume":6320,"pages":6322,"issue":6324},{"VOID":6321},"24",{"VOID":6323},"6-12",{"VOID":6325},"1",{"total":182,"publishYear":23,"statisticByYear":6327},{"2012":205,"2013":1512,"2014":205,"2015":69,"2016":375,"2017":1512,"2018":500,"2019":500,"2020":1593,"2022":1593,"2023":500},"2010-01-01",2010,[6331,6335,6339,6343,6347,6351,6355,6358,6361,6365,6369,6372,6376,6380,6384,6388,6391,6395,6399,6403,6407,6411,6415,6419,6423,6427,6431,6434,6437,6441,6445,6449,6453,6456,6460,6464,6467,6471,6475,6479,6482,6486,6490,6494,6498,6502],{"id":23,"text":6332,"url":23,"identifiers":6333},"Rowley JD . Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973; 243: 290–293.",{"doi":6334},"10.1038\u002F243290a0",{"id":23,"text":6336,"url":23,"identifiers":6337},"Bartram CR, de Klein A, Hagemeijer A, van Agthoven T, Geurts van Kessel A, Bootsma D et al. Translocation of c-ab1 oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia. Nature 1983; 306: 277–280.",{"doi":6338},"10.1038\u002F306277a0",{"id":23,"text":6340,"url":23,"identifiers":6341},"Sawyers CL . Chronic myeloid leukemia. N Engl J Med 1999; 340: 1330–1340.",{"doi":6342},"10.1056\u002FNEJM199904293401706",{"id":23,"text":6344,"url":23,"identifiers":6345},"Sessions J . Chronic myeloid leukemia in 2007. J Manag Care Pharm 2007; 13: 4–7.",{"doi":6346},"10.18553\u002Fjmcp.2007.13.s8-a.4",{"id":23,"text":6348,"url":23,"identifiers":6349},"Deininger MW, Goldman JM, Melo JV . The molecular biology of chronic myeloid leukemia. Blood 2000; 96: 3343–3356.",{"doi":6350},"10.1182\u002Fblood.V96.10.3343",{"id":23,"text":6352,"url":23,"identifiers":6353},"Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996; 2: 561–566.",{"doi":6354},"10.1038\u002Fnm0596-561",{"id":23,"text":6356,"url":23,"identifiers":6357},"Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2006; 108: 1809–1820.",{"doi":2577},{"id":23,"text":6359,"url":23,"identifiers":6360},"National Comprehensive Cancer Network. NCCN: clinical practice guidelines in oncology. Chronic Myelogenous Leukemia. Version (V.1.2010), 2009.",{},{"id":23,"text":6362,"url":23,"identifiers":6363},"Hochhaus A, O'Brien SG, Guilhot F, Druker BJ, Branford S, Foroni L et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 2009; 23: 1054–1061.",{"doi":6364},"10.1038\u002Fleu.2009.38",{"id":23,"text":6366,"url":23,"identifiers":6367},"O'Brien SG, Guilhot F, Goldman JM, Hochhaus A, Hughes T, Radich JP et al. International Randomized Study of Interferon and STI571 (IRIS) 7-year follow-up: sustained survival, low rate of transformation and increased rate of major molecular response (MMR) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib (IM). Blood 2008; 112: 76.",{"doi":6368},"10.1182\u002Fblood-2008-05-158535",{"id":23,"text":6370,"url":23,"identifiers":6371},"Hochhaus A, Kreil S, Corbin AS, La Rosée P, Müller MC, Lahaye T et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 2002; 16: 2190–2196.",{"doi":6114},{"id":23,"text":6373,"url":23,"identifiers":6374},"Hochhaus A, La Rosée P . Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance. Leukemia 2004; 18: 1321–1331.",{"doi":6375},"10.1038\u002Fsj.leu.2403426",{"id":23,"text":6377,"url":23,"identifiers":6378},"Apperley JF . Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol 2007; 8: 1018–1029.",{"doi":6379},"10.1016\u002FS1470-2045(07)70342-X",{"id":23,"text":6381,"url":23,"identifiers":6382},"Kantarjian HM, Larson RA, Guilhot F, O'Brien SG, Mone M, Rudoltz M et al. Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase. Cancer 2009; 115: 551–560.",{"doi":6383},"10.1002\u002Fcncr.24066",{"id":23,"text":6385,"url":23,"identifiers":6386},"Jabbour E, Kantarjian H, O'Brien S, Wierda W, Faderl S, Garcia-Manero G et al. Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia post cytogenetic failure on standard-dose imatinib therapy. Blood 2008; 113: 2154–2160.",{"doi":6387},"10.1182\u002Fblood-2008-04-154344",{"id":23,"text":6389,"url":23,"identifiers":6390},"Hughes T, Deininger M, Hochhaus A, Branford S, Radich J, Kaeda J et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors—review and recommendations for ‘harmonizing’ current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 2006; 108: 28–37.",{"doi":1717},{"id":23,"text":6392,"url":23,"identifiers":6393},"Jabbour E, Cortes J, O'Brien S, Rios MB, Giles F, Kantarjian H . Management of patients with newly diagnosed chronic myeloid leukemia: opportunities and challenges. Clin Lymphoma Myeloma 2007; 7 (Suppl 2): S51–S57.",{"doi":6394},"10.3816\u002FCLM.2007.s.002",{"id":23,"text":6396,"url":23,"identifiers":6397},"Cortes JE, Baccarani M, Guilhot F, Druker BJ, Branford S, Kim D-W et al. A phase III, randomized, open-label study of 400 versus 800 mg of imatinib mesylate (IM) in patients (pts) with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase (CML-CP) using molecular endpoints: 1-year results of TOPS (Tyrosine Kinase Inhibitor Optimization and Selectivity) study. Blood 2008; 112: 130–131.",{"doi":6398},"10.1182\u002Fblood.V112.11.130.130",{"id":23,"text":6400,"url":23,"identifiers":6401},"Baccarani M, Castagnetti F, Simonsson B, Porkka K, Haznedaroglu IC, Nagler A et al. Cytogenetic and molecular response to imatinib in high risk (Sokal) chronic myeloid leukemia (CML): results of a European LeukemiaNet prospective study comparing 400 and 800 mg front-line. Blood 2008; 112: 75.",{"doi":6402},"10.1182\u002Fblood.V112.11.75.75",{"id":23,"text":6404,"url":23,"identifiers":6405},"Golemovic M, Verstovsek S, Giles F, Cortes J, Manshouri T, Manley PW et al. AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia. Clin Cancer Res 2005; 11: 4941–4947.",{"doi":6406},"10.1158\u002F1078-0432.CCR-04-2601",{"id":23,"text":6408,"url":23,"identifiers":6409},"Weisberg E, Manley PW, Breitenstein W, Bruggen J, Cowan-Jacob SW, Ray A et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005; 7: 129–141.",{"doi":6410},"10.1016\u002Fj.ccr.2005.01.007",{"id":23,"text":6412,"url":23,"identifiers":6413},"Hantschel O, Rix U, Superti-Furga G . Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib. Leuk Lymphoma 2008; 49: 615–619.",{"doi":6414},"10.1080\u002F10428190801896103",{"id":23,"text":6416,"url":23,"identifiers":6417},"Cortes J, O'Brien S, Jones D, Ferrajoli A, Konopleva M, Borthakur G et al. Efficacy of nilotinib (formerly AMN107) in patients (Pts) with newly diagnosed, previously untreated Philadelphia chromosome (Ph)-positive chronic myelogenous leukemia in early chronic phase (CML-CP). Blood 2008; 112: 170.",{"doi":6418},"10.1182\u002Fblood.V112.11.170.170",{"id":23,"text":6420,"url":23,"identifiers":6421},"Rosti G, Castagnetti F, Poerio A, Breccia M, Levato L, Capucci A et al. High and early rates of cytogenetic and molecular response with nilotinib 800 mg daily as first line treatment of Ph-positive chronic myeloid leukemia in chronic phase: results of a phase 2 trial of the GIMEMA CML Working Party. Blood 2008; 112: 73–74.",{"doi":6422},"10.1182\u002Fblood-2007-12-128835",{"id":23,"text":6424,"url":23,"identifiers":6425},"Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL . Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004; 305: 399–401.",{"doi":6426},"10.1126\u002Fscience.1099480",{"id":23,"text":6428,"url":23,"identifiers":6429},"Cortes J, O'Brien S, Borthakur G, Jones D, Ravandi F, Koller C et al. Efficacy of dasatinib in patients (pts) with previously untreated chronic myelogenous leukemia (CML) in early chronic phase (CML-CP). Blood 2008; 112: 74.",{"doi":6430},"10.1182\u002Fblood.V112.11.74.74",{"id":23,"text":6432,"url":23,"identifiers":6433},"Sprycel (dasatinib) [package insert]. Bristol-Myers Squibb Company: Princeton, NJ, 2007.",{},{"id":23,"text":6435,"url":23,"identifiers":6436},"Sprycel (dasatinib) [package insert]. Bristol-Myers Squibb Company: Princeton, NJ, 2009.",{},{"id":23,"text":6438,"url":23,"identifiers":6439},"Hochhaus A, Kantarjian HM, Baccarani M, Lipton JH, Apperley JF, Druker BJ et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood 2007; 109: 2303–2309.",{"doi":6440},"10.1182\u002Fblood-2006-09-047266",{"id":23,"text":6442,"url":23,"identifiers":6443},"Cervantes F, Baccarani M, Lipton J, Matloub Y, Sinha R, Stone RM et al. Dasatinib long-term efficacy in patients with chronic myeloid leukemia in chronic phase (CML-CP) with resistance or intolerance to imatinib: A two-year update of the START-C study. Haematologica 2008; 93: 372.",{"doi":6444},"10.3324\u002Fhaematol.12053",{"id":23,"text":6446,"url":23,"identifiers":6447},"Rousselot P, Corm S, Paquette R, Bleickardt E, Dejardin D, Kantarjian H et al. Dasatinib compared with high-dose imatinib in patients with chronic myelogenous leukemia in chronic phase (CML-CP) after failure of standard-dose imatinib—a two-year update of the START-R study. Haematologica 2008; 93: 48.",{"doi":6448},"10.3324\u002Fhaematol.13015",{"id":23,"text":6450,"url":23,"identifiers":6451},"Shah NP, Kim DW, Kantarjian HMea . Dasatinib 50 or 70 mg BID compared to 100 or 140 mg QD in patients with CML in chronic phase (CP) who are resistant or intolerant to imatinib: one-year results of CA180034. J Clin Oncol 2007; 25: 358s.",{"doi":6452},"10.1200\u002FJCO.2007.12.5062",{"id":23,"text":6454,"url":23,"identifiers":6455},"Tasigna (nilotinib) [package insert] Novartis Pharmaceuticals Corporation: East Hanover, NJ, 2007.",{},{"id":23,"text":6457,"url":23,"identifiers":6458},"Kantarjian HM, Giles F, Bhalla KN, Larson RA, Gattermann N, Ottmann OG et al. Nilotinib in chronic myeloid leukemia patients in chronic phase (CML-CP) with imatinib resistance or intolerance: 2-year follow-up results of a phase 2 study. Blood 2008; 112: 1112.",{"doi":6459},"10.1182\u002Fblood.V112.11.1112.1112",{"id":23,"text":6461,"url":23,"identifiers":6462},"Jabbour E, Kantarjian HM, Baccarani M, le Coutre P, Haque A, Gallagher NJ et al. Minimal cross intolerance between nilotinib and imatinib in patients with imatinib-intolerant chronic myeloid leukemia in chronic phase (CML-CP) or accelerated phase (CML-AP). Blood 2008; 112: 1103.",{"doi":6463},"10.1182\u002Fblood.V112.11.1103.1103",{"id":23,"text":6465,"url":23,"identifiers":6466},"Hochhaus A, Müller MC, Cortes JE, Kim DW, Matloub Y, Ploughman L et al. Dasatinib efficacy after imatinib failure by dosing schedule and baseline BCR-ABL mutation status in patients with chronic myeloid leukemia in chronic phase (CML-CP). Haematologica 2008; 93: 371–372.",{},{"id":23,"text":6468,"url":23,"identifiers":6469},"Hughes T, Saglio G, Branford S, Soverini S, Kim D, Müller M et al. Impact of baseline BCR-ABL mutations on response to nilotinib in chronic myeloid leukemia patients in chronic phase (CML-CP). J Clin Oncol 2009; 27: 4204–4210.",{"doi":6470},"10.1200\u002FJCO.2009.21.8230",{"id":23,"text":6472,"url":23,"identifiers":6473},"Bradeen HA, Eide CA, O'Hare T, Johnson KJ, Willis SG, Lee FY et al. Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations. Blood 2006; 108: 2332–2338.",{"doi":6474},"10.1182\u002Fblood-2006-02-004580",{"id":23,"text":6476,"url":23,"identifiers":6477},"Tanaka R, Kimura S . Abl tyrosine kinase inhibitors for overriding Bcr-Abl\u002FT315I: from the second to third generation. Expert Rev Anticancer Ther 2008; 8: 1387–1398.",{"doi":6478},"10.1586\u002F14737140.8.9.1387",{"id":23,"text":6480,"url":23,"identifiers":6481},"Cortes J, Khoury HJ, Corm S, Nicolini F, Lipton J, Jones D et al. Safety and efficacy of subcutaneous omacetaxine mepesuccinate in imatinib-resistant chronic myeloid leukemia patients with the T315I mutation—results of an ongoing multicenter phase 2\u002F3 study. Blood 2008; 112: 1112–1113.",{"doi":6459},{"id":23,"text":6483,"url":23,"identifiers":6484},"Quintas-Cardama A, Kantarjian H, O'Brien S, Borthakur G, Bruzzi J, Munden R et al. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol 2007; 25: 3908–3914.",{"doi":6485},"10.1200\u002FJCO.2007.12.0329",{"id":23,"text":6487,"url":23,"identifiers":6488},"Lipton JH, Sriharsha L, Bogomilsky S, Casciaro L, Keating A, Messner H et al. Pleural effusions in patients treated with dasatinib: results from two institutions, risk factors and management. J Clin Oncol 2007; 25: 680s.",{"doi":6489},"10.1200\u002FJCO.2007.11.8604",{"id":23,"text":6491,"url":23,"identifiers":6492},"Carpiuc KT, Stephens JM, Liou SY, Botteman MF . Incidence of grade 3\u002F4 adverse events in imatinib resistant\u002Fintolerant chronic phase CML (CP-CML): a comparison of nilotinib and dasatinib. J Clin Oncol 2007; 25: 680s.",{"doi":6493},"10.1200\u002Fjco.2007.25.18_suppl.17501",{"id":23,"text":6495,"url":23,"identifiers":6496},"Hochhaus A, Neubauer A, Mueller MC, Napieralski S, Erben P, Bostel T et al. Sustained molecular responses with interferon alpha 2a maintenance therapy after imatinib plus IFN induction treatment for chronic phase chronic myelogenous leukemia. Blood 2007; 110: 16a–17a.",{"doi":6497},"10.1182\u002Fblood.V110.11.16.16",{"id":23,"text":6499,"url":23,"identifiers":6500},"Mahon F, Huguet F, Guilhot F, Legros L, Nicolini FE, Charbonnier A et al. Is it possible to stop imatinib in patients with chronic myeloid leukemia? An update from a French pilot study and first results from the multicentre ‘Stop Imatinib’ (STIM) study. Blood 2008; 112: 76.",{"doi":6501},"10.1182\u002Fblood.V112.11.76.76",{"id":23,"text":6503,"url":23,"identifiers":6504},"Jain N, Kantarjian HM, Garcia-Manero G, Borthakur G, Ebarb T, Cortes JE . Synthetic tumor-specific breakpoint peptide vaccine in patients (pts) with chronic myeloid leukemia (CML) and minimal residual disease: a phase II trial. J Clin Oncol 2008; 26: 386s.",{"doi":6505},"10.1200\u002FJCO.2006.09.5448"]